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RÉSUMÉ 
La polyarthrite rhumatoïde (PR) est une maladie auto-immune chronique. Elle est caractérisée 
par une inflammation persistante touchant de multiples petites articulations, causant douleurs, 
rougeurs, gonflements et déformations. Des études menées auprès de patients et d’animaux ont 
démontré que certains auto-anticorps, cytokines et enzymes tissue-déstructives sont des 
médiateurs importants dans le développement de la PR. Au cours des deux dernières 
décennies, les traitements de fond (DMARDs en anglais) ont été démontrés très efficaces pour 
traiter la PR. D'autre part, des effets secondaires ont été rapportés pour ces traitements, par 
exemple l'augmentation du risque d'infections opportunistes. L’objectif de ce travail est 
d’acquérir des connaissances sur le rôle du TL1A (TNF-like molécule 1 A; TNFSF15) et son 
partenaire Nob1 (Pno1 ; YOR145c) dans la pathogenèse de la PR afin de découvrir de 
nouveaux médicaments contre ces molécules dans l'avenir. 
TL1A est un membre de la famille du TNF. Il déclenche des signaux co-stimulateurs via le 
récepteur de mort 3 (DR3) et induit la prolifération ainsi que la production des cytokines pro 
inflammatoires par les lymphocytes. Des données multiples suggèrent l'implication de la 
cascade TL1A-DR3 dans plusieurs maladies auto-immunes. Donc, nous avons proposé les 
hypothèses suivantes:1) la production locale de TL1A dans les articulations est un composant 
d’un cercle vicieux qui aggrave la PR; 2) dans la PR, la production de TL1A dans les organes 
lymphoïde augmente la production d’auto-anticorps pathogénique. Au cours de ce travail, 
nous avons démontré que la TL1A aggrave la maladie chez les souris où l’arthrite a été induite 
par le collagène (AIC). Par ailleurs, nous avons constaté que l’expression de TL1A est élevée 
dans les tissus atteints de PR ainsi que dans les  ganglions lymphatiques drainant de la souris 
AIC. Mécaniquement, nous avons découvert que la TL1A est induite par le TNF-α et IL-17 
produits par les cellules T in vitro. Ces résultats montrent directement que les TL1A-DR3 
jouent un rôle essentiel dans la pathogenèse de la PR. De plus, afin de poursuivre notre étude, 
la TL1A a été génétiquement supprimée dans les souris (TL1A KO). Nous avons montré que 
les souris TL1A KO n’ont aucune anomalie apparente et aucun dysfonctionnement du système 
immunitaire dans des conditions normales. Cependant, ces souris manifestent des AIC 
améliorées et une réduction significative des niveaux d'anticorps, anti-collagène du type II 
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dans le sérum. Nous avons trouvé que les ganglions lymphatiques de drainage (dLNs) de 
souris KO étaient plus petites avec une cellularité inférieure comparativement aux souris WT 
de 14 jours après l’immunisation. De plus, nous avons découvert que le DR3 a été exprimé par 
les cellules plasmatiques dans l’étape de la différenciation terminale et ces cellules surviennent 
mieux en présence de TL1A. La conclusion de cette étude apporte des nouvelles 
connaissances sur le rôle de TL1A qui amplifie les réponses humorales d’AIC. Nous avons 
suggéré que TL1A pourrait augmenter la réponse d’initiation d'anticorps contre collagène II 
(CII) ainsi que prolonger la survie des cellules plasmatiques. 
Une autre molécule qui nous intéresse est Pno1. Des études antérieures menées chez la levure 
ont suggéré que Pno1 est essentielle pour la néogénèse du protéasome et du ribosome Le 
protéasome étant crucial pour la différenciation terminale des cellules plasmatiques pendant 
les réponses humorales chez les mammifères, nous avons donc supposé que Pno1 joue un rôle 
dans la production d'anticorps pathogenique dans la PR via la voie du protéasome. Nous avons 
donc généré des souris génétiquement modifiées pour Pno1 afin d’étudier la fonction de Pno1 
in vivo. Cependant, une mutation non-sens dans le Pno1 provoque une létalité embryonnaire à 
un stade très précoce chez les souris. D'autre part, une réduction de 50% de Pno1 ou une 
surexpression de Pno1 n’ont aucun effet ni sur le fonctionnent des cellules T et B, ni sur les 
activités du protéasome ainsi que sur la réponse humorale dans l’AIC. Ces résultats suggèrent 
que Pno1 est une molécule essentielle sans redondance. Par conséquent, il n’est pas une cible 
appropriée pour le développement de médicaments thérapeutiques. 
En conclusion, nos études ont révélé que la TL1A n’est pas essentielle pour maintenir les 
fonctions du système immunitaire dans des conditions normales. En revanche, il joue un rôle 
critique dans la pathogenèse de la PR en favorisant l'inflammation locale et la réponse 
humorale contre des auto-antigènes. Par conséquent, une  inhibition de la TL1A pourrait être 
une stratégie thérapeutique pour le traitement de la PR. Au contraire, Pno1 est essentiel pour la 
fonction normale des cellules. Une délétion totale pourrait entraîner des conséquences graves. 
Il n’est pas une cible appropriée pour développer des médicaments de la PR. 
Mots-clés: l'arthrite rhumatoïde, TL1A, DR3, inflammation, les cytokines, les cellules 
plasmatiques, Pno1, protéasome  
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ABSTRACT 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by persistent 
inflammation of multiple small joints, which manifests pain, redness, swelling, and 
deformation. Studies with patients and animal models have found that autoantibodies, 
cytokines and tissue-destructive enzymes are important mediators of the pathogenesis of RA. 
In the past two decades, biologic disease-modifying antirheumatic drugs (DMARDs) have 
achieved great success in the treatment of RA. On the other hand, they are also associated with 
adverse effect like increasing the chance of opportunistic infections. The aim of present work 
was to investigate the roles of TNF-like molecule 1A (TL1A; TNFSF15) and partner of Nob1 
(Pno1; YOR145c) in the pathogenesis of RA for developing novel drugs based on these 
molecules in the future.  
TL1A is a member of the TNF superfamily. It triggers costimulatory signals though death 
receptor 3 (DR3) and induces the proliferation and pro-inflammatory cytokine production in 
lymphocytes. Multiple lines of evidence suggest the implication of TL1A-DR3 signaling in 
several autoimmune diseases. Therefore, We hypothesized that 1) local TL1A production in 
the joints is a component of a vicious circle aggravating RA; 2) in RA, TL1A production in 
lymphoid organs enhances pathogenic autoantibody production. We demonstrated that the 
TL1A aggravates disease in murine collagen-induced arthritis (CIA). Moreover, we found 
elevated TL1A expression in RA-affected tissues, as well as in the draining lymph nodes 
(dLNs) of CIA mice. Mechanistically, we discovered that TL1A induces TNF-α and IL-17 
production by T cells in vitro. These findings provided direct evidence that TL1A-DR3 
signaling plays a critical role in the pathogenesis of RA. TL1A knockout (TL1A KO) mice 
were generated to further our study. We showed that TL1A KO mice have no visual anomaly, 
and no malfunction of immune system under a normal circumstance. However, they display 
ameliorated CIA and significantly reduced anti-Collagen II antibody levels in sera. We found 
that the draining lymph nodes (dLNs) from KO mice were smaller in size and lower in 
cellularity compared with their WT counterparts 14 days after immunization. Furthermore, we 
discovered that terminally differentiated plasma cells express DR3 and they survive better in 
the presence of TL1A. Our findings in this study present novel knowledge about the role of 
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TL1A promoting the humoral responses in CIA; we suggest that TL1A could elevate the 
initial Ab response against Collagen II (CII), as well as prolong the survival of plasma cells 
producing such pathogenic Abs. 
Another molecule we were interested in present study is Pno1. Previous studies conducted in 
yeast suggest that Pno1 is essential to the proteasome and ribosome neogenesis. Since 
proteasome is crucial for the terminal differentiation of plasma cells during the humoral 
response in mammals, we hypothesized that Pno1 plays a role in the pathogenic Ab production 
in RA by affecting the proteasome assembly. For this purpose, we generated pno1 gene-
modified mice to investigate the function of Pno1 in vivo. However, null-mutation in pno1 
causes embryonic lethality in mice at a very early stage. On the other hand, a half amount 
reduction or overexpression of Pno1 is neither harmful nor useful to the T and B cell function, 
proteasome activities as well as humoral immune responses in CIA. These findings suggest 
that Pno1 is a vital molecule with no redundancy and is absolutely required for cell function, 
but animals can function normally with a small fraction of the normal Pno1 expression level. 
Thus, it might not be an appropriate target for developing therapeutic drugs.  
In conclusion, our studies suggest that TL1A seems not essential in maintaining the immune 
functions under normal circumstances, but plays critical roles in the pathogenesis of RA by 
promoting local inflammation and humoral immune responses against autoantigens. 
Therefore, inhibiting TL1A could be a propitious therapeutic strategy for treating RA. In 
contrast, Pno1 is vital to the normal cell function, and its disruption could cause disastrous 
consequences. Thus, it might not be a good drug target for treating RA.  
Keywords: Rheumatoid arthritis, TL1A, DR3, inflammation, cytokine, plasma cells, Pno1, 
proteasome 
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CHAPTER 1 INTRODUCTION 
1.1 Overview of Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, manifesting redness, 
swelling, tenderness and destruction of the joint tissues (Aletaha et al., 2010). It is caused by 
chronic immune system disorder, which primarily affects the joints and their surrounding 
tissues, but also affects many other parts of our body (Firestein, 2003). Tissues and organs 
involved in RA complications include: the skin (rheumatoid nodules, ulcers and rash), eyes 
(scleritis, Sjogren’s syndrome), cardiovascular system (pericarditis, heart attack and stroke), 
circulation system (vasculitis, anemia, Felty’s syndrome), kidney (renal amyloidosis) and lung 
(collapsed lungs, plural effusion and pulmonary hypertension). There is no cure for RA, but 
current treatment can delay the disease progression and prevent the joint damage (Upchurch 
and Kay, 2012).  
1.1.1 Diagnosis and Classifications of RA 
The original diagnostic criteria for RA were published by the Committee of the American 
Rheumatism Association in 1956, and quickly updated by a revised version after two years 
(Committee of the American Rheumatism Association, 2008; Ropes et al., 1957). The criteria 
was again revised and published in 1987, formulated from computerized analysis of RA 
patients and healthy controls, with fewer criteria, improved sensitivity and specificity (Arnett 
et al., 1988). In 2010, a joint group of American College of Rheumatology (ACR) and 
European League Against Rheumatism (EULAR) published new classification criteria, aiming 
to differentiate RA patients at early-stage (Aletaha et al., 2010). It is noteworthy that the 
criteria in this version were designed for better classification of RA patients for clinical 
studies, rather than for a diagnostic purpose (Aletaha et al., 2010). Several studies have 
compared them with the 1987 diagnostic criteria and found that the 2010 criteria are more 
robust and sensitive, but slightly less specific (Britsemmer et al., 2011; Radner et al.; Van der 
Linden and Knevel, 2011). More evidence remain to be collected to determine whether these 
new criteria are appropriate to be used for diagnosis.  
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Table 1.1 Comparison of 1987 and 2010 versions of RA criteria   
Criterion Versions 
 1987 2010 
Joint involvement Joint type and quantity Joint type and quantity 
Radiographic changes Included Included 
Serology RF RF, ACPA 
Acute-phase reactants N/A CRP, ESR 
Duration of symptoms N/A Included 
Rheumatoid nodules Included N/A 
RF: rheumatoid factor; ACPA: anti-cyclic citrullinated peptide; CRP: C-reactive protein; ESR: 
erythrocyte sedimentation rate 
1.1.2 Epidemiology of RA 
RA occurs in 0.5-1% of the general population (Firestein, 2003). Several epidemiological 
studies have shown variations of disease incidence across populations. One half to 1.1% of the 
population in North America and Northern Europe are affected by RA, while lower prevalence 
of 0.3-0.7% is found in Southern Europe (Tobón et al., 2010). The prevalence of RA in East 
Asia is similar to those in Southern Europe. Developing countries in South Asia, Middle East 
and Africa have lowest prevalence of RA, which is around 0.38% (Hammoudeh et al., 2013; 
Tobón et al., 2010; Zeng et al., 2008). The low prevalence of RA found in developing 
countries may not reflect the actual situations due to the limited prevalence studies and 
incomplete data collection (Alamanos et al., 2006). Prevalence and incidence of RA also 
display a gender-specific disparity, with approximately 2-4 fold more RA patients and higher 
incidence among women than men in different populations (Alamanos et al., 2006; 
Hammoudeh et al., 2013). Multiple studies have suggested that the average onset age of RA is 
rising (Gabriel et al., 1999; Imanaka et al., 1997; O et al., 1996). At the same time, there are 
progressive decreases in both incidence and prevalence of RA across several different regions 
(Doran et al., 2002; Jacobsson et al., 1994; Kaipiainen-Seppanen et al., 1996; Kaipiainen-
Seppanen and Kautiainen, 2006; O and K, 2000; Shichikawa et al., 1999). On the other hand, 
despite our better knowledge of pathogenic mechanisms and great improvement of the RA 
management, the mortality rate in RA patients seems not decreasing in the last few decades 
(Myasoedova et al., 2010).  
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1.1.3 Risk Factors of RA 
1.1.3.1 Genetic Factors 
Various evidence from migration studies, familial clustering studies and twin studies have 
indicated the importance of genetic factors to the susceptibility, severity and responsiveness to 
treatment of RA (Criswell et al., 1998; John and Worthington, 2001; Lin et al., 1999; Plant et 
al., 2011). From genetic association studies, growing numbers of RA genetic risk factors have 
been uncovered in the past decades (Huizinga, 2003; McInnes and Schett, 2007; van der 
Helm-van Mil et al., 2005). The first and most well-established disease locus is HLA-DRB1, 
alleles in HLA-DRB1 region containing “shared epitope” confer disease risk, and account up 
to one third of the total genetic risk of susceptibility of RA (Cornélis et al., 1998; Gregersen et 
al., 1987). To date, most potential risk genes are found in the genes encoding molecules 
important to immune regulations, such as NF-κB, PTPN22 (protein tyrosine phosphatase, non 
receptor 22), CTLA4 (cytotoxic T-lymphocyte antigen 4), STAT4 and CD40, as well as those 
encoding pro-inflammatory cytokines (IL-10, IL-1β, IL-2 and IL-21) (Begovich et al., 2004; 
Cantagrel et al., 1999; Daha et al., 2009; Eskdale et al., 1998; Li et al., 2012b; Orozco et al., 
2010; Plenge et al., 2007; Remmers et al., 2007). Moreover, single nucleotide polymorphisms 
(SNPs) discovered in sequence encoding type IV peptidylarginine deiminase (PADI4), an 
enzyme believed to produce autoantigens by posttranslationally converting arginine residues 
to citrulline, are also reported to have association with susceptibility to RA(Suzuki et al., 
2003). It is worth mentioning that many of risk genes listed above are also related to other 
autoimmune diseases, such as Type 1 diabetes and systemic lupus erythematosus (SLE), 
implicating the shared mechanisms in these common autoimmune disease (Begovich et al., 
2004; Remmers et al., 2007). In addition, polymorphisms proved to be the risk factors in one 
population are not necessary to be the risk factors in other populations (Barton et al., 2004; 
Suzuki et al., 2003).  
1.1.3.2 Gender and Hormonal Factors 
Gender is probably the most important risk factors for RA. Since females have higher risk of 
developing RA, it is conceivable that sex hormones might also have a role in RA. Early study 
has found that RA patients have decreased levels of serum testosterone; the reduction of serum 
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testosterone levels occur prior to the onset of RA (Pikwer et al., 2013; Spector et al., 1988). 
The negative association of testosterone levels and risk of disease indicate the protective 
function of testosterone, and its potential to be a pre-clinical marker to predict the RA risk. No 
consensus has been achieved regarding to the effect of estrogen on RA. Serum levels of 
estrogen are normal in men with RA, but elevated local concentration of estrogen is 
discovered in Synovial Fluid (SF), which is believed to aggravate the disease (Cutolo et al., 
2003). Interestingly, women who take oral contraceptives containing high concentration of 
estrogen have a moderate decrease of RA risk (Doran et al., 2004). A possible explanation 
could be the different biological functions of systematically administered exogenous estrogen 
versus local endogenous estrogen. Additionally, female patients could have a “temporary 
exemption” from RA during the pregnancy due to the hormones changes in that period 
(Silman et al., 1992) 
1.1.3.3 Environmental Factors 
Several studies have indicated that smoking has a strong association with RA incidence as 
well as the disease activity and severity (Papadopoulos et al., 2005). Besides smoking, other 
forms of bronchial stress, such as exposure to silica and traffic pollution have also been 
confirmed as novel environmental risk factors for RA (Hart et al., 2009; Yahya et al., 2013). 
Other environmental factors associated with RA include obesity, blood transfusion, virus 
infection and stress (Cutolo and Straub, 2006; Meron et al., 2010; Symmons et al., 1997). On 
the other hand, coffee, tea and caffeine consumption don’t seem to be risk factors of RA, at 
least to women (Karlson et al., 2003; Mikuls et al., 2002).  
The development of RA is believed to depend on the interactions between multiple risk 
factors. Substantial evidence indicated that the interaction between the genetic background and 
environmental factors could have synergistic effect that greatly increases the risk of RA. For 
example, individuals who are genetically susceptible and cigarette smoking at the same time 
are at higher risk to develop RA than those with either of these risk factors alone (Costenbader 
et al., 2008; Lundström et al., 2009; Padyukov et al., 2004; van der Helm-van Mil et al., 2007; 
Verpoort et al., 2007). Taken together, understanding the role of various risk factors and the 
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interactions among them could help us to have a better knowledge in etiology, pathogenesis, 
as well as prevention and the treatment of RA. 
1.1.4 Management and Challenges in the Treatment of RA 
The goals of RA management and the treatment are relieving the swelling and pain, slowing 
down the progression of the disease, and preventing joint deformity and other extra-articular 
complications (American College of Rheumatology Subcommittee on Rheumatoid Arthritis 
Guidelines, 2002; Wasserman, 2011). Current RA treatment mainly relies on medications. 
However, invasive measures such as joint replacement surgery is also carefully considered in 
patients with unacceptable pain, lost joint motions or end-stage joint damage (American 
College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, 2002; Scott et 
al., 2010). Medications adopted in RA treatment fall into two main classes: non-steroidal anti-
inflammatory drugs (NASIDs) and disease-modifying anti-rheumatic drugs (DMARDs). In the 
first half of 19th century, NASIDs were first introduced to RA treatment for their symptomatic 
benefits as reducing the pain and stiffness of the affected joints. However, drugs of this class 
have limited impact on reducing disease activity and slowing down the disease progression 
(Upchurch and Kay, 2012). DMARDs were wildly accepted as the key therapeutic agents in 
the past two decades as they are able to modify the disease outcome such as, decelerating the 
progression of the disease, improving joints’ functions and reducing the disability (Scott et al., 
2010; Wasserman, 2011). DMARDs could be further divided into non-biologics and biologics. 
The first non-biologic DMARDs, gold salt, was reported on 1929, and many others were 
discovered thereafter (Hartung, 1943; Upchurch and Kay, 2012). Most of the early DMARDs 
are not recommended anymore for use today because of the high incidence of adverse events 
or poor tolerance (Saag et al., 2008). Currently, only five non-biologic DMARDs are included 
in the recommendations for the treatment of RA (Table 2) (Saag et al., 2008; Singh et al., 
2012). The biologic DMARDs are antibodies and cell surface receptor inhibitors that target 
key cytokines and molecules regulating the inflammatory responses in RA (McInnes and 
Schett, 2007). According to clinical studies and meta-analysis, it is safe to conclude that these 
biologic DMARDs are generally effective and safe, but whether they are superior to the 
conventional DMARDs is still inconclusive (Aaltonen et al., 2012; Breedveld et al., 2005; 
Keystone et al., 2004). However, the combination use of biologics and MTX is better tolerated 
 6 
and more efficacious than the use of either MTX or biologics alone (Aaltonen et al., 2012; Ash 
and Emery, 2012; Chen et al., 2006; Klareskog et al., 2004; Lipsky et al., 2000; Weinblatt et 
al., 1999). As immunosuppressive agents, elevated infection risk is the main adverse drug 
reaction observed in patients taking biologics to treat RA (Singh et al., 2011). There are 
currently five TNF-α blockers, one IL-1 receptor antagonist, one IL-6 blocker, one T cell co-
stimulation blocker, and one B cell stimulation blocker, approved by FDA and recommended 
by ACR for treatment of RA (Table 2) (Saag et al., 2008; Scott, 2012; Singh et al., 2012; 
2011).  
Table 1.2 DMARDs recommended by ACR 2008 and ACR 2012 
D
ru
gs
 ACR 2008 ACR2012 Function or 
Targets 
Adverse effects 
C
on
ve
nt
io
na
l 
D
M
A
R
D
s 
Hydroxychloroquine Hydroxychloroquine Antimicrobial Rare ocular toxicity 
Methotrexate (MTX) Methotrexate (MTX) Dihydrofolate reductase 
Liver effects, teratogenesis, hair 
loss, oral ulcers 
Sulfasalazine Sulfasalazine Folate depletion 
Anemia in G6PD deficiency, 
gastrointestinal effects 
Leflunomide Leflunomide Pyrimidine Liver effects, gastrointestinal effects, teratogenesis 
Minocycline Minocycline Antimicrobial 
Drug-induced lupus 
erythematosus, Clostridium 
difficile colitis 
     
B
io
lo
gi
c 
D
M
A
R
D
s 
Abatacept Abatacept CD28 Opportunistic infection 
Rituximab Rituximab CD20 
Infusion reaction, opportunistic 
infection, progressive multifocal 
leukoencephalopathy 
 Tocilizumab IL-6 Opportunistic infection 
Adalimumab Adalimumab 
TNF-α TB, opportunistic infection 
Etanercept Etanercept 
Infliximab Infliximab 
 Certolizumab pegol 
 Golimumab 
Adapted from Singh et al. and Wasserman et al. (Singh et al., 2012; Wasserman, 2011) 
Historically, newly diagnosed RA patients were first treated with NSAIDs and followed by 
DMARDs. But growing evidence have suggested that the early intervention of RA by 
DMARDs achieves significant reduction of radiographic progression in RA patients (Finckh et 
al., 2006). Since the past decade, more aggressive strategy has been adopted to treat early RA 
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(Upchurch and Kay, 2012). The ACR suggests patients to start DMARDs therapy within 3 
months of diagnosis, and with periodically reassessment of disease progression and update of 
treatment regimen accordingly (American College of Rheumatology Subcommittee on 
Rheumatoid Arthritis Guidelines, 2002). Single (monotherapy) or combination conventional 
with DMARDs (dual-therapy or triple therapy) is recommended to patients with different 
levels of disease and features of prognosis, regardless of disease duration. However, biologic 
DMARDs are used with more caution; early RA patients are not recommended to, except 
those one with high disease activity and poor prognosis; for established RA, biologic 
DMARDs are only considered after the failure of combination DMARDs therapy (American 
College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, 2002). In 
addition, tuberculosis has to be treated before using the biologic DMARDs (Saag et al., 2008; 
Singh et al., 2012).  
1.2 Collagen-Induced Arthritis (CIA) 
In 1977, Trentham et al. first reported that rat immunized with type II collagen in either 
complete Freund’s adjuvant (CFA) or incomplete Freund’s adjuvant (IFA) developes a 
chronic inflammatory arthritis, which they designated as Collagen-Induced Arthritis (CIA) 
(Trentham et al., 1977). A subsequent study hypothesized that there are two stages of disease 
development. In the first stage, as early as day 12 after the immunization, hyperplasia and 
fibrin deposition could be seen in the synovium; the second stage starts earliest on day19, it is 
characterized by the inflammatory cells infiltration, which form the pannus and cause the 
destruction of cartilage and bone eventually (Caulfield et al., 1982). Similar to the rat model, 
the CIA mouse model starts with edema and synovial hyperplasia, and is followed by 
infiltration of polymorphonuclear and mononuclear cells. As the disease progresses, pannus 
forms in the affected joins causing cartilage damage, and finally bone erosion (Courtenay et 
al., 1980).  
Since CIA resembles many pathological features found in RA, it is still the most wildly used 
model for studying the pathogenesis of human RA in animals, as well as a gold standard for 
testing the therapeutic drugs for RA in the pharmaceutical industry (Brand et al., 2007). 
During the past three decades, CIA model made substantial contributions to understand the 
 8 
role of individual cell types (T cells, B cells, master cells, etc) and cytokines (TNF-α, IL-1β, 
IL-17, etc) in RA (Brahn et al., 1992; Hom et al., 1992; Kadowaki et al., 1994; Morgan et al., 
2005; Nakae et al., 2003b; Nigrovic and Lee, 2005; Tada et al., 1996; Yanaba et al., 2007). 
Furthermore, the arthritogenicity of autoantibody was also revealed by the fact that the 
arthritis could be transferred by serum from rodents immunized with Collagen II (Stuart et al., 
1984). Of course, there are also certain discrepancies between CIA animal models and human 
RA.  For example, vasculitis which often could be found in RA, is not presented in CIA; on 
the other hand, periostitis develops in CIA but not in RA(Stuart et al., 1984). 
1.3 Mechanisms of RA 
1.3.1 Synovial Architecture of Normal Joint 
The synovial joints are the most common type of joints in our body, providing precise and 
smooth movement and maintain the stability and strength as well. The major components of 
synovial joints are synovial capsule and articulating bones; the outer layer of synovial capsule 
is a fibrous layer, uniting the articulating bones by attaching their periosteum linings; the inner 
layer is a one to three cell layer called synovial membrane which contains fibroblast-like 
synoviocytes and macrophages, secreting synovial fluid to fill up the synovial cavity. The 
synovial cavity is enclosed by the synovial capsule(Perlman and Pope, 2010). Synovial fluid 
contains high concentrations of hyaluronic acid and albumin; it absorbs shocks, and lubricates 
and nourishes the joint. The articulating bones are covered by a thin layer of connective tissue 
called cartilage, which is made up with a well-organized network of type II collagen fibers. 
These collagen fibers are produced by chondrocytes scattered in the cartilage. Importantly, 
there is no blood supply to articular cartilage, while its nourishment depends exclusively on 
synovial fluid. The synovial fluid also contains phagocytes which are responsible for cleaning 
up the tissue debris generated from wear and tear of cartilage in our daily life (Rogers, 2010).  
1.3.2 Architecture Changes of RA Joint 
The normal joint structure goes through a series of changes in RA. It involves synovial 
hyperplasia and lymphocyte infiltration. In RA, synovium increases its thickness, due to the 
synovial lining cell proliferation and blood-derived lymphocytes influx trough the vessel wall 
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into the synovium (Figure 1.1) (Konisti et al., 2012). Moreover, the increased cell numbers in 
the affected joint contribute to hypoxia and ischemia, posing a signal for angiogenesis; 
Neovessels exuberate the synovial inflammation by transporting more inflammatory cells and 
delivering nutrients and oxygen to the RA synovium (Marrelli et al., 2011). As inflammatory 
cells accumulate in the synovial membrane, where they protrude and form a unique structure 
called pannus. Pannus invades the cartilage and bone, and causes the cartilage degradation and 
bone erosion (McInnes and Schett, 2007; Neumann et al., 2010). 
 
Figure 1.1. Synovial architecture joint.  (a) normal joint; (b) joints affected by RA. Adapted 
from Strand V. et al. (Strand et al., 2007)  
1.3.3 Autoantigens, Autoantibodies and B cells 
The presence of autoantibodies in the serum and synovial fluids of RA patients has been 
known for a long time. Since the first description of  “a factor” that agglutinate sheep blood 
cells (late designated as rheumatoid factor (RF)), growing number of autoantibodies have been 
discovered, and some of them are utilized in clinical diagnostics (Bläss et al., 1999; Waaler, 
1940). While most attention to the autoantibodies is focused on their diagnostic value, less 
contemplation has been given to their role in the pathogenesis of RA. In fact, how those 
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normal molecules turn into “autoantigens”, and stimulate the production of autoantibodies is 
the fundamental question that needs to be answered. The followings are four most prominent 
pairs of autoantigen and autoantibodies related to RA. 
1.3.3.1 Rheumatoid Factor 
Rheumatoid factor (RF) was first discovered in 1940s and later identified as antibodies that 
bind the Fc region of Ig (FRANKLIN et al., 1957; Waaler, 1940).It was quickly included as a 
criterion for clinical diagnosis of RA in 1958, and remains the exclusive diagnostic 
autoantibody for more than 50 years (Aletaha et al., 2010; Arnett et al., 1988; Committee of 
the American Rheumatism Association, 2008). Healthy humans or animals are reported to 
produce a transient wave of RFs after vaccination or immunization, while 80% of RA patients 
have persistent increased level of RF in sera(Coulie and Van Snick, 1983; M J Welch, 1983; 
Nell et al., 2005). The physiological roles of RFs are 1) promoting complement fixation, 2) 
helping the clearance of immune complexes (IC), and 3) increasing the avidity and specific of 
functional antibodies(Carson et al., 1987). RF is believed to be pathogenic in RA as it induces 
the RA-related cytokines production. Early studies have shown that RF induces monocytes to 
produce prostaglandin E2 and mononuclear cell factor (MCF), two potent stimulator of bone 
resorption (Gowen et al., 1983; Nardella et al., 1983). Moreover, IC formed by RF and 
immunoglobulin (Ig) from arthritic synovial tissue has been demonstrated to stimulate the 
production of TNFs from monocytes (Ishikawa et al., 1975; Mathsson et al., 2006).  
1.3.3.2 Anti-Citrullinated Protein Antibody (ACPA) 
Citrullination is a biological process of converting amino acid arginine into citrulline; it is 
conducted by peptidylarginine deminase enzymes (PAD), which have 5 isoforms (PAD1, 2, 3, 
4/5 and 6)(Vossenaar et al., 2003). Many essential physiological activities require PADs, such 
as embryo development, electrical insulation in the nervous system and transcriptional control 
for DNA, and so on (Vossenaar et al., 2003). Citrullination may also occur under certain 
pathogenic conditions, notably in RA, producing autoantigens. Both PADs (2 and 4) and 
citrullinated protein (fibrinogen, fibronectin, vimentin and Collagen II) are found in affected 
RA joints, but not healthy joints (Baeten et al., 2001; Kinloch et al., 2008; Tabushi et al.; 
Vossenaar et al., 2004; Yoshida et al., 2006). Anti-citrullinated protein antibodies (ACPAs) 
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are antibodies against citrullinated proteins of various origins. They are present in around 70% 
of RA patients, and included in the RA classification criteria, due to their high specificity for 
RA (90-95% compare to 40-90% of RF) and strong association with a severe disease status 
(Aggarwal et al., 2009; Aletaha et al., 2010; Schellekens et al., 2000). Generally, citrullination 
of protein and their further conjugation with their autoantibodies increase their 
immunogenicity and arthritogenicity (Lundberg et al., 2005; Shelef et al., 2012; Sokolove et 
al., 2011). For examples, citrullinated fibrinogen (cFib) and myelin binding protein, but not 
their natural forms, are capable of activating basophils from ACPA+ RA patients (Schuerwegh 
et al., 2010). Both cFib and cFib-IC are more potent in inducing TNF production from 
macrophages compared to the natural form of fibrinogen (Clavel et al., 2008; Sokolove et al., 
2011). In vivo, immunizing rat with citrullinated Collagen II (cCII) in incomplete Freund’s 
adjuvant (IFA) induces earlier arthritis with higher incidences than with natural CII (Lundberg 
et al., 2005). Immunization with cFib but not natural fibrinogen in CFA or intra-articular 
administration of cFib plus transferring of cFib-specific T cells induces arthritis in mice 
carrying a RA susceptible MHC-II allele (Hill et al., 2008). The ACPAs might not be 
pathogenic under a healthy condition, but they could play a role in aggravating the disease 
after the onset of arthritis (Kuhn et al., 2006). A novel study discovered that ACPAs could 
bind to the citrullinated vimentin on osteoclast precursor cells and promote their 
differentiation into osteoclasts, leading to the bone erosion and joint destruction (Harre et al., 
2012).These results are in accordance with the clinical finding that the presence of ACPAs in 
serum is usually related to the more advanced bone erosion condition in RA (Aggarwal et al., 
2009). 
1.3.3.3 Anti-Collagen II (CII) Antibody 
Type II collagen (collagen II, CII) is the major component of articular cartilage in joints. The 
association between RA and CII antibodies has been found in the several clinical studies. The 
presence of anti-CII antibodies in serum is observed in about 30% of RA patients with 
indications of an early inflammatory/destructive disease phenotype (Beard et al., 1980; Cook 
et al., 1996; Fujii et al., 1992; Mullazehi et al., 2007; 2012; Raza et al., 2007; S et al., 1988). 
Anti-CII antibodies are also found in the synovial fluids of some RA patients who are 
genetically HLA-DR4 positive (Rönnelid et al., 1994). Both CII and anti-CII antibody are 
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arthritogenic: immunization of CII emulsified with either IFA or CFA induces arthritis in rat 
and mice (Courtenay et al., 1980; Trentham et al., 1977; 1978). The pathogenic role of anti-
CII antibodies has been demonstrated by successful induction of arthritis in naïve rats/mice 
passively transferred with anti-CII antibodies-containing sera from CIA rats/mice; it has been 
further confirmed by the fact that direct administration of combination of anti-CII monoclonal 
antibodies caused full-blown arthritis (HOLMDAHL et al., 1990; Stuart and Dixon, 1983; 
Stuart et al., 1982; Terato et al., 1992). Moreover, anti-CII antibodies have been reported to 
cause thickening, aggregation and disorganization of CII fibrils in newly synthesized 
extracellular matrix (ECM), as well as alter the secretion rate of matrix metalloproteinase 
(MMPs) in culture, by interfering chondrocytes (Takagi and Jasin, 1992). Furthermore, CII-
ICs have been shown to activate PBMCs and induce RA-like disease pro-inflammatory 
cytokine (TNF-α, IL-1β and IL-8) production (Mullazehi et al., 2006).  
1.3.3.4 Anti-Glucose-6-Phosphate Isomerase (GPI) Antibody 
The pathogenic role of GPI and its antibody in RA was discovered by chance. When 
transgenic mice overexpressing the TCR that recognizes peptide of bovine pancreas 
ribonuclease (RNase) in the context of Ak (KRN TCR) are crossed with NOD mice which bear 
a unique MHC-II (I-Ag7), the transgenic offspring (K/BxN) exhibits spontaneous 
inflammatory arthritis (Kouskoff et al., 1996). GPI, a ubiquitously expressed enzyme 
converting glucose-6-phosphate into fructose-6-phosphate, is later identified as the 
autoantigen in this arthritis murine model (Matsumoto et al., 1999). In the joints of arthritic 
K/BxN mice, thick linings of GPI molecules, accompanied by the deposition of IgG and C3 
complement fragments could be seen on the surface of cartilage, synovium and pannus 
(Matsumoto et al., 2002). Accordantly, extremely high level of anti-GPI antibody is presented 
in the serum of K/BxN mice (Matsumoto et al., 2002). The mechanistic study has revealed that 
the joint inflammation in this particular arthritic model is caused by the GPI-IC formed in the 
joints which triggers the alternative complement pathway activation (Maccioni et al., 2002; 
Matsumoto et al., 2002). In the clinical study, deposition of GPI molecules is also observed in 
the synovial tissues from RA patients. However, most studies have shown anti-GPI antibodies 
are either rarely or non-specifically detected in RA serum (Kassahn et al., 2002; Matsumoto et 
al., 2003; Schaller et al., 2001; Schubert et al., 2002). Collectively, although the anti-GPI 
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antibody is proved to be athrogenic in mice, whether it is involved in the initiation and 
development of human RA is still unclear.  
1.3.3.5 Other Autoantigens and Autoantibodies 
In addition to those mentioned above, many other autoantigens and autoantibodies have been 
found related to RA. Some of them have potential to be novel diagnostic markers, while others 
attract less attention due to the inconsistent data and low disease specificities. Some of them 
are listed in Table 1.3. 
Table 1.3 Autoantigens and autoantibodies found in rheumatoid arthritis 
Autoantigen Target Disease Reference 
Articular 
components 
Chondrocyte 
membranes (CH65)  
RA (Bang et al., 1994; Steinert et al., 
1985) 
HC gp39 (YKL-40)  OA, RA (Hakala et al., 1993; JOHANSEN 
et al., 1996) 
Osteopontin OA, RA (Sakata et al., 2001) 
Ubiquitous Heterogeneous nuclear 
ribonucleoprotein A2 
(Ra33 or hnRNP A2) 
SLE, RA (Hassfeld et al., 1989; 1995) 
Calpstatin SLE, RA (Mimori et al., 1995) 
BiP  (Bläss et al., 1995; 2001) 
 α-enolase Autoimmune 
retinopathy, RA 
(Kurz et al., 2011; Saulot et al., 
2002) 
Cytokines B7-H1 (PD-L1)  RA (Dong et al., 2003) 
IL-1α RA (Hansen et al., 1994) 
IL-8 Myasthenia gravis, 
RA 
(Burbelo et al.; Peichl et al., 1992) 
 
In summary, there are three possibilities for the pathogenic roles of a pair of autoantigen and 
its autoantibody. First, autoantigen is pathogenic by itself. Natural or modified proteins could 
become autoantigens and involved in the pathogenesis of RA by inducing the pro-
inflammatory cytokine production, angiogenesis and synoviocyte proliferation (Sokolove et 
al., 2011; Yoo et al., 2012). Importantly, these autoantigens are not necessarily to be the joint 
exclusive proteins. However it is crucial for them to be present in the joint tissues of 
individuals with certain genetic background, given that immunization of these autoantigens is 
only able to induce arthritis in mice with the susceptible genetic background. Second, free Abs 
could be pathogenic. Certain autoantibodies such as anti-CII or anti-calpastatin Abs are able to 
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interfere with the interactions among cartilage proteins in joints, and cause degradation of 
cartilage components (Amirahmadi et al., 2005; Ménard and el-Amine, 1996). Third, 
autoantigen and its autoantibody contribute to the RA by forming immune complexes (IC). 
Transferring sera (or IgG fraction but not IC fraction) from CIA or K/BxN arthritic mice to 
naive mice causes arthritis (HOLMDAHL et al., 1990; Korganow et al., 1999; Matsumoto et 
al., 1999; Stuart and Dixon, 1983; Stuart et al., 1982; Terato et al., 1992). In accordance, anti-
GPI autoantibodies have been reported to locate to distal joints within minutes after 
intravenous injection, whereas preformed ICs have difficulties to get into the joints (Wipke et 
al., 2002). It is believed that the autoantibody penetrates into the joints, forms articular ICs 
with pre-deposited autoantigens (like GPI or cCII), and initiates the disease (Matsumoto et al., 
1999). These ICs then bind to the FcγR on the surface of monocytes/macrophages and induce 
the production of TNF, IL-1β, and IL-8 (Mathsson et al., 2006; Mullazehi et al., 2006; 
Sokolove et al., 2011). Besides FcγR, ICs are also reported to interact with toll-like receptor 4 
(TLR4), which works synergistically with FcγR and elevates the TNF production by 
macrophage (Sokolove et al., 2011). More detailed in vivo studies using knockout mice have 
revealed that FcγRI and FcγRIII are responsible for the successful induction of CIA or 
antibody-induced arthritis (AIA) (Kleinau et al., 2000; Nandakumar et al., 2003a). 
1.3.3.6 Functions of B cells Other Than Producing Autoantibodies 
In addition to producing autoantibodies, several novel roles B cells playing in RA have been 
discovered by recent studies. Firstly, B cell is able to serve as an APC for autoreactive T cells. 
In a proteoglycan induced arthritis (PGIA) model, when transferring T cells from proteoglycan 
(PG)-immunized Ig-deficient mice to SCID mice, only those T cells that received adequate 
priming from cognate B cells are able to elicit the disease (O'Neill et al., 2005). A later study 
from the same group has shown that CD80/CD86, two costimulatory molecules expressed on 
B cells, are essential for the activation of autoreactive T cells in PGIA (O'Neill et al., 2007). 
Accordant with animal studies, a human study has also reported that B cell is essential for the 
activation of synovial follicular T cells, since adoptively transferred follicular CD4 T cells 
fails to get activated and secret pro-inflammatory cytokines in SCID mice chimeras with 
human RA tissues lacking B cells (Takemura et al., 2001). Secondly, B cell could affect the 
pathogenesis of RA by secreting cytokines. The B cells are reported to secrete various 
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cytokines to promote inflammation (TNF, IL-1, IL-6, G-CSF, GM-CSF and IL-12) and 
angiogenesis (VEGF-A), two prominent features in RA (Angeli et al., 2006; Pistoia, 1997). On 
the other hand, a novel subset of B cells called B regulatory cells have been discovered to 
attenuate the harmful immune responses by secreting IL-10 and TGF-β (Mizoguchi and Bhan, 
2006).  Two studies have shown that regulatory B cells ameliorate CIA in DBA mice through 
the secretion of IL-10 (Evans et al., 2007; Mauri et al., 2003).  
1.3.4 T cells 
1.3.4.1 Th1 and Th2 Cells 
Th1 cells produce IFN-γ, which primarily activates macrophages and mediates the immune 
responses against intracellular infections (Kindt et al., 2007; Szabo et al., 2000). Th2 cells 
secrete IL-4, 5, 10 and 13 and are responsible for humoral responses to protect against 
infections from extracellular pathogens (Kindt et al., 2007). Early studies on RA patients 
found mRNA expression of IL-12 and IFN-γ in RA synovial fluid mononuclear cells, and 
identified Th1 cells as the predominant T cell subsets in synovial fluid (SF) from RA patients 
(Bucht et al., 1996; Kusaba et al., 1998; Morita et al., 1998). Th2 cytokine-producing cells are 
also detectable in the synovial tissues and peripheral blood of RA patients, but at a 
significantly lower frequency comparing to cells producing Th1 cytokines (Kusaba et al., 
1998; Morita et al., 1998; Yudoh et al., 2000). Messenger RNA levels of IL-4 and IL-10 in 
synoviocytes become significantly lower as RA progresses (Miyata et al., 2000). It was 
believed that Th1 responses are generally associated with inflammation, whereas Th2 
responses are protective to some extent. Based on this belief and clinical findings, a Th1/Th2 
imbalance hypothesis is proposed for the pathogenesis of RA. However, emerging evidence 
from animal studies have shown complicated role of Th1 and Th2 cells in RA. 
IFN-γ receptor deficient mice are more susceptible to CIA, and this is accompanied by 
accelerated and exacerbated disease, but less anti-CII antibodies (Manoury-Schwartz et al., 
1997; Vermeire et al., 1997). More detailed studies by the same group and other groups have 
been performed to understand the protective role of this cytokine. The possible mechanisms 
are as follows: 1) the presence of IFN-γ signaling suppresses the arthritogenic myelopoiesis of 
the splenic Mac-1+ cells elicited by the mycobacterial component of CFA (Matthys et al., 
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2001). Using IFA instead of CFA for immunization or inhibition of CFA-induced splenic 
Mac-1+ cell expansion abolishes the exacerbated CIA in IFN-γ receptor KO mice (Matthys et 
al., 1999). 2) It is suggested by the same group that deficiency in IFN-γ signaling diminishes 
the function of Treg cells by bringing down Foxp3 transcription levels in Treg, and also 
dampens the function of APC cells (Kelchtermans et al., 2005). This finding is in accordance 
with recent discovery of regulatory role of IFN-γ (Wood and Sawitzki, 2006). 3) Two studies 
using streptococcal cell wall (SCW)-induced arthritis in rat have shown IFN-γ inhibits 
leukocyte chemotactic migration to the synovium, and prostaglandin E2 (PGE2) production 
and synoviocytes proliferation, indicting IFN-γ could suppress the arthritis through 
suppressing the mesenchymal cells (Allen et al., 1991; Wahl et al., 1991). 4) IFN-γ suppresses 
the Th17 cells. It is known that IFN-γ suppresses the in vitro differentiation of IL-17-
producing Th17 cells (Bettelli et al., 2008). In vivo, neutralization of IFN-γ in CIA increases 
circulating and articular levels of IL-17, which causes accelerated disease (Sarkar et al., 2009). 
IFN-γ knockout mice in antigen-induced arthritis (AIA) have similar phenotypes as IFN-γ 
receptor deficiency mice in CIA; Articular administration of IFN-γ or treatments with mAb 
neutralizing IL-17 alleviates the disease (Irmler et al., 2007). It is suggested that deficiency of 
IFN-γ releases the suppression of IL-17 and leads to the aggravated disease (Irmler et al., 
2007). A controversial result has been reported recently showing reduced arthritis in IFN-γ 
receptor KO mice in glucose-6-phosphate isomerase (G6PI)-induced arthritis (Frey et al., 
2011). Doodes et al. has shown similar results using IFN-γ KO mouse models of 
proteoglycan-induced arthritis model (Doodes et al., 2010). Although IFN-γ is implied to 
exacerbate the arthritis in their findings, the suppressions of IL-17 production by IFN- γ in 
these studies are still obvious and negatively correlate with the disease (Doodes et al., 2010; 
Frey et al., 2011). Collectively, either IFN-γ or IL-17 alone is pathogenic in RA. The latter is 
much more avid, but is negatively regulated by the former. When the disease condition is in 
favor of IL-17 production, IFN-γ exhibits a protective role. Otherwise, IFN-γ would be 
pathogenic for the disease. 
Administration of exogenous IL-4 reduces the histological score, pathogenic anti-CII 
antibodies’ level and pro-inflammatory cytokine secretion by joint tissues in CIA mice 
(Horsfall et al., 1997). Similar results are obtained when treating the mice with IL-4 or IL-10, 
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or both, in PGIA and SCW models (Finnegan et al., 2003; Lubberts et al., 1998). More 
specifically, either systemic administration or articular overexpression of IL-4 appears to 
protect against bone destruction of CIA (Joosten et al., 1999; Lubberts et al., 2000a). The 
protective effect of IL-4 against bone destruction is through the suppression of IL-6 and LIF, 
and inhibition of osteoclasts (Miossec et al., 1994). Conversely, depletion of IL-4 or IL-10 has 
caused elevated disease in several different arthritis models (Finnegan et al., 2003; 2002; Hata 
et al., 2004). The change of disease caused by adding or removal of IL-4 is closely associated 
with the levels of specific arthritogenic IgG2a, indicating the IL-4 may prevent the class 
switching towards the pathogenic IgG isotope (Brand et al., 2003; Finnegan et al., 2002; 
Horsfall et al., 1997; Joosten et al., 1999; Kim et al., 2001b; Myers et al., 2002). IL-10 also 
confers a protective role in RA. It reduces TNF-α and IL-1 secretion from cultured synovial 
membrane tissues of RA patients, and costimulatory molecule expression of synovial 
cells(Katsikis et al., 1994; Kawakami et al., 1997). A Korean group has reported that the IL-10 
suppresses the arthritis by diminishing IL-17 expression and inducing the Treg cells 
generation (Heo et al., 2010). Furthermore, IL-10 has an additive effect, or even a synergistic 
effect with IL-4 on the inhibition of proinflammatory cytokine production by activated 
mononuclear cells from RA patients (van Roon et al., 1996). In the SCW arthritis model, 
administration of IL-10 with IL-4 reduces both IL-1β and TNF-α levels in the synovium, while 
IL-10 alone only brings down the latter cytokine (Lubberts et al., 1998). In addition, IL-10 and 
IL-4 were also reported to have additive effect on stimulating the cartilage proteoglycan 
synthesis (van Roon et al., 1996). While most studies acknowledge the protective role of IL-4 
in RA, there is a recent study implying that IL-4 can be pathogenic. In the K/BxN model, IL-4 
has been demonstrated to be essential in initiating the arthritis by activating B cells (Ohmura 
et al., 2005). This result indicates that different settings of the arthritis models and genetic 
backgrounds could change the disease phenotypes drastically.  
1.3.4.2 Th17 Cells 
Th17 is a T cell lineage, producing a distinct cytokine profile including IL-17, IL-21 and IL-
22. It is the major source of IL-17 (Weaver et al., 2006). IL-17, also known as IL-17A, 
belongs to the IL-17 family, which contains 7 different members. It is a potent 
proinflammatory cytokine and plays an essential role in autoimmune diseases (Gaffen, 2008). 
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Elevated IL-17 levels are observed in sera and synovial fluids from RA patients (Hussein et 
al., 2008; Kotake et al., 1999; Ziolkowska et al., 2000). The target cells of IL-17 in RA include 
synovial fibroblasts, macrophages, chondrocytes and osteoblasts, all of which are directly 
related to the pathogenesis of RA (van den Berg and Miossec, 2009). IL-17 alone, or 
synergistically with IL-1β or TNF-α, induces the production of IL-6, IL-8, granulocyte-
colony-stimulating factor (G-CSF), prostaglandin E2 (PEG2) and leukemia inhibitory factor 
(LIF) by synoviocytes (Chabaud et al., 1998; Fossiez et al., 1996). In a Th17 cell and synovial 
fibroblast co-culture system, IL-17 increases the secretion of matrix metalloproteinase-1, -3 
(MMP-1, -3), as well as IL-6 and IL-8, by synovial fibroblasts. Synovial fibroblasts, on the 
other hand, increase autocrine IL-17 production by Th17 cells through the cyclooxygenase 
(COX)/PEG2 pathway. Together, they built up a proinflammatory loop contributing to the 
pathogenesis of RA (Paulissen et al., 2013; van Hamburg et al., 2010). In addition, IL-17 has 
been reported to promote the survival of synovial fibroblasts (Lee et al., 2013). A similar 
proinflammatory loop is suspected to exist between IL-17 and synovial macrophages too. IL-
17 stimulates macrophages and upregulates their arthritogenic cytokine (such as IL-1β and 
TNF-α) production, and synovial macrophages could, in turn, support the generation of Th17 
cells (Egan et al., 2008; Jovanovic et al., 1998). Moreover, IL-17 was also suggested to 
promote the migration of macrophages (Shahrara et al., 2009; 2010). Chondrocytes are 
believed to be the target of IL-17 in RA as well. Chondrocytes stimulated with IL-17 elevate 
the production of nitro oxide (NO), inducible nitric oxide synthase (iNOS) and COX-2, as well 
as IL-1β, IL-6 and stromelysin; NO and IL-1β then cause cartilage proteoglycan (PG) loss and 
inhibit its synthesis in chondrocyte (Lubberts et al., 2000b; Shalom-Barak et al., 1998). IL-
17’s function on osteoclastogenesis was first demonstrated by a mouse hematopoietic cell and 
primary osteoblast co-culture system. Adding IL-17 stimulates PEG2 synthesis and elevates 
osteoclast differentiation factor (ODF) mRNA levels of osteoblasts. This then promotes the 
differentiation of osteoclasts in a cell-cell contacting fashion (Kotake et al., 1999). 
Mechanistically, it was suggested that IL-17 breaks the balance of the receptor activator of 
NF-κB ligand (RANKL)/RANK pathway, leading to osteoclastogenesis (Lubberts et al., 
2003). Various arthritis murine models have been used in the in vivo studies of the essential 
roles of IL-17 in RA. Intra-articular injection of IL-17 could induce cartilage degradation in 
naive mice (Chabaud et al., 2001). Articular-specific adenoviral overexpression of IL-17 
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exacerbates the disease in terms of joint inflammation, cartilage degradation and bone erosion 
in CIA mice (Lubberts et al., 2003). Conversely, knockout of IL-17 or treatment with IL-17 
antagonist antibodies confers great protective effect to mice in experimental arthritis models 
(Bush et al., 2002; Lubberts et al., 2004; Nakae et al., 2003a).  
IL-22, another Th17 cell cytokine, could also be produced by synovial fibroblasts and 
macrophages (Ikeuchi et al., 2005). A recent report have shown IL-22-/- mice are less 
susceptible to CIA and have decreased disease incidence and clinical score, and oddly, higher 
levels of anti-CII IgG2c comparing to WT counterparts (Geboes et al., 2009). In vitro study in 
the same model has also revealed show that IL-22, similar to IL-17, could promote 
osteoclastogenesis (Geboes et al., 2009). Human studies have demonstrated that increased IL-
22 serum levels are associated with the disease progression of RA, and its mRNA is detected 
in synovial tissues and macrophages from RA patients (Leipe et al., 2011). These findings 
indicate the potential role of IL-22 in RA. 
IL-21 is a type I cytokine, produced by CD4 T cells and NKT cells. The most well known 
function of IL-21 is to drive B cells to differentiate into plasma cells (Spolski and Leonard, 
2008). Besides its function on B cells, IL-21 could act as an autocrine to regulate Th17 cells 
and induce RANKL expression and enhance the osteoclastogenesis in RA (Kwok et al., 2012). 
Niu et al. have discovered that IL-21 promotes the proliferation of Th17 cells while suppresses 
Treg cells, and the levels of IL-21 in serum and synovial fluids from RA patients are 
correlated to the percentage of Th17 cells (Niu et al., 2010). IL-21 is also detected in cultured 
synovial membrane cells from RA patients, and blocking IL-21 signaling in this culture 
system significantly downregulates TNF-α, IL-6 and IL-1β productions in these cells 
(Andersson et al., 2008). Recent animal studies have also shown an elevated level of IL-21 in 
the serum and synovium of mice with CIA (Kwok et al., 2012).  
1.3.4.3 CD4 Treg cells 
CD4+ Treg cells express cell surface marker CD25 and transcription factor forkhead box P3 
(FoxP3). They are inhibitory in the immune system and prevent the autoimmunity (Bacchetta 
et al., 2006; Shevach, 2009; Wildin et al., 2001). Treg cells could work on a wide variety of 
immune cells including T cells, DCs, B cells, macrophage, osteoblasts, mast cells, NK cells, 
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NK T cells and so on. They suppress immune responses by 1) directly targeting on T cells, 
inducing cell cycle arrest and apoptosis, and inhibiting cytokine production (Gondek et al., 
2005; Pandiyan et al., 2007; Taylor et al., 2006); or 2) indirectly, through antigen presenting 
cells (APCs), inhibiting their maturation and providing the costimulatory signals to the T 
cells(Borsellino et al., 2007; Liang et al., 2008; Sarris et al., 2008; Shalev et al., 2008; 
Shevach, 2009; Wing et al., 2008). 
Treg cells play an active role in the mouse arthritis model. Mice depleted of Tregs have much 
severer CIA. Adoptive transfer of Treg to Treg-depleted or normal mice decreases clinical 
scores but not autoantibody levels, which might be a consequence of reduced serum levels of 
TNF and IL-6 (Kelchtermans et al., 2009; Morgan et al., 2005; 2003). Similar results have 
been obtained from antigen-induced arthritis (AIA) model as well (Frey et al., 2005). Studies 
focused on circulating Treg number changes in RA patients haven’t reached a 
consensus(Chavele and Ehrenstein, 2011). Although the presence of Treg cells in the synovial 
tissue and peripheral blood of RA patients is well documented, mechanism studies of Treg 
cells on human RA yield mixed results. Several studies reported that CD4+CD25+FoxP3+ Treg 
cells isolated from SF of RA patients show normal suppressive effect on the proliferation of 
CD4 T cells (Cao et al., 2003; Lawson et al., 2006; Möttönen et al., 2005), whereas others 
suggested that the suppressive effect of Treg cells from RA synovial tissue is compromised 
(Ehrenstein et al., 2004; Skapenko et al., 2005). One study has demonstrated that Treg cells 
from SF of RA patient show stronger suppressive ability compare to those from PB, but the 
synovial T effector cells are less susceptible for Treg suppression (van Amelsfort et al., 2004). 
Similarly, Ohata et al. have shown that effector T cells from a later stage of mouse CIA are 
more resistant to the suppression (Ohata et al., 2007). It has been suggested by another study 
that the resistance acquired by effector T cells is probably induced by IL-6 produced by DC 
(Pasare and Medzhitov, 2003). On the other hand, two studies have found that the Treg cells 
from RA PBMC are capable of suppressing the T cell proliferation, but are defective in 
suppressing proinflammatory cytokine production (Ehrenstein et al., 2004; Valencia et al., 
2006). Mechanistically, the malfunction of CTLA-4 expression and recruitment to the 
immunological synapse may cause the abnormal Treg function in RA (Flores-Borja et al., 
2008). Furthermore, a recent study has identified Ser418a, phosphorylation site of FoxP3, 
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which is dephosphorylated by the TNF-α-induced protein phosphatase 1(PP1) in the RA 
synovium. Dephosphorylation of Ser418 severely impairs the transcription of FoxP3, and 
consequently the function of Treg cells(Nie et al., 2013).  
1.3.4.4 Tfh Cells 
The description of Tfh first appeared around 2000, when several studies reported a T cell 
population from human tonsils expressing CXCR5 and capable of promoting the B cell 
antibody production (Breitfeld et al., 2000; Kim et al., 2001a; Schaerli et al., 2000). Tfh cells 
were reported to express high levels of ICOS and CD40L on their cell surface, and secrete 
various cytokines including IL-4, IL-5, IL-13, IL-17, IL-21 and IFN-γ(Crotty, 2011). 
Although few studies have been conducted to investigate the pathogenic role of Tfh in RA, it 
is conceivable that the mechanism of Tfh in RA has to be related to the production of the 
autoantibodies. In mouse CIA, blocking B7RP-1, the ICOS ligand, significantly lowers down 
the disease incidence and clinical score due to the reduction of Tfh cells as well as anti-CII 
antibodies (Hu et al., 2009). Dysregulation of Tfh cells could break the immune tolerance by 
providing inappropriate helps to autoreactive B cells (Leavenworth et al., 2013; Lim et al., 
2004; Vinuesa et al., 2005). For example, Sanroque mice, defective in ring-type ubiquitin 
ligase which playing suppressive role in regulating Tfh cells, gain features of lupus due to the 
excessive Tfh cells and GCs (Linterman et al., 2009). Elevated circulating Tfh cell percentages 
are also observed in a subset of SLE patient (Simpson et al., 2010). Similar finding in RA 
were reported by several Chinese groups showing a correlation between the increased 
frequencies of peripheral Tfh-like cells (CXCR5+PD-1+CD4+) and serum level of IL-21 and 
ACPA, as well as disease active score (DAS28) (Liu et al., 2012; Ma et al., 2012; Wang et al., 
2013). One of these studies further showed that the percentage of Tfh cells decreased 
significantly in the drug-responding patients after the treatment with DMARDs (Wang et al., 
2013).  
1.3.4.5 CD8 T Cells 
CD8 T cell knockout in B10.Q mice shows negligible effects other than delaying the disease 
onset of CIA (Ehinger et al., 2001). In transgenic mice (B6/129 background) overexpressing 
human RA-susceptible gene HLA-DQ8, CD8 deficiency increases the incidence and severity, 
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as well as autoantibody levels (Taneja et al., 2002). CD8 T cell knockout mice in the DBA 
background have a significantly lower incidence of CIA than their heterozygous counterparts 
(Tada et al., 1996). Depletion of CD8 T cells in K/BxN mice ameliorates the spontaneous 
arthritis, whereas transfering SKG CD8 T cells to nude mice elicits arthritis (Raposo et al., 
2010; Wakasa-Morimoto et al., 2008). The presence of CD8 T cell affects the pathogenesis of 
arthritis, but whether it protects or aggravates the autoimmune disease is still under debate. 
Recently, two studies found that CD8 regulatory T cells (CD8 Treg) in CIA mice showing 
strong inhibition of the disease by eliminating the autoreactive Tfh and Th17 cells 
(Leavenworth et al., 2013; Notley et al., 2010). On the other hand, two autoreactive CD8 T 
cell clones that able to kill syngeneic synovial cells are identified in the SKG mice mentioned 
above (Wakasa-Morimoto et al., 2008).  
Similar situations are also observed in human studies. In synovial fluids from RA patients, 
CD8+ T cells comprise around 40% of T cells (McInnes, 2003). One study has reported that 
15.5% percent of synovial CD8+ T cells from different patients recognize a single EBV 
epitope, and secrete proinflammatory cytokines upon stimulation of this peptide (Tan et al., 
2000). Analysis of T cell subsets and cytokine production in RA patients has also reveled a 
direct correlation between synovial CD8+ T cells and disease severity (Hussein et al., 2008). 
Based on the cytokine production profiles, CD8+ T cells of human origin could be classified 
into 3 subsets: Tc1, producing IFN-γ and other cytokines but no IL-4; Tc0, producing IL-4, 
IFN-γ and other cytokines; and Tc2 producing IL-4 but no IFN-γ (Vukmanovic-Stejic et al.). 
A study showed that the RA patients have significantly higher percentage of Tc1 in their 
synovial fluid (SF), but not in their peripheral blood (PB). Interestingly, the percentage of IL-
10-producing Tc2 cells in the SF is unregulated in the same group of patients(Berner et al., 
2000). These Tc2 cells are generally believed to be human regulatory/suppressive CD8 T 
cells, and exhibit suppressive phonotype upon their specific peptide stimulation(Bodman-
Smith et al., 2003). In addition to Tc0, Tc1 and Tc2, a special fraction of CD8 T cell 
exclusively localized in the synovial membranes is found to regulate the ectopic GC 
formation(Wagner et al., 1998). It is characterized by expressing CD40L and producing IFN-γ, 
but not having perforin, the pore-forming enzyme (Wagner et al., 1998). Depletion of these 
synovial CD8 T cells results in GC dissociation, disappearance of follicular dendritic cell 
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(FDC) and reduced Ig productions, although the detailed mechanisms are yet unknown(Kang, 
2002; Wagner et al., 1998). Collectively, these results indicate that the total CD8 T cell pool 
might contain different subpopulations of CD8 T cells that play distinct roles. Thus, a 
plausible explanation to the discrepancies found in the animal studies as well as RA patients 
could be that different strains of animals and methods of arthritis induction may result in 
variation of the CD8 T cell pools. The composition of CD8 T cell pools would decide the net 
effect of total CD8 T cells. 
1.3.5 Monocytes/Macrophages 
Macrophages appear in RA joints at a very early phase of RA(Singh et al., 2004). The number 
of macrophages on the synovial lining and sub-lining is correlated with either early joint pain 
or later stage symptom like articular destruction (Mulherin et al., 1996; Tak et al., 1997). It has 
been suggested that most RA synovial macrophages are derived from infiltrated pre-activated 
monocytes from peripheral blood. These macrophages have prolonged survival and 
constitutive activation status, but less proliferation (Catrina et al., 2005; Ceponis et al., 1998; 
Huang et al., 2007). Synovial macrophages play a central role in RA. It affects every stage of 
disease progression by producing a broad spectrum of cytokines in the RA synovium (Kinne et 
al., 2000). Depletion of macrophages alleviates the experimental arthritis (Brühl et al., 2007; 
Li et al., 2012a; Misharin et al., 2012). The major cytokines produced by macrophage and 
their potential functions in RA are listed in Table 1.4.  
Table 1.4 Monocyte/macrophage cytokines and their potential functions 
Family Cytokine Target Function 
IL-1 
IL-1α/β 
SF Activation, ↑ cytokine, chemokine, MMP, iNOS and PG release; 
MN ↑ cytokine, ROI and PG release, osteoclast activation 
CD ↓GAG synthesis, 
EN iNOS, MMP and aggrecanase, adhesion molecule expression 
IL-18 
EN ↑Angiogenesis (Koch, 2003) 
Th ↑Th1 differentiation 
NK ↑Activation, cytokine release and cytotoxicity 
CD ↓GAG synthesis, iNOS expression 
MN ↑Cytokine release and adhesion molecule expression 
PMN ↑Activation, cytokine release and migration 
IL-1Ra  ↓inflammatory reaction 
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TNF 
TNF-α 
EN ↑Angiogenesis (Koch, 2003) 
MN ↑Activation, cytokine and PG release 
PMN ↑Priming, apoptosis and oxidative burst 
Th ↑↓Apoptosis, clonal regulation and TCR dysfunction 
EN ↑Adhesion molecule expression, cytokine release 
SF ↓proliferation and collagen synthesis 
AP ↑FFA release 
BAFF B ↑Proliferation, Ab secretion, isotype switching and survival T ↑costimulating 
APRIL B ↑Proliferation 
 
IL-6 
    IL-6 B ↑Proliferation and Ab production 
T ↑Proliferation, differentiation and cytotoxicity 
MN ↑Cytokine release 
 Activation (Gibbons and Hyrich, 2009) 
OSM 
MK ↑Differentiation 
SF ↑TIMP, cytokine release and protease inhibitor 
MN ↓TNF release and IL-1 effector function 
 
Type II 
IFN 
IL-4 
EN ↑Activation, adhesion molecule expression and Angiogenesis 
(Koch, 2003) 
Th2 ↑Differentiation, maturation; ↓apoptosis 
B ↑Maturation; ↑isotype switch (IgE) 
EI ↑Migration; ↓apoptosis 
IFN-γ 
SF ↑Collagen sythesis 
MP ↑Activation 
DC ↑APC function, MHC-II expression 
EN ↑Adhesion molecule expression 
T Th1 response 
 ↓Bone resortpion 
IL-10 
MP ↑Cytokine release, iNOS and soluble receptor, ROI 
T ↓cytokine release and MHC expression; ↑anergy 
Treg ↑suppressive function (Chaudhry et al., 2011), maturation 
DC ↓Activation and cytokine release 
SF ↓MMP and collagen release 
B ↑Isotype switching 
    
IL-12 
IL-12 
Th1 ↑Proliferation, differentiation, cytotoxicity 
NK ↑Cytotoxicity 
B ↑Activation 
IL-23 Th17 ↑Expansion 
IL-27  ↑↓Inflammation (Villarino and Hunter, 2004) 
 
Growt
h 
TGF-β 
 
Th17 ↑differentiation; ↓proliferation and function 
Treg ↑differentiation; ↓proliferation and function 
NK ↓proliferation and function 
MP Activation then suppression; ↓iNOS expression 
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factor LK ↑Chemoattractant, gelatinase and intergrin expression 
SF Activation (Rico et al., 2010; Rosengren et al., 2010) 
FGF 
MCY ↑Growth and differentiation 
EP ↑Growth and differentiation 
SF Activation (Malemud, 2007) 
VEGF  ↑Angiogenesis (Koch, 2003) 
G-CSF PMN ↑Function 
M-CSF MN Activation and maturation 
This table is adapted and updated from(Firestein et al., 2012; McInnes and Schett, 2007) 
SF, synovial fibroblast; MN, Monocyte; MMP, matrix metalloproteinase; iNOS, inducible 
nitric-oxide synthase; PG, prostaglandin; ROI, reactive oxygen intermediate; GAG, 
glycosaminoglycans; EN, endothelial cell; Th1, T helper cell1; NK, Nature Killer cell; CD, 
Chondrocyte; PMN, polymorphonuclear; AP, adipocyte; FFA, free fatty acid; MP, 
Macrophage; Treg, regularly T cell; DC, dendritic cell; MK, Megakaryocyte; LK, leukocyte; 
EI, Eosinophil; COX, Cyclooxygenase; PLA, phospholipase A; OSM, Oncostatin M; BAFF, B 
cell activating factor; RANKL, receptor activator of nuclear factor-κB ligand.  
In addition to modulating the pathogenesis process in the RA synovium through secreting 
cytokines, monocytes/macrophages are capable of differentiating into osteoclast-like cells, 
which are believed to be unique in RA, playing a direct role in the bone destruction (Fujikawa 
et al., 1996; Gravallese et al., 2000). Collectively, main functions of macrophages/monocytes 
related to RA pathogenesis include 1) cell recruitment; 2) cell differentiation, activation and 
proliferation; 3) helping the antigen presenting cells and inducing both cellular and humoral 
autoimmunity; 4) neovascularization and angiogenesis; 5) cartilage and bone destruction. It is 
worth noting that, although the net outcome is promoting the disease, not all these functions 
are restricted to the disease aggregating side. The RA synovium also benefits from the anti-
inflammatory cytokines produced by monocytes/macrophages. Furthermore, certain cytokines 
such as IL-6 and TGF-β exhibit dual functions, and could play opposite roles in the different 
stages of disease.   
1.3.6 Synovial Fibroblasts (SF) 
SF is a key type of pathogenic cells in the cellular network in the RA synovium. In healthy 
joints, SF provides various substances for nourishment and lubrication of the joints. It also 
contributes to the matrix remodeling and wound healing (Neumann et al., 2010). In RA, SF 
acquires activated phenotype, and secrets proinflammatory factors and enzymes contributing 
to the joint inflammation and structure destruction (Neumann et al., 2010). The activation of 
SF was suggested to be depending on the inflammatory environment and could be detected 
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shortly after the display of clinical signs (Lefèvre et al., 2009). Multiple factors are able to 
activate SF. Matrix and necrotic cell components released from the cartilage degradation in the 
early RA stage activates SFs by increasing their production of proinflammatory factors and 
MMPs as well as inducing their long-range migration potential (Brentano et al., 2009; Lefèvre 
et al., 2009; Müller-Ladner et al., 2007). Growth factors, inflammatory cytokines and 
chemokines were also reported to activate SFs and induce their proliferation, and cytokines 
and destructive enzyme secretion (Malemud, 2007; Müller-Ladner et al., 2007; Rico et al., 
2010; Rosengren et al., 2010). In addition to soluble stimuli, several studies have 
demonstrated that the SFs are able to be activated by cell-cell contacting with endothelial cells 
or T cells through adhesion molecules (McGettrick et al., 2009; Müller-Ladner et al., 2007). 
Activated SFs assume multiple roles in the disease progression of RA. Firstly, SFs in RA 
joints (RASFs) have an increased proliferation rate and are resistance to apoptosis. IL-17 has 
been shown to promote the proliferation of RASFs directly, whereas down-regulating the 
adhesion molecule N-cadherin on the surface of SFs contributes to the proliferation by 
reducing their cell contact inhibition (NONOMURA et al., 2009; Zhang et al., 2009b). On the 
other hand, increased expression of apoptosis inhibitor molecules such as sentrin, FLICE-
inhibitory protein (FLIP) and small ubiquitin-like modifier (SUMO)-1 in RASFs dampen their 
sensitivities to the apoptosis signaling (Ahn et al., 2010; Franz et al., 2000; Meinecke et al., 
2009; Schedel et al., 2002). Accumulated RASFs due to the dysregulation of proliferation and 
apoptosis would cause synovial hyperplasia followed by local hypoxia, which eventually 
induce neoangiogenesis. Secondly, RASFs cause the cartilage and bone destruction in RA. 
Similar to macrophages, RASFs act as a source of inflammatory factors in the pathogenesis of 
RA. It produces a great mount of MMPs and cathepsin, which contribute to cartilage invasion 
(Hou et al., 2002; 2001; Müller-Ladner et al., 2007). RASFs also express high levels of 
RANKL which is essential in the bone erosions (Kim et al., 2007). Thirdly, activated RASFs 
are able to produce proangiogenic factors such as angiogenin, angiogenin-1, FGF-2, placenta 
growth factor (PIGF) and VEGF (Gravallese et al., 2003; Lioté et al., 2003; Presta et al., 2009; 
Yoo et al., 2009). Moreover, Lefevre et al. recently discovered a very unique role of RASFs 
contributing to disease spreading in RA(Lefèvre et al., 2009). The study showed that RASFs 
could crawl out from RA-affected joints, travel a long distance to healthy joints through blood, 
and cause cartilage degradation (Lefèvre et al., 2009).  
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1.3.7 Mast Cell, Dendritic Cell and Neutrophil 
In addition to those cells mentioned above, mast cells (MCs), dendritic cells (DCs) and 
neutrophils are also found to be enriched in the RA synovium (Maruotti et al., 2006). MCs 
consist approximately 5% of the total synovial cells in RA joints(Maruotti et al., 2006). They 
produce a variety of cytokines that activating macrophages and SFs, and chemokines 
recruiting the inflammatory cells migrating into the RA joints (Maruotti et al., 2006). A recent 
study pointed out that, instead of Th 17 cells, MCs are the primary source of IL-17 in RA 
synovium (Hueber et al., 2010). DCs are also implicated in the local joint inflammation in RA. 
Both myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) are presented in the synovial fluid 
from RA patients, and contribute to autoantigen presentation and proinflammatory cytokine 
production (Jongbloed et al., 2006; Zvaifler et al., 1985). Moreover, DCs are suggested to help 
the T effector cell differentiation and antibody production in RA joints by providing 
costimulatory signals and cytokines to the local T and B cells (Khan et al., 2009). The 
importance of neutrophils in RA is more than expected, since deletion of neutrophils protects 
the mice against arthritis in several experimental arthritis models (Nandakumar et al., 2003b; 
Tanaka et al., 2006; Wipke and Allen, 2001). Similar to MCs, neutrophils secrete 
proinflammatory cytokines and participate in the autoantibody-mediated RA pathogenesis 
(Németh and Mócsai, 2012).  
As discussed above, the pathogenesis of RA is a complicated process mediated by numerous 
types of cells, cytokines and matrix enzymes. Studies focusing on role of individual cell and 
molecule in RA help us to have a big picture of disease progression of RA, and answer three 
important questions: (1) How is the immune response initiated? (2) How does the immune 
response lead to local joint inflammation? (3) How does the inflammation cause cartilage and 
bone destruction. Two models were proposed to explain the initiation of RA: B cell centric 
and T cell centric. In the B cell centric model, the B cells break tolerance in the lymph nodes 
and start to produce pathological autoantibodies. Because the blood-tissue barrier in the joints, 
unlike other tissues, lacks a basal membrane, it allows autoantibodies to pass through and form 
immune complex (ICs) with autoantigens in the joints. ICs then activate synovial phagocytes 
(macrophages) and the complement cascade, which triggers the release of cytokines and 
chemokines that stimulate the proliferation of synoviocytes and recruit inflammatory cells into 
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the joints (Benoist and Mathis, 2000). The T cell centric model argues that the disease is 
initiated by the activation of autoreactive T cells against synovial specific antigens in the joints 
(Benoist and Mathis, 2000). The activated T cells then secrete inflammatory cytokines, which 
trigger the synovial fibroblasts- and macrophages-mediated inflammation as mentioned above 
(Benoist and Mathis, 2000). The answers to the third question are less controversial. Cartilage 
degradation is caused by matrix enzymes that break down cartilage components, such as 
matrix metalloproteinases (MMPs) and A Distintergin And Metalloproteinase with 
Thrombospondin Motifs (ADAMTS) (McInnes and Schett, 2007). As disease progresses, 
inflammatory cytokines in the RA joints promote cartilage destruction by inducing the release 
of these enzymes from synovial fibroblasts, neutrophils, chondrocytes and osteoclasts. 
Osteoclasts are able to reabsorb bone tissue by secreting acid and a collagenase. The 
inflammatory cytokine environment within RA joints tends to drive the differentiation of 
osteoclasts from their precursor cells, thus enhance the bone erosion (McInnes and Schett, 
2007) (Figure 1.2).  
 
Figure 1.2. The pathogenesis of RA.  
1.4 TNF-Like Ligand 1A and Death Receptor 3 
TNF-like ligand 1A (TL1A), also known as TNFSF15 was first discovered in 2002. It binds to 
death receptor 3 (DR3, TNFRSF25) and Decoy receptor 3(DcR3, TR6).  Interaction between 
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TL1A and DR3 triggers T cell proliferations and proinflammatory cytokine secretion. In the 
past ten years, emerging data have shown a strong relationship between TL1A and 
autoimmune diseases.  
1.4.1 Characterization of DR3 and TL1A 
DR3 (TNFRSF25, Apo3, WSL-1, TRAMP and LARD) was discovered in mid-90’s with 
several papers published in high-profile journals.  In 1996, Farrow and colleagues found a 
previously unknown protein which interacts specifically with the cytoplasmic portion of 
TNFR1 in HeLa cells based on the yeast two-hybrid assay, and designated it as WSL-1 
(Kitson et al., 1996). The same protein was identified by several other groups at the same time 
though searching the cDNA libraries (Bodmer et al., 1997; Chinnaiyan et al., 1996; Marsters 
et al., 1996; Screaton et al., 1997). DR3 shares around 27% sequence identity to TNF-R1, and 
is by far a TNF family receptor most similar to TNF-R1 (Screaton et al., 1997). Mouse DR3 
was later identified using labeled hDR3 cDNA as a probe (Wang et al., 2001). It shows great 
homology to its human counterpart (63% in total, and 94% in the death domain) (Wang et al., 
2001). Both human and mouse full-length DR3s contain four cysteine rich domains (CRD), a 
transmembrane region and a death domain (Screaton et al., 1997; Wang et al., 2001). The 
crystal structure of DR3 has yet to be achieved. Shortened forms of DR3 are observed in both 
human and mice. There are at least 12 variants of human DR3 and 3 variants of murine DR3 
(Figure 1.3) (Screaton et al., 1997; Wang et al., 2001). Variants missing one or more exon(s) 
would skip the transmembrane region or introduce an early stop codon before the 
transmembrane region. These variants become the secreted form of DR3 (hDR3-b, c, d, e, f, g, 
h, i and j; mDR3-b). Other variants such as hDR3-8 and mDR3-3 have intact transmembrane 
part and death domain, but lack one CRD in their extracellular domains (Screaton et al., 1997; 
Wang et al., 2001). Earlier attempts were failed to identify the ligand of DR3. However, these 
studies at least indicated that DR3 does not cross-react with other TNF family members other 
than its specific ligand (Bodmer et al., 2002; Marsters et al., 1996).  
Human TL1A (hTL1A, 251aa) was first cloned and identified as the ligand of DR3 and TR6 
(Migone et al., 2002). Like most of other TNF ligands, TL1A expresses on the cell surface, 
but also can be cleaved subsequently by metalloproteinase to become a soluble molecule. 
However, the cleavage of TL1A only happens on DC but not on T cells (Biener-Ramanujan et 
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al., 2010; Kim and Zhang, 2005; Migone et al., 2002). Prior to the discovery of full-length 
TL1A, a short form of hTL1A, TNF-like 1 (TL1;or vascular endothelial growth inhibitor, 
VEGI, 174aa) was discovered by two different groups using homology searches in the human 
umbilical vein endothelial cell (HUVEC) cDNA library (Tan et al., 1997; Zhai et al., 1999). 
Oddly, this TL1/VEGI does not have function unless the first 22aa from N-terminus are 
replaced with an IL-6 signal peptide (sVEGI), which converts it into a secreted protein. Later, 
several lines of evidence suggested that that the VEGI might be just a cloning artifact due to 
incompletely spliced nuclear RNA (Migone et al., 2002). In addition, VEGI-192 (192aa) and 
TL1AV84-L251 were found and reported to induce cell growth arrest and apoptosis (Chew et al., 
2002; Mück et al., 2010). The situation in the mouse is simple with no variant other than full- 
length TL1A (251aa) reported.  
 
Figure 1.3. Isoforms of TL1A (upper panel) and DR3 (lower panel) in human and mouse. 
Adapted from Screaton et al. with modification (Screaton et al., 1997). 
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1.4.2 Expression of TL1A and DR3 
Tissue-specific expression pattern of human DR3 was reported by several early studies with 
consistent results. There is an predominant 4kb transcript in the peripheral blood leukocytes 
(PBLs), spleen and thymus, and a mild expression in the intestine and colon in adults 
(Chinnaiyan et al., 1996; Kitson et al., 1996; Migone et al., 2002; Screaton et al., 1997). 
Additional larger transcripts at around 7 kb and 9 kb are observed in the brain, lung and 
kidney of the fetus (Marsters et al., 1996). Different expression patterns have been found 
between the human and mouse. There are three major transcripts (1.8 kb, 2.8 kb and 7.0 kb) in 
mice: two smaller transcripts are abundantly expressed in the spleen and thymus, and a bigger 
one is expressed in the brain, heart and kidney (Wang et al., 2001). Given that the DR3 
transcriptions are found predominantly in the lymphoid organs, lymphocytes are analyzed for 
the expression of DR3 at the cell level. Screaton et al. detected DR3 mRNA in PBLs, B cells 
and CD4 or CD8 T cells, but not in macrophages and immortalized lymphocyte cell lines 
(Screaton et al., 1997). However, Bodmer et al. found DR3 proteins can also be detected in 
various human immortalized or tumor cell lines originated from epithelial, neuronal tissues 
(Bodmer et al., 1997). It is worth noting that although the total amount of DR3 mRNA in 
different types and status of lymphocytes might be the same, the splicing patterns could be 
remarkably different. For example, activated lymphocytes only express full-length DR3 (DR3-
a) instead of short isoforms which are predominantly present in the resting lymphocytes 
(Screaton et al., 1997). Most of these short isoforms are secreted proteins, which are not able 
to transduce signals. It implies a potential mechanism to regulate the homeostasis of 
lymphocytes by expressing functional/non-functional isoforms of DR3.  
TL1A mRNA is most abundant in the kidney, followed by the pancreas and prostate. Trace 
amount of transcriptions is found in the lung, intestine and thymus (Migone et al., 2002; Tan 
et al., 1997; Zhai et al., 1999). At the cellular level, only some endothelial cells (HUVEC and 
early passage of venous endothelial cells) and an erythroleukemic cell line TF1 cells were 
reported in early studies to express TL1A mRNA (Migone et al., 2002; Screaton et al., 1997; 
Zhai et al., 1999). Later studies revealed that monocytes/macrophages, dendritic cells, T cells 
and NKT cells also produce TL1A either upon stimulation or in the local inflammation sites 
(Bamias et al., 2006; Fang et al., 2008; Prehn et al., 2004; 2007; Takahashi et al., 2011).  
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1.4.3 Signaling Pathway of TL1A-DR3 Interaction 
Before the ligand of DR3, TL1A, was identified, the downstream pathway of DR3 was already 
studied with ectopic expression systems. Signals through DR3 was found to be able to trigger 
activation of NF-κB and, at the same time, cell apoptosis (Bodmer et al., 1997; Chinnaiyan et 
al., 1996; Kitson et al., 1996; Marsters et al., 1996). Overexpression of DR3 in cell lines leads 
to apoptosis, while inhibiting the apoptosis made the effect of DR3 on NF-κB activation 
became more pronounced (Bodmer et al., 1997). As there is a high degree of homology 
between DR3 and TNFR1, TNFR1 downstream signaling molecules such as TRADD, RIP, 
FADD and ICE-like protease FLICE are potential candidates involved in the signaling 
pathways of DR3 (Baker and Reddy, 1998). Yeast-two hybrid studies showed that DR3 can 
form homodimers itself or heterodimers with TNFR1, but has very weak or no interaction with 
RIP, FADD or TRAFs (Bodmer et al., 1997; Chinnaiyan et al., 1996; Kitson et al., 1996). 
However, DR3, RIP and TRAF2 were found to be able to form a complex in the presence of 
TRADD, and induce NF-κB activation (Chinnaiyan et al., 1996). TRADD also serves as a 
bridge between the interaction of DR3 and FADD. FADD then recruits FLICE and triggers 
caspase activation and cell apoptosis (Chinnaiyan et al., 1996; Marsters et al., 1996). Unlike in 
the overexpression system, TL1A or DR3 agonistic antibody does not induce apoptosis of TF-
1 cells that express endogenous DR3 at a physiological level. DR3 assembles the signaling 
complex containing the same adaptor protein as mentioned above, and triggers the NF-κB, 
ERK, JNK and p38-MAPK pathways, which play an anti-apoptotic role (Wen et al., 2003). On 
the other hand, DR3 has weaker associations with FADD, FLICE and caspase-8 in TF-1 cells 
compared to those cells overexpressing DR3 (Wen et al., 2003). Addition of TL1A-triggered 
anti-apoptotic protein c-IAP2 expression, through activation of NF-κB, blocking the NF-κB 
activation or protein synthesis in TF-1 cell results in apoptosis (Wen et al., 2003). 
1.4.4 Relationship Between TL1A-DR3 and Human Diseases 
The expression of TL1A is mainly confined to the lymphoid organs, which suggest its 
essential role in the immune system. More importantly, in contrast to TNFR1, expression of 
TL1A is under tight regulations. In fact, accumulating evidence have suggested that increased 
expression of TL1A is related to the inflammation in certain autoimmune diseases.  
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Immunohistochemical analysis has shown the presence of intense signals of both DR3 and 
TL1A in surgical specimens from inflammatory bowel disease (IBD) patients. More 
specifically, TL1A is co-localized with lymphocytes and isolated LPMCs from Crohn’s 
disease (CD) specimens, and with CD138+ plasma cells of ulcerative colitis (UC) specimens 
(Bamias et al., 2003; Kamada et al., 2010). Circulating levels of TL1A in UC patients are also 
significantly higher than those in healthy controls (Bamias et al., 2010). Furthermore, It was 
reported that there is five-fold elevation of serum TL1A concentration in RA patients, with 
more pronounced increase seen in RF+ patients or those having severe/terminal disease 
conditions (Bamias et al., 2008). TL1A is also expressed in RA synovium with similar 
distribution patterns of CD68+ cells and CD14+ cells, which surround the central area of 
fibrinoid necrosis; In accordance with Bamias’s report, plasma cells expressing TL1A are 
occasionally presented in the RA synovial tissues (Cassatella et al., 2007). In acute cellular 
rejection specimens of renal allografts, upregulated DR3 and TL1A are observed in human 
renal tubular epithelial cells (TEC) and vascular endothelial cells (VEC), and in infiltrating 
mononuclear cells, respectively (Al-Lamki et al., 2003; 2008). Moreover, TL1A were reported 
to co-localize with monocytes/macrophages in the atherosclerotic plaques in carotid 
endoarteretomy tissues (Kang et al., 2005; Kim et al., 2008). 
1.4.5 TL1A and T Cell Functions 
T cells are known to express DR3 on their cell surface. They also produce a small amount of 
membrane TL1A but not its secreted form upon activation (Fang et al., 2008; Meylan et al., 
2008; Papadakis et al., 2005; Prehn et al., 2004). Interestingly, TL1A elevation in T cells 
depends on the DR3 expression, as DR3 knockout T cells have defect in responding to TCR 
stimulation and producing TL1A (Meylan et al., 2008). TL1A affects T proliferation, cytokine 
secretion and differentiation through autocrine, but mainly paracrine signaling.   
1.4.5.1 Proliferation 
Exogenous TL1A has limited effect on the proliferation of T cells from human peripheral 
blood (PB) during activation. However, it enhances the expression of IL-2 receptors on these 
cells, and increases their responsiveness to IL-2-induced proliferation (Migone et al., 2002; 
Prehn et al., 2004). In contrast, murine T cells proliferate better in the presence of TL1A upon 
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suboptimal TCR stimulation (Meylan et al., 2008). TL1A can promote T effector cell as well 
as Treg cell proliferation in vivo, as transgenic TL1A expression in mice or TL1A-Ig 
administration to mice enhances the T cells expansion in lymphoid organs (Khan et al., 2013; 
Meylan et al., 2011a; Taraban et al., 2011). TL1A’s costimulatory function in murine T cells is 
IL-2 dependent, and it is more pronounced on memory T cells(Bamias et al., 2006; Meylan et 
al., 2008).  
1.4.5.2 Cytokine Production 
TL1A increases the IFN-γ production in T cells from human peripheral blood or lamina 
propria mononuclear cells (LPMC) upon TCR stimulation (Migone et al., 2002; Prehn et al., 
2004). TL1A was also reported to enhance the IFN-γ production in peripheral blood 
mononuclear cell (PBMC), and more significantly in isolated T cells, with the activation of IL-
12 and IL-18 (Prehn et al., 2004). Later study revealed that two T cell subsets, CCR9+CD4+ 
and CD161+ T cells, which resemble the gut T cell phenotypes, present increased production 
of IFN-γ upon activation in the presence of exogenous TL1A (Cohavy et al., 2011; Papadakis 
et al., 2005). Furthermore, CCR9+CD4+ T cells are able to express TL1A by themselves on the 
cell surface after stimulation, and this endogenous TL1A is enough to provide autocrine 
signaling to the cell surface DR3 in IL-12/IL-18-stimualted IFN-γ production (Papadakis et 
al., 2005). On the other hand, CD161+ T cells only receive paracrine signaling of TL1A from 
monocyte and produce IFN-γ and IL-2, these T cells in turn promote the maturation of 
monocytes (Cohavy et al., 2011). TL1A has a similar effect on the induction of IFN-γ 
production in murine T cell (Bamias et al., 2006). However, TL1A only works in synergy with 
IL-12 for the induction of IFN-γ production in T cells, while its synergy with IL-18 is 
negligible (Bamias et al., 2006). Of note, secreted form of TL1A is more potent than its 
membrane form in terms of inducing IFN-γ production (Biener-Ramanujan et al., 2010; Kim 
and Zhang, 2005; Migone et al., 2002).  
TL1A could also affect the cytokine production of NKT cells. It was reported that NKT cells 
from mouse lymph nodes express a high level of DR3， TL1A-DR3 could augment their Th2 
cytokines produced in vivo; (Fang et al., 2008).  
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The T cell activation signal is critical in TL1A’s costimulatory effect mentioned above. TL1A 
alone is not able to induce either proliferation or cytokine production of T cells. Memory T 
cell is, however, the exception due to its pre-deposited surface DR3. It is conceivable that cell 
activation contributes to TL1A’s effect by upregulating its receptor expression levels on the 
target cell surface (Bamias et al., 2006; Cohavy et al., 2011; Papadakis et al., 2005). 
Interestingly, CD28 co-stimulation signal exhibit different effects on TL1A induced cytokine 
production of T cells. TL1A promotes the IL-4 production of murine T cells only under the 
condition with both anti-CD3 and anti-CD28 stimulations (Meylan et al., 2008). On the other 
hand, TL1A’s effect on the upregulation of IFN-γ in T cells is diminished if T cells are 
activated by both CD3 and CD28 signalings, which give the cells the maximal stimulation 
(Meylan et al., 2008). Antigen-specific stimulation is a different story. In contrast to the 
antigen non-specific stimulation, the absence of TL1A-DR3 signaling in the OTII-Ova system 
results in less IL-2 and IL-4, but more IFN-γ production from the antigen specific T cells 
(Meylan et al., 2008).  
1.4.6 TL1A and Macrophages 
When DR3 was first identified, monocytes/macrophages were excluded from the cells 
expressing DR3 (Screaton et al., 1997). Later, in vitro studies showed DR3 was inducible in 
primary monocytes from peripheral blood (PB) upon either TNF-α or LPS stimulation (Kang 
et al., 2005). Furthermore, CD14+ monocytes from human PB and two monocytic tumor cell 
lines (THP-1 and U937) were found constitutively expressing both DR3 and TL1A (Kang et 
al., 2005; Kim et al., 2008; Su et al., 2006). TL1A’s effects on macrophages are mainly related 
to atherosclerosis. Treating THP-1 with agonistic anti-DR3 antibody or TL1A induced pro-
atherogenic cytokines production, like TNF-α, IL-8, MMP-9 and monocyte chemoattractant 
protein (MCP)-1. In these cells, IFN-γ further increased the IL-8 production synergistically 
with TL1A (Kang et al., 2005; Su et al., 2006). A recent study further demonstrated, in both 
THP-1 cells and human monocyte-derived macrophages (HMDMs), that TL1A-DR3 signaling 
regulates key proteins governing the uptake and efflux of cholesterol, causing the imbalance in 
cholesterol homeostasis which eventually turns the macrophages into foam cells (McLaren et 
al., 2010).  
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In fact, monocytes/macrophages are more TL1A producers rather than TL1A responders. 
Stimulating monocytes from human PB with plate-bound IgG induce significant expression of 
TL1A mRNA and both soluble and membrane form of TL1A (Prehn et al., 2007). In line with 
this finding, Cassatella et al. showed that immune-complex, and precipitates from peripheral 
blood or synovial fluid of RF+/RA patients induced both membrane TL1A (mTL1A) and 
soluble TL1A (sTL1A) from cultured monocytes (Cassatella et al., 2007). Furthermore, IFN-γ 
or IL-4 promoted or abrogated the IC-simulated sTL1A production, respectively (Cassatella et 
al., 2007). Co-culture of monocytes and CD4+ T cells primed with IL-12 and IL-18 produced 
more IFN-γ than CD4+ T cells cultured alone; addition of IC significantly increased IFN-γ 
production in this system (Cassatella et al., 2007; Prehn et al., 2007). It was further 
demonstrated that the effect of the ICs on sTL1A production is through FcγrII and FcγrIII, but 
not FcγrI(Cassatella et al., 2007). Importantly, this IC-induced TL1A expression can be 
inhibited by TLR8 stimulation in an IFN-α independent manner (Saruta et al., 2009). 
Furthermore, many types of bacteria were reported to induced TL1A in monocytes and 
monocyte-derived DC partially through TLR, as a mechanism against enteric microorganisms 
(Shih et al., 2009). Macrophages from lamina propria (LP) affected by Crohn’s disease (CD) 
upregulate membrane TL1A and IL-23 upon stimulation by commensal bacteria (Kamada et 
al., 2010; Uo et al., 2012). Mechanistically, LPS-induced TL1A expression in monocytes 
involves NF-κB-binding to the 5’ flank region of TL1A (Endo et al., 2010). 
1.4.7 TL1A and Dendritic Cells 
Dendritic cell presents antigens and provides costimulatory signals to the T cell and it is the 
major source of endogenous TL1A. Human monocyte-derived DC (MDC) respond to 
stimulation of plate-bound IgG with rapid induction of TL1A mRNA, whereas LPS, 
Pam3CSK4, CBri1 flagellin and IFN-γ fail to induce TL1A in MDC (Prehn et al., 2007). 
Compared to the monocytes, human MDC express much less TL1A mRNA at peak of 
induction, but produce more soluble TL1A (Prehn et al., 2007). Accordantly, plate-bound Ig 
has similar effect on murine BMDC. TL1A mRNA of murine DC after stimulation reaches a 
peak level almost 200-folds higher than the basal level and that drops rapidly to the baseline 
(Meylan et al., 2008). In contrast to human MDC, murine BMDC also produce TL1A mRNA 
upon the stimulation of LPS, which acts through the TLR4/MyD88/TIRAP pathway (Meylan 
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et al., 2008). Expression of DR3 on DC is less known with Only one study reported a small 
subpopulation of CD11c+ cells from LN expressing DR3 (Fang et al., 2008) 
1.4.8 TL1A Induced Apoptosis 
Ectopic expression of DR3 in tumor cell lines, such as 293, MCF7 and 3T3 results in rapid 
apoptosis (Bodmer et al., 1997; Chinnaiyan et al., 1996; Kitson et al., 1996; Marsters et al., 
1996). Addition of TL1A to TF-1 cells in the presence of cycloheximide (CHX) induces the 
activation of caspase and cell apoptosis. Surprisingly, primary activated T cells are resistant to 
TL1A-induced apoptosis in the presence or absence of CHX (Migone et al., 2002). Similar 
results are observed using IC-primed monocytes as the source of TL1A (Cassatella et al., 
2007). Further study reveals that TL1A-induced NF-κB plays a counterbalanced role to TL1A-
induced apoptosis, it increases the synthesis of anti-apoptotic molecule c-IAP2 that keeping 
TF-1 cells from apoptosis (Wen et al., 2003). The presence of protein synthesis inhibitor, CHX 
or NF-κB inhibitor breaks the balance and introduces apoptosis to TF-1 cells(Wen et al., 
2003). Similarly, TL1A plays dual roles in tubular epithelial cells (TEC) in renal inflammation 
and injury. It activates NF-κB and upregulates TNFR2 to promote repairing the injury on one 
hand, and induces the caspase-3 activation and apoptosis of TEC on the other (Al-Lamki et al., 
2008). Interestingly, the addition of TL1A in the cultured kidney of DR3 knockout mice fails 
to activate the NF-κB pathway and increase the apoptosis of TEC, but it is still able to induce 
TNFR2 (Al-Lamki et al., 2008). Furthermore, DR3 knockout TECs show elevated apoptosis 
under the cisplatin-induced renal injury, and TL1A could play a counter effect on TNF-
induced apoptosis in TECs during renal injury (Al-Lamki et al., 2003).  
1.4.9 TL1A-DR3 in Animal Disease Models 
1.4.9.1 Inflammatory Bowel Disease 
SAMP1/YitFc and TNFΔARE mice develop spontaneous chronic ileitis resembling clinical 
features of human CD (Kontoyiannis et al., 1999; Rivera-Nieves et al., 2003). It was found 
that DR3 mRNA increases in terminal ileum of SAMP1/YitFc and TNFΔARE mice with ileitis, 
and mucosal dendritic cells (CD11c++MHC-II+) are identified as a source of TL1A in the 
intestine of mice with spontaneous ileitis (Bamias et al., 2006).  
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Upregulated levels of TL1A and DR3 mRNA have been found in the mesenteric LN (mLN) 
and colon in the chronic DSS mice model. Stimulating CD4+ T cells from mLN or LPMC with 
TL1A alone induce a significant amount of IFN-γ, IL-6 and IL-17, which is further increased 
in the presence of IL-12 or IL-23 (Takedatsu et al., 2008). Treatment before or after the onset 
of the disease with anti-TL1A antibody prevents or alleviates the clinical and pathological 
scores of DSS- and TNBS-induced colitis (Meylan et al., 2011a; Takedatsu et al., 2008).  
1.4.9.2 Experimental Allergic Asthma 
Meylan et al. showed TL1A-DR3 signaling was essential in developing experimental allergic 
asthma in mice(Meylan et al., 2008). Reduced disease severity was observed in DR3 knockout 
mice, accompanied by reduced number of T cells, NKT cells and eosinophils cells, and 
pathogenic Th2 cytokines in the lung (Meylan et al., 2008). They also pinpointed that the DR3 
signaling in T cells was the critical requirement in this disease model (Meylan et al., 2008). 
Another group reported an antagonistic anti-DR3 antibody (L4G6) to prevent experimental 
allergic lung inflammation in mice by inhibiting the eosinophils exudation and pathogenic Th2 
cytokine production (Fang et al., 2008). Although TL1A had been shown to be able to block 
IL-4, 5, 10 and 13 production in CD4+ T cells from the lung, NKT cells were believed, in this 
study, to be the principle mediator of the TL1A blocking effect, as NKT-deficient mice 
adoptive transferred with DR3-domain negative transgenic NKT cells were resistant in the 
disease-transfer lung inflammation model (Fang et al., 2008). The same group later found an 
agonistic anti-TL1A antibody (4C12) strongly induced specific expansion of Treg cells in 
vivo. Treating mice before experimental allergic lung inflammation with 4C12 increased the 
ratio of Treg and T effector, suppressed the Th2 cytokine secretion and prevented the disease 
(Schreiber et al., 2010). They also showed that a format of recombinant TL1A with an Ig tag 
(TL1A-Ig) had similar effects (Khan et al., 2013). Since it appeared to be controversy that 
both agonist and antagonistic anti-DR3 antibodies were able to inhibit the allergic lung 
inflammation, the author claimed that the sequences of anti-DR3 treatment and immunization 
of OVA played a critical role (Schreiber et al., 2010). 
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1.4.9.3 Experimental Autoimmune Encephalomyelitis (EAE) 
EAE is an experimental models for human multiple sclerosis (MS). It is also a very common 
model in mice to examine Th1 and Th17 immune responses (Constantinescu et al., 2011). 
EAE has been assessed in both TL1A knockout and DR3 knockout mice. DR3 knockout mice 
have drastically reduced clinical scores and fewer T cells, especially Th1 cells accumulated in 
CNS, compared to their WT counterparts (Meylan et al., 2008).  
Roles of TL1A in the inflammatory responses were summarized in Figure 1.4.  
 Figure 1.4. Role of TL1A in the inflammatory responses. RA: Rheumatoid Arthritis; CIA: 
Collagen indueced arthritis; IBD: Inflammatory Bowel Diesease; MS: Multiple sclerosis. 
EAA: Experimental allergic asthma.  
1.5 Pno1  
Pno1, also called Dim2, Yor145C and RPR20 in yeasts, was first described in 2002 as a 
binding partner of Nob1 in the maturation of proteasomes (Tone et al., 2000). Pno1 is highly 
conserved across different species. The mouse and yeast share 52% identity and 46.7% 
homology in protein sequence (Figure 1.4). Murine Pno1 mRNA contains a 746-nt open-
reading frame with 7 exons; and Pno1 protein comprises 248 amino acid residues, with a 
molecule weight around 30kDa.  
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Figure 1.5. Comparison of yeast, human and mouse Pno1 amino acid sequences. 
1.5.1 Subcellular Location 
The subcellular location of Pno1 is highly dynamic but strictly regulated according to the cell 
growth phases (Vanrobays et al., 2004). It presents equally in both the nucleus and cytoplasm 
through the log growth phase, but is progressively trafficked into the nucleus at the transitional 
phase, and eventually is condensed into a small dot in the nucleus in the stationary phase 
(Vanrobays et al., 2004). Pno1 is quickly expanded to the cytoplasm and regain the equal 
distribution pattern once the cells transit to the log growth phase (Vanrobays et al., 2004). 
Additionally, the change of subcellular location of Pno1 is accompanied by its shifting in the 
sedimentation fractions (Vanrobays et al., 2004). It has been suggested that the dynamic 
distribution is due to the location transition in the process of small ribosomal RNA maturation 
(Vanrobays et al., 2004). Subsequent studies have indicated that the translocation of Pno1 to 
the nucleus is in response to nutritional, osmotic and oxidative stress controlled by the 
mammalian target of rapamycin (mTOR) pathway (Vanrobays et al., 2008). 
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1.5.2 Pno1 and Ribosome 
Ribosome is one of the fundamental molecular machines in all the living cells as being the 
primary site for the protein synthesis. The eukaryotes ribosome comprises a small (40S) and a 
large (60s) subunit. During the protein translation process, 40S unit uses mRNA as templates 
matching the codon with specific tRNA, which carries the amino acid. In the large subunit, 
amino acid is then added to a growing polypeptide, which is eventually decorated and folded 
into protein. A mature ribosome has 4 RNAs (5.8S, 18S, 25S/28S and 5S) and around 80 
ribosome proteins (Tschochner and Hurt, 2003).  
Ribosome assembly is a multistep but highly regulated process involving as many as 200 
assembly factors, many of which associate with the pre-RNA transiently or persist for certain 
period of time during the assembly, but are not present in mature ribosome (Tschochner and 
Hurt, 2003). Three rRNAs (5.8S, 18S and 25S/28S) are initially produced as a single transcript 
by RNA polymerase I (Pol I). There will be sequential cleavages at the 5’ end of the single 
transcript at site A0 and A1, followed by a third cut at A2 to release the 20S fragment into the 
cytoplasm. The remaining part eventually will be cleaved multiple times and mature into 5.8S 
and 25S/28S rRNA, which form 60S large subunit. The 20S will be cleaved again at site D 
close to the 3’ end to generate 18S rRNA for 40S small subunit (Tschochner and Hurt, 2003).   
The protein sequence of Pno1 has a KH domain, which is known to bind to RNAs (Gibson et 
al., 1993). As expected, Pno1 is found to be essential in the small ribosome subunit synthesis 
in the yeast (Senapin et al., 2003; Vanrobays et al., 2004). It is associated with Dim1p and 
ensures the correct cleavage and dimethylation in the early pre-RNA. Another study 
discovered that the KH domain of Pno1 is involved in the interaction between Pno1 and Nob1. 
It is suggested that the Pno1 could enhance the RNA binding ability of Nob1 and increase its 
cleavage activity at site D (Fatica et al., 2003; Lamanna and Karbstein, 2009; Pertschy et al., 
2009; Woolls et al., 2011). In contrast, the interactions between Pno1 and Dim1 have been 
later proved to be indirect through kinases Rio2 (Campbell and Karbstein, 2011). 
Nevertheless, Pno1 is crucial to the ribosome assembly as deficiency of Pno1 in the yeast 
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abolishes 18S rRNA generation and lead to lethality (Senapin et al., 2003; Vanrobays et al., 
2004; Woolls et al., 2011). 
1.5.3 Pno1 and Proteasome 
Proteasome is essential large protein complex responsible for ATP-dependent degradation of 
proteins tagged with ubiquitin. Every 26S proteasome contains a 20S proteolytic core particle 
(CP) and a 19S regulatory particle (RP). CP comprises 4 heptameric rings, stacking up to form 
a barrel-like structure. There are two identical inner rings (also called β ring) with 7 different β 
units of each, providing 6 catalytic sites in total (Groll et al., 1997). β1, β2 and β5 are those 
subunits contain catalytic sites with distinct proteolytic activities, referred as caspase-, trypsin- 
and chymotrypsin-like activities, respectively (Groll et al., 2005). The two outer rings share a 
similar structure as the β-ring, consisting 7 different α subunits. Regulatory particle (RP) is 
composed of more than 19 subunits. Its functions include recognition of ubiquitylated 
proteins, and unfolding and transporting those proteins into the 20S proteasome (Murata et al., 
2009).  
Assembly of proteasome requires help from different sets of chaperone proteins and consumes 
a great amount of energy. The assembly of CP is suggested to start from α-ring formation, and 
followed by β-ring. Four proteasome-assembling chaperones (PAC, Pba in the yeast) and 
ubiquitin-mediated proteolysis 1 (UMP1, Pomp in mammalian cells) are the major chaperone 
proteins assisting the assembly process (Murata et al., 2009). Four PACs form two 
heterodimeric chaperone complexes, known as PAC1-PAC2 and PAC3-PAC4. PAC1-PAC2 
binds α5 and α7 to help α-ring formation and avoid aggregation of the two α-rings. PAC3-
PAC4, however, is responsible of error checking, assuring the correct arrangement of each α-
subunit. It is released from the α-ring during β-ring formation. β-ring formation is 
characterized by the existence of β subunit precursor peptides; and the precise sequential order 
of assembling, which is maintained by UMP1 (Gallastegui and Groll, 2010; Murata et al., 
2009). In addition, UMP1 is required to initiate β-ring formation in mammal cells but not in 
yeasts. Once the β-ring formation is finished, two half-proteasomes (an α-ring plus a β-ring) 
dimerize into 20S proteasomes.  UMP1 as well as PAC1-PAC2 are degraded at this step. RP 
contains a lid complex and a base complex, each of which is assembled individually and joint 
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together afterwards. Nas2, Nas6, Hsm3 and Rpn14 are four chaperone proteins required for 
the assembly of the base complex. Each chaperone protein binds to certain RP subunits and 
form three intermediates. These intermediates are subsequently joint together with two other 
RP subunits to complete the base complex assembly (Gallastegui and Groll, 2010). Similar to 
the base complex, two sets of lid subunits are formed independently and joint together with 
two additional RP proteins to generate the lid complex (Gallastegui and Groll, 2010). Lid and 
base complex then attach together through a regulatory particle non-ATPase 10(RPn10) to 
generate RP. Finally, RP is mounted on one or both end of 20S CP to form 26S proteasomes.  
The role of Nob1 in rRNA maturation as a nuclease has been discussed above. In fact, Nob1 
was first discovered to be able to interact with two subunits of regulatory particle of 26S 
proteasome, Rpn12 and regulatory particle triple-A protein1 (Rpt1), implicating its 
involvement in the proteasome activity (Tone et al., 2000). Subsequent study found Nob1’s 
role in 26S proteasome assembly, as mutation of Nob1 causes the accumulation of precursors 
of β-subunits and defects of proteasome activity (Tone and Toh-E, 2002). Pno1 is proposed in 
this study to participate in the assembly of proteasome though its interaction with Nob1 (Tone 
and Toh-E, 2002). Mutation of Pno1 diminishes the integration of β2-subunit and β5-subunit 
into 20S CP, and causes the dislocation of α4-subunit (Tone and Toh-E, 2002).  
1.5.4 Proteasome and Plasma Cells 
Plasma cells are terminally differentiated B cells that participate in humoral immune responses 
by secreting a large amount of antibodies. There are two types of plasma cells: short-lived 
plasma cells (SLPC) and Long-lived plasma cells (LLPC). Certain antigen-stimulated B cells, 
with or without assistance from T cells, proliferate as plasma blasts in extra-follicular foci and 
differentiate into SLPC (MacLennan et al., 2003). SLPCs produce antigen specific IgM or IgG 
on site, and last for a few days up to a couple of weeks before going apoptosis (Smith et al., 
1996). In contrast, LLPC could survive for several years or persist for a lifetime. Majority of 
LLPC are derived from B cells that go through the affinity maturation process in the germinal 
center. Interestingly, recent report has showed LLPCs can also be generated in the absence of 
germinal center (Bortnick et al., 2012; Sze et al., 2000). 
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The maturation of plasma cells is accompanied by down-regulation of typical B cell surface 
markers, such as Ig, B220, CD19, MHC-II and costimulatory molecule CD86, and up-
regulation of CD138 (Oracki et al., 2010). B cells also go through dramatic morphological 
changes to become plasma cells. The size of individual cells is enlarged, especially the 
cytoplasmic part. Extensive Golgi apparatus and endoplasmic reticulum (ER) occupy the 
plasma cell cytosol, providing a physiological basis of producing large amounts of antibodies 
(Gass et al., 2004). To cope with the challenge of mass production of antibody, plasma cells 
acquire a unique unfolded protein response (UPR) (Gass et al., 2002). In regular cells, when 
there are overloaded unfolded or missfolded proteins in the ER, the UPR is activated to 
alleviate the ER stress by decreasing the protein folding load and increasing the folding 
capacity. Concomitantly, those misfolded protein failed in the re-folding process are 
retrogradely translocated from ER, and ubiquitylated and shredded in the 26S proteasome 
(Kostova and Wolf, 2003). If the stress cannot be mitigated overtime, the UPR signaling will 
eventually induce cell apoptosis (Walter and Ron, 2011).  During the B cell differentiation to 
plasma cells, UPR is triggered before the large-scale antibody production rather than being 
induced by the ER stress. ER chaperone expression levels are enhanced to assist the protein 
folding, and the signaling in the plasma cells do not induce the expression of C/EBP 
homologous protein (CHOP), a transcription factor linked to apoptosis (Gass et al., 2002; van 
Anken et al., 2003; Wiest et al., 1990). At the molecular level, the initiation of plasma cells 
starts with the repression of PAX5 gene, and upregulation of transcription factor Blimp-1, a 
“master regulator” of plasma cells (Kallies et al., 2007). Blimp-1 blocks the B cells from 
entering the cell cycle, and activates XBP-1 production as well as ATF6 and IL-4 production 
(Lin et al.). XBP-1 rules the late stage of plasma cell differentiation, and it is crucial to the 
large scale antibody production machinery (Iwakoshi et al., 2003; Martins and Calame, 2008; 
Shaffer et al., 2004; Todd et al., 2009).  
Proteasome inhibitors (PI) have been reported to be able to induce apoptosis of multiple 
myeloma (MM) cells, plasma cell tumors, regardless the elevated expression of UPR survival 
components in these cells (Lee et al., 2003; Obeng et al., 2006). The mechanisms have been 
elucidated by two research groups with different explanations. Glimcher’s group has claimed 
that the PI increase the ER stress, but dampen the UPR through impairing the generation of an 
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active form of XBP-1 while sustaining the inactive form. Another group has suggested that the 
pro-apoptotic effect by PI is mediated by rapid induction of sets of terminal UPR components 
including Bax, PERK (a type 1 transmembrane serine/threonine protein kinase) and ATF4, 
which further induce the expression of CHOP, and lead to the ER stress-induced apoptosis 
(Harding et al., 2000; 1999; Meister et al., 2007; Obeng et al., 2006).  
A later study has found that Bortezomib, a food and drug administration (FDA) proved PI to 
treat multiple myeloma, also induces apoptosis of normal plasma cells in vitro, and causes a 
transient reduction of plasma cells in bone marrow and alters alloantibody production and 
specificities (Perry et al., 2009). Furthermore, multiple studies have demonstrated the 
therapeutic roles of Bortezomib in autoimmune disease. Bortezomib is able to remove anti-
dsDNA-Ab-producing autoantibody SLPC and LLPC in mice under two experimental lupus-
like disease models, reducing the clinical symptoms and prolonging the survival of affected 
mice(Neubert et al., 2008). Similar effects are observed in rat with experimental autoimmune 
myasthenia gravis (EAMG) after Bortezomib treatment (Gomez et al., 2011).  
1.6 Rational for Present Studies  
RA is the most common from of inflammatory arthritis, which primarily affects the joints and 
their surrounding tissues. Great achievements have been made during the past two decades in 
understanding the pathogenic mechanisms of RA. Studies with patients and animal models 
have found that autoantibodies, cytokines and tissue-destructive enzymes produced by the 
infiltrating cells and local mesenchymal cells within the synovium are important mediators of 
the persisting synovitis and joint destruction. These findings helped us to design therapeutic 
strategies based on inhibiting these key molecules or removing the cells producing them. For 
examples, therapeutic drugs targeting TNF-α and IL-6, and B cell surface antigens CD20 have 
been accepted by the ACR as recommended biological DMARDS to treat RA. However, since 
these cytokines play vital roles in our immune system, blocking their activities often increase 
the chance of infections and malignancies. Treatment with drugs that eliminating B cells 
results similar side effects. Furthermore, current DMARDS sometimes fail or produce partial 
response in certain patients. Therefore, great efforts are still needed to keep looking for new 
molecular candidates to develop safer and more efficacious RA therapies. As discussed in 
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Section 1.4, multiple studies suggest the implication of TL1A in the autoimmune disease; 
however, its role in RA has not been previously investigated. In section 1.5, two recent studies 
have shown that proteasome inhibitors were effective in protecting mice from experimental 
autoimmune diseases. Since Pno1 is essential for the proteasome assembly, blocking its 
function might ameliorate the autoantibody production in RA by disrupting the proteasome 
assembly.  
Here, we chose these two molecules from different categories to investigate their roles in the 
pathogenesis of RA in order to provide information for rational design of better therapeutic 
strategies based on these molecules.  
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CHAPTER 2 ARTICLE-1 
As discussed in Section 1.3, TNF superfamily members play vital roles in the pathogenesis of 
RA. They are involved in the activation, survival, apoptosis and cytokine production of 
various types of cells implicated in RA. In section 1.4, we reviewed the research progress of 
TL1A, a novel TNF superfamily member. Multiple studies have suggested that this molecule 
plays a vicious role in the EAA, EAE and animal disease models of IBD. A recent study has 
further shown the presence of TL1A in synovial tissue of RA patients. However, direct 
evidence showing that TL1A promotes the pathogenesis of RA are yet to be established. In 
this part, in vivo studies using CIA mouse models were performed to confirm the pathogenic 
roles of TL1A in RA. Furthermore, in vitro approaches were used to investigate the 
mechanisms underlying the effect of TL1A. 
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Abstract 
TL1A, a member of the TNF superfamily, is the ligand of DR3 and DcR3.  Several types of 
cells, such as endothelial cells, monocytes/macrophages, dendritic cells and CD4 and CD8 T 
cells, are capable of producing this cytokine. In present study, we demonstrated that TL1A 
aggravated collagen-induced arthritis (CIA) in mice. It increased CIA penetrance and clinical 
scores as well as the severity of the pathological findings. TL1A administration led to the 
occurrence of multiple enlarged germinal centers in the spleen, and boosted serum anti-
collagen Ab titers in vivo. In vitro, TL1A augmented TNF-α production by T cells upon TCR 
ligation, and greatly enhanced Th17 differentiation and IL-17 production. We further showed 
that, human RA synovial fluids had elevated TL1A titres, and human chrondrocytes and 
synovial fibroblasts were capable of secreting TL1A upon TNF-α or IL-1β stimulation. Taken 
together, these data suggest that and TL1A secretion in lymphoid organs might contribute to 
RA initiation by promoting auto-antibody production, and TL1A secretion stimulated by 
inflammatory cytokines in rheumatoid arthritis (RA) joints might be a part of a vicious circle 
that aggravates RA pathogenesis,  
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Introduction 
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting mainly the small joints. 
It is characterized by persistent inflammation of multiple joints. Pathologically,  the major 
finding is synovial hyperplasia, which is mainly composed of fibroblast-like synoviocytes 
combined with an infiltration of a large proportion of T lymphocytes and monocytes1. 
Antibodies appear to be important in causing synovitis2. In addition, the production of various 
cytokines within the synovium plays a crucial role in the inflammatory process. TNF-α and 
IL-1β are considered important mediators of inflammation and tissue destruction in RA3. 
Recently, it has been found that IL-17 plays a significant part in RA pathogenesis4. It induces 
local TNF-α, IL-1β and IL-6 production in the joints. These pathological changes in the joints 
lead to the eventual cartilage and bones damages and loss of mobility at a later stage of the 
disease5-7. 
 
TL1A, a member of the TNF superfamily of cytokines, is designated as TNFSF15. It is coded 
by the TNFSF15 gene located on chromosome 9q32 in humans. TL1A is coded by all 4 exons 
of TNFSF15. Its mRNA is 2.02 knt in length, containing an open reading frame of 251 amino 
acids. However, the 3.3-kb continuous DNA sequence from the beginning of the 3rd  exon 
until the end of the 4th exon of TNFSF15 encodes a different protein called vascular 
endothelial growth inhibitor, or TL18. X-ray crystallography shows that TL1A proteins form 
homotrimers in solution9, like other TNF family members.   
 
Initially, TL1A was believed to be produced only by endothelial cells, and its production was 
induced by TNF-α and IL-1β8. Further studies have shown that it is also secreted by 
monocytes/macrophages and dendritic cells upon immune complex stimulation, and 
constitutively expressed in NKT cells; it is also present in human synovial tissue and 
exudates10-12. In certain chronic inflammatory conditions, such as Crohn’s disease, CD4 and 
CD8 T cells produce this cytokine 13. A repertoire of all TL1A-producing cells has not yet 
been completed.  
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TL1A binds to two proteins, DcR3 and DR3, both of them being TNFR family members.  
DcR3 is a secreted protein. As such, it does not transduce signals into cells, but simply 
interferes with interactions between several ligands and receptors, such as FasL/Fas, 
LIGHT/LTβR, LIGHT/HVEM, and TL1A/DR38,14-16. The DR3 gene produces several 
alternative splicing variants, which can be membrane-bound as well as in secreted form17,18. 
DR3 is expressed on T cells and NK cells, and is upregulated upon their activation17,19. Its 
expression is induced by TGFβ1 and, hence, Th17 cells present especially high DR3 levels20. 
It is detectable in B cells, osteocytes and renal tubule epithelial cells21-23. In DR3 null mutant 
mice, thymocytes experience compromised negative selection24. T- and B-cell populations are 
normal in the periphery lymphoid organs of these mice, but detailed studies on the 
pathogenesis of various diseases have not been conducted.  
 
Soluble TL1A increases IFN-γ and GM-CSF secretion in T cells with TCR ligation, and it 
synergizes with IL-12 to enhance IFN-γ production in T and NK cells25. TL1A enhances the 
ability of NKT cells to secrete IL-13. Mice receiving anti-TL1A Ab or transgenic mice with T 
cells/NK cells expressing dominant negative TL1A are resistant to lung inflammation10. TL1A 
also promotes adhesion of monocytes to endothelial cells, and presumably enhances their 
exudates to extravascular space26. Intracellular IL-17-positive CD4 cells are increased when 
TL1A is present in a condition favoring Th17 differentiation. Conversely, TL1A null mutant 
DC cells have a reduced capability of supporting Th17 cell differentiation20. Furthermore, 
TL1A null mutant mice are resistant to experimental autoimmune encephalitis induction, 
which requires Th1720. These in vitro and in vivo data have demonstrated that TL1A is an 
important mediator of inflammation.   
 
In this study, we explored TL1A’s role in RA pathogenesis. TL1A administration exacerbated 
collagen-induced arthritis (CIA) and augmented serum Abs against collagen in a mouse 
model. Further mechanistic experiments showed that fibroblast-like synoviocytes were 
capable of producing TL1A upon TNF-α and IL-1β stimulation, and TL1A, in turn, enhanced 
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the production of inflammatory cytokines, including TNF-α and IL-17, by T cells. The 
implications of these findings in RA pathogenesis are discussed. 
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Materials and methods 
Reagents 
Recombinant human TL1A (aa 72-251) was produced in CHO cells and subsequently 
processed to more than 95% purity, as described earlier8. Recombinant mouse IL-1β, TNF-
α, TGF-β1, and IL-6 were purchased from R & D systems (Minneapolis, MN). Neutralizing 
mAbs against IFN-γ and IL-4 were obtained from R & D Systems. PE-conjugated anti-IL-17 
mAb was from BD Biosciences (San Jose, CA).   
 
Mouse CIA model 
Eight to 10-wk-old DBA/1LacJ male mice (The Jackson Laboratory, Bar Harbor, ME) were 
used for this study.  The Human Genome Sciences’ Institutional Animal Care and Use 
Committee approved all experimental protocols used in this work. 
 
The scheme of the mouse CIA model is depicted in Fig. 1A. Briefly, DBA/1LacJ mice were 
immunized at the base of the tail with 100 µg of bovine type II collagen (BTIIC; Chondrex, 
Redmond, WA), which was emulsified in equal volumes of Freund’s complete adjuvant (2 
mg/ml Mycobacterium tuberculosis, strain H37Ra; Difco, Detroit, MI) on day 0.  Three 
groups of immunized mice were then injected i.p. daily with buffer (PBS), TL1A (1 
mg/kg/day) or heat-denatured TL1A (HD-TL1A), respectively, from day 5 to 20. As a positive 
control, a fourth group was challenged on day 15 with a single s.c. injection of LPS (60 
mg/mouse).  The mice were examined for the development and severity of arthritis from day 5 
to 50. Disease severity was scored on a scale from 0 to 3 by visual inspection of paws, and 
score criteria were as follows: 0.5, one or more swollen digits; 1.0, entire paw swollen; 2.0, 
deformity following acute edema; and 3.0, ankylosis, i.e., total loss of joint function. The 
scoring was done by two independent observers without knowledge of the experimental 
groups. The scores for each of four paws were added together to give a final score, such that 
the maximal severity score was 12 for a given mouse. The mice were considered as having 
arthritis if their clinical score was equal to or above 0.5. 
 
Histology 
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After sacrificing animal on day 50, fore-paws and hind-paws (including the paw and ankle) 
were surgically removed and fixed in 10% buffered formalin. Following decalcification in 5% 
formic acid, the specimens were processed for paraffin embedding. Tissue sections (7 µm) that 
were stained with hematoxylin and eosin, were scored by a certified pathologist for mean 
inflammation, pannus formation, cartilage damage, and bone damage. The overall score was 
based on a set of three to four joints per animal and all were scored on a 0–5 scale, as 
previously described27. A mean score for each animal was determined for each parameter, and 
these were averaged to determine group means. 
 
Chondrocyte culture 
Human osteoarthritis (OA) cartilage samples from femoral condyles and tibial plateaus were 
obtained from OA patients undergoing total knee replacement (n = 4; mean ± SD of age: 64 ± 
11 years). All OA patients were diagnosed according to the criteria developed by the 
American College of Rheumatology Diagnostic Subcommittee for OA28. At the time of 
surgery, the patients had symptomatic disease requiring medical treatment in the form of non-
steroidal anti-inflammatory drugs or selective COX-2 inhibitors. Patients who had received 
intraarticular injections of steroids were excluded. The Clinical Research Ethics Committee of 
Notre-Dame Hospital approved the study protocol and the use of human articular tissues. 
 
Chondrocytes were released from cartilage by sequential enzymatic digestion, as described 
previously 29[36]. In brief, this consisted of 2 mg/ml pronase for 1 h followed by 1 mg/ml type 
IV collagenase (Sigma, St. Louis, MO) for 6 h at 37°C in DMEM and antibiotics (100 U/ml 
penicillin, 100 µg/ml streptomycin). The digested tissue was briefly centrifuged and the pellet 
was washed. The isolated chondrocytes were seeded at high density in tissue culture flasks and 
cultured in DMEM supplemented with 10% heat-inactivated FCS. At confluence, the 
chondrocytes were detached, seeded at high density, and allowed to grow in DMEM, 
supplemented as above.  The culture medium was changed every second day, and 24 h before 
the experiment, the cells were incubated in fresh medium containing 0.5% FCS. Only first-
passage chondrocytes were used. 
 
Synovial fibroblast (SF) culture 
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Human SF was isolated from synovial membranes obtained from OA patients undergoing total 
knee replacement as described above. They were released by sequential enzymatic digestion 
with 1 mg/ml pronase (Roche Applied Science, Laval, Quebec, Canada) for 1 h, followed by 
6-h incubation with 2 mg/ml type IV collagenase (Sigma) at 37°C in DMEM supplemented 
with 10% heat-inactivated FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells 
were incubated for 1 h at 37°C in Primaria 3824 tissue culture flasks (Falcon, Lincoln Park, 
NJ), allowing the adherence of nonfibroblastic cells possibly present in the cell preparation. 
After removing the adherent nonfibroblastic cells, non-adherent cells were seeded in tissue 
culture flasks and cultured until confluence in DMEM supplemented with 10% FCS and 
antibiotics. Only cells between passages 3 and 7 were used.   
 
Human synovial fluids 
Normal human synovial fluids were obtained at necropsy, within 12 hours of death, from 4 
donors (54 ± 8 years,) with no history of arthritic diseases.  RA synovial fluids were obtained 
from 7 patients (57 ± 14 years, mean ± SD) undergoing total knee replacement. All patients 
were diagnosed on criteria developed by the American College of Rheumatology. Patients 
who had received intra-articular injections of steroids were excluded.  
 
ELISA 
For TL1A assays, flat-bottom 96-well plates (Costar EIA/RIA plate #3590, Fisher Scientific, 
Pittsburgh, PA) were coated with anti-TL1A capture mAb (15E09) (50 µl/well at 3 µg/ml) 
diluted in NaHCO3 buffer (pH 9.0), and incubated overnight at 4oC. After blocking for 1h at 
room temperature with 3% BSA in PBS, the plates were washed with washing buffer (0.05% 
Tween 20 in PBS). Samples (50 µl/well) were added to the wells and incubated overnight at 
4oC. After an extensive wash, 50µl/well of affinity-purified biotinylated-anti-TL1A rabbit 
polyclonal Ab at 0.1 µg/ml were added and incubated at room temperature for 2h. Fifty 
microliters/well of horseradish peroxidase-conjugated streptavidin (R & D Systems) diluted 
1/200 in washing buffer were added after extensive washing. One hour later, the plates were 
washed, and 50 µl/well of tetramethylbenzidine (Sigma) were added and incubated for 30 min 
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at room temperature in the dark. Fifty microliters/well of 2N H2SO4 were added to stop the 
reaction, and optical densities were determined at 450 nm. Samples were assayed in duplicate. 
 
To detect serum anti-bovine collagen Ab (total IgG and IgG2a), mice were tail bled before 
being sacrificed on day 50. Serum samples were analyzed with ELISA kits from Chondrex 
following the manufacturer’s instructions.   
 
IFN-γ, TNF-α, IL-2 and IL-17 were measured by ELISA with kits from R & D Systems, 
according to the manufacturer’s instructions.  Samples were assayed in triplicate. 
Reverse transcription-quantitative PCR (RT-qPCR) 
Total RNA was isolated from chondrocytes, SF or mouse joints with the Trizol reagent. TL1A 
and DR3 mRNA in human chondrocytes, SF and mouse joints was measured by RT-qPCR. 
For human TL1A mRNA measurement, the forward primer 5’-
AGGACAGGAGTTTGCACCTTCACA-3’ and reverse primer 5’-
AGTGCTGTGTGGGAGTTTGTCTCA-3’ were employed to generate a 110-bp fragment. For 
mouse TL1A mRNA measurement, the forward primer 5’-
TCATTTCCCATCCTCGCAGGACTT-3’ and reverse primer 5’-
TAATTGTCAGGTGTGCTCTCGGCT-3’ were employed to generate a 166-bp fragment. For 
DR3 human mRNA measurement, the forward primer 5’-
AAGGCGAAGAAGCACGAACGAATG-3’ and reverse primer 5’-
ACTCCGGCCGAGAAGTTGAGAAAT-3’ were employed to generate a 66-bp fragment. 
The PCR conditions for these reactions were as follows: 2 min at 95oC, followed by 45 cycles 
of 10 s at 95oC and 15 s at 56oC, and 20 s at 72oC. Samples were in triplicate. β-actin mRNA 
levels was taken as internal controls, and the data were expressed as signal ratios of TL1A 
mRNA/β-acting mRNA and DR3 mRNA/β-actin mRNA. 
  
In vitro Th1, Th2 and Th17 polarization 
Th1 and Th17 populations were polarized from naïve DBA/1LacJ CD4+ T cells, which were 
isolated from pooled splenocytes and lymph node cells using Naïve CD4+ T Cells Isolation Kit 
(R&D Systems, Minneapolis, MN). The purity of naïve CD4+ cells was routinely greater than 
95%. Purified naïve T cells (0.25×106/well) were mixed with  T-cell-depleted irradiated 
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(3000 Rads) DBA/1LacJ feeder splenocytes  (1.25×106 cells/well), and cultured in 96-well 
plates in RPMI medium 1640 containing 10% FCS, 100 µg/ml streptomycin, 100 units/ml 
penicillin G, 1× nonessential amino acids, 1 µM sodium pyruvate, and 2.5 µM β-
mercaptoethanol, and soluble anti-CD3ε mAb (clone 145-2C11, 2µg/ml. Th2 polarization was 
started with total CD4+ T cells, which were purified with EasySep Mouse CD4 Positive 
Selection Kit (STEMCELL Technologies, Vancouver, BC, Canada). Purified total CD4+ T 
cells (0.4×106/well) were mixed with  irradiated (3000 Rads) T-cell-depleted DBA/1LacJ 
feeder splenocytes  (0.2×106 cells/well), and cultured in 96-well plates in the same medium 
used for Th1 and Th17 polarization. 
 
For Th1 polarization, 10 ng/ml rmIL-12 and 10 µg/ml anti-IL-4 mAb (clone 11B11) were 
added to the culture. For Th2 polarization, 20ng/ml rmIL-4 and 10 µg/ml of both anti-IL-12 
mAb (10 µg/ml; BD Bioscience) and anti-IFN-γ mAb (10 µg/ml; R & D Systems) were added. 
For Th17 polarization, cultures were supplemented with recombinant mouse IL-6 (20 ng/ml; R 
& D Systems), recombinant human TGF-β1 (5 ng/ml; R & D Systems) and anti-IL-4 and anti-
IFN-γ mAb (10 µg/ml; R & D Systems). Recombinant human TL1A was added at 
concentrations of 0, 40, 200, 1000 ng/ml. 
 
For IL-17 assays, cells were washed and stimulated with 5 nM of PMA and 500 ng/ml of 
ionomycin in the last 4 hours of 3 days culture; the supernatants were then collected for 
cytokine analysis. For IFN-γ and IL-4 assays, the cells were kept in culture for 5 days, and 
then stimulated with 5 nM of PMA, 500 ng/ml of ionomycin and 50U/ml rhIL-2 in the last 12 
hours, and the following steps are as same as that of IL-17. 
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Results 
TL1A aggravated CIA in mice 
With mouse CIA as a model, we investigated the roles of TL1A in disease development. 
DBA/1LacJ mice were immunized i.p. with BTIIC in CFA. A group was injected with PBS as 
negative controls, which did not develop any disease, as expected. Eighty percent of the 
BTIIC-immunized mice (CIA-PBS group) developed CIA within 50 days (Fig. 1B). Disease 
onset followed a slow kinetics, as CIA was not detected before day 24, and at day 40, only 
35% of the mice showed CIA. As a positive control, a group of BTIIC-immunized mice was 
boosted with LPS (CIA-LPS group) on day 14, and it induced a rapid onset of arthritis within 
2 days, i.e., on day 16, 80% of the mice became arthritic, and on day 20, 90%. When human 
recombinant TL1A (in all experiments of this study, the recombinant TL1A used was of 
human) was administered from day 5 to 20 (CIA-TL1A group), it significantly aggravated 
CIA induction. The disease started its manifestation earlier (day 20), compared to BTIIC 
immunization alone (day 24), and presented 100% penetrance on day 40, compared to only 
35% for BTIIC immunization alone. On the other hand, BTIIC-immunized mice treated with 
heat-inactivated TL1A (CIA-HDTL1A group) showed disease development kinetics similar to 
that of BTIIC immunization alone. This ruled out the possibility that the aggravated CIA in 
TL1A-injected mice (CIA-TL1A group) was due to pyrogen contamination in the TL1A 
preparation, or due to its non-specific effect as a foreign antigen, as the recombinant human 
TL1A was used in our experiment. 
 
The data are also presented in the form of clinical scores (Fig. 1C and 1D). Throughout the 50-
day observation period, the BTIIC-immunized group did not present a mean clinical score 
above 2. Administration of heat-denatured TL1A from day 5 to 20 had no obvious effect (Fig. 
1C). In the positive control group with LPS injection at day 15, the clinical score rapidly 
increased from 0 to a mean of 2.5 in 2 days. In the group that received TL1A for 15 days from 
day 5 to 20, the clinical score was significantly elevated, as its mean scores reached 3.0 on day 
38 and 5.0 on day 50, compared to the CIA-PBS control group (Fig. 1C). At the end of the 
study on day 50, the score of this test group was significantly higher than that of the CIA-PBS 
group and the CIA-HDTL1A group (p=0.0015 and p=0.004, respectively) (Fig. 1D). 
 59 
Representative histology sections of hind paws of CIA-PBS and CIA-TL1A mice at day 50 are 
illustrated in Fig. 2A. The left panel shows relatively normal histology of a CIA-PBS hind 
paw.  The right panel is from a paw affected by TL1A-aggravated CIA. The pathological 
findings included obvious cartilage damage with synovial layer loss, severe pannus formation, 
and bone destruction and deformation. There were severe inflammatory changes including 
congestion, edema and significant cell infiltration within the articular space, and around or 
between joints. Diffused cell infiltration in the subcutaneous area was also observed. The 
histopathology of each treatment group was scored semiquantitatively, and the results were 
depicted in Fig. 2B. While CIA-PBS and CIA-HDTL1A groups showed no difference in their 
scores, the score of the CIA-TL1A group was significantly higher than that of these two 
groups.  
 
It is to be noted that LPS-treated mice presented high clinical but low pathological scores. LPS 
triggers innate immune responses and inflammatory cytokine releases. It mainly causes 
swelling and loss of function of joints, but results in little cartilage and bone damage. Thus, 
LPS-treated mice showed high clinical scores, which were based on joint swelling and 
function. On the other hand, severe pathological scores were based on pannus formation, 
cartilage damage, and bone damage, which were absent in LPS-treated mice.  
 
TL1A increased humoral immune responses in vivo 
Collagen-specific auto-Abs are pathogenic in RA, and are directly disease-causative in CIA. 
Serum collagen-specific IgG and IgG2a levels were measured at the end of the study on day 50 
in mice receiving different treatments (Fig. 3). Naïve mice (naïve-PBS group) presented no 
anti-collagen IgG (Fig. 3A) and IgG2a Abs (Fig. 3B). The CIA-PBS and CIA-HDTL1A groups 
had similar levels of collagen-specific IgG and IgG2a Abs, but these Abs were elevated in the 
CIA-LPS group, as expected. In the CIA-TL1A group, levels of these Abs were significantly 
higher  than those of the CIA-PBS group (for both IgG and IgG2a, p<0.05 between the CIA-
TL1A and CIA-PBS groups, and p<0.01 between the CIA-TL1A and CIA-HDTL1A groups).  
 
Secondary lymphoid organs, such as the spleen, are the place where B cells undergo activation 
and differentiation, and become Ab-producing plasma cells. We examined the effect of TL1A 
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on spleen histology. As shown in Figure 3C, in the normal spleen (left panel), small germinal 
centers were occasionally present in the white pulp. However, in the spleen of mice treated 
with TL1A (3 mg/kg/day for 10 days without any additional immunization), there were many 
enlarged germinal centers displayed lightly stained areas, which might have been due to cell 
proliferation.  This suggests that TL1A could promote humoral immune responses, and 
explains the significantly augmented anti-collagen Ab levels in mice with BTIIC-
immunization followed by TL1A treatment. 
 
TL1A expression in synovial fluids and cells in joints 
Inflammatory cytokines locally produced in joints play an important role in RA pathogenesis. 
To test whether TL1A was produced locally in joints, we first assessed its presence in RA 
synovial fluids. As shown in Fig. 4A, TL1A was below the detection level in synovial fluids 
of 4 non-RA individuals. On the other hand, 5 out of 6 synovial samples from RA patients 
showed elevated TL1A levels.  
 
We also tested TL1A expression in joints from CIA mouse joints, and found its mRNA level 
was significantly augmented, compared to that of joints of naïve mice (Fig. 4B), suggesting 
the involvement of local TL1A in CIA pathogenesis. 
  
To identify the cell source of synovial fluid TL1A, human chondrocytes and SF were cultured 
in plain medium or in the presence of inflammatory cytokines IL-1β or TNF-α, and their 
TL1A mRNA levels were quantified by RT-qPCR. As shown in Figure 4C, chondrocytes in 
the resting state had barely detectable TL1A mRNA, but its expression increased in the 
presence of TNF-α but not IL1β after 24 h. SF presented higher constitutive TL1A mRNA 
level, and the expression increased slightly after IL1-β treatment, but significantly after TNF-
α stimulation (Fig. 4C). Careful kinetic study revealed that TL1A mRNA was rapidly elevated 
in SF within 3-6 h after IL-1β stimulation, while it took 20 h to reach high levels after TNF-α 
stimulation (Fig. 4D). At the protein level, both IL-1β and TNF-α dose-dependently enhanced 
TL1A secretion by SF at 24 h after culture (Fig. 4E, top panel), and 48-h supernatants 
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contained more TL1A than 24-h supernatants (Fig. 4E, bottom panel). This result revealed that 
SF was a source of local TL1A, which might influence inflammation in situ in the joints.  
 
On the other hand, neither chodrocytes nor SF showed apparent constitutive DR3 mRNA 
expression, nor did they upregulate DR3 expression after IL-1β and TNF-α stimulation (Fig. 
4C), indicating that TL1A was unlikely to exert an autocrine effect on these cells. Indeed, 
TL1A did not affect proliferation of chondrocytes and SF, nor did it impact their apoptosis 
(data not shown). Therefore, chondrocytes and SF seemed not to be the intended targets of 
locally produced TL1A by SF. 
 
TL1A expression in secondary lymphoid organs 
In mouse CIA, systemic TL1A administration increased titres of anti-collagen Ab, which are 
pathogenic. In RA patients, particularly those rheumatic factor positive patients, their serum 
TL1A levels are increased 30.This implies that extra-articular TL1A might also be involved in 
pathogenesis of RA and mouse CIA. We assessed whether TL1A was produced in secondary 
lymphoid organs in our CIA model. We showed that TL1A expression was induced in MHC 
class II+/CD11c+ DC (Fig. 5A) and F4/80+ macrophages/monocytes (Fig. 5B) in draining 
inguinal lymph nodes 2 weeks after tail base injection of CFA or of CFA plus collagen. CFA 
alone was sufficient to upregulate TL1A, and the presence of collagen alone with CFA further 
increased TL1A expression in these cells.  
 
Effect of TL1A on lymphokine production 
In RA, considerable T lymphocyte infiltration occurs in joints once the disease starts. What is 
the effect of local TL1A on these cells, which are known to express TL1A receptors, i.e., 
DR3? We assessed the influence of TL1A on lymphokine secretion by T cells, With TCR 
ligation, TL1A enhanced TNF-α production in a dose-dependent manner (Fig. 6A). Under a 
Th17-differentiation condition, the presence of TL1A in culture drastically increased IL-17 
secretion (Fig. 6B). It is conceivable these local inflammatory cytokines, i.e., TNF-α and IL-
17, triggered by TL1A could aggravate RA pathogenesis. On the other hand, under Th1 and 
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Th2 differentiation condition, the production of Th1 cytokine IFN-γ (Fig. 6C) and Th2 
cytokine IL-4 (Fig. 6D) by T cells was not apparently influenced by the present of TL1A.  
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Discussion 
In this study, we reported that TL1A aggravated RA in a mouse CIA model. Mechanistic 
investigation discerned that under stimulation of inflammatory cytokines, such as IL-1β and 
TNF-α, SF was capable of producing TL1A, which, in turn, could enhance the production of 
inflammatory cytokines, such as IL-17 and TNF-α. This study revealed a possible role of 
TL1A in RA pathogenesis.  
   
In our CIA mouse model, the systemic administration of TL1A could have pathogenic effects 
on two fronts. One is in the joints locally. As demonstrated in our in vitro study, TL1A 
promoted T cells to secrete locally TNF-α, an established culprit in RA development3. It also 
promoted local IL-17 production, which has also been implicated in RA pathogenesis4. The 
second front is probably in the lymphoid organs, such as the spleen and bone marrow, where 
Abs are produced. TL1A drastically increased the size and number of germinal centers in the 
spleen, suggesting that it could drive B-cell activation and differentiation. Indeed, mice 
receiving TL1A showed heightened titers of serum anti-collagen Ab, which is pathogenic in 
both mouse CIA and RA patients31. The effect of TL1A on B cells is probably indirect via T 
cells, because B cells display almost no DR38, and we could not detect any direct effect of 
TL1A on B-cell activation and proliferation (data not shown).  
 
Is TL1A a relevant factor involved in RA pathogenesis? In mouse CIA, we identified 
increased TL1A mRNA in inflammatory joints. In humans, we discovered elevated TL1A 
titres in RA synovial fluids, and found that SF under the influence of IL-1β and TNF-α could 
evoke TL1A secretion. This puts TL1A into a possible loop of a vicious circle that aggravates 
RA pathogenesis. Once RA is in progress, local IL-1β and TNF-α  levels are increased in the 
joints, produced mainly by monocytes/macrophages32. In addition to their harmful effects in 
causing local inflammation33,34, these cytokines could also trigger SF to produce TL1A, which 
could, in turn, augment TNF-α production by infiltrating T cells in the joints. The IL-17 
induced by TL1A could be another detrimental factor ramified from this vicious loop, causing 
further local inflammation in the joints.  
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In a study that was published while our manuscript was under revision, Bamias et al. 
demonstrated that rheumatic factor-positive RA patients showed elevated serum TL1A titres30. 
The increased serum TL1A titres in RA patients suggest that TL1A outside the joints may also 
play a role in RA pathogenesis. We have shown that bacterial antigen stimulation in the form 
of CFA was sufficient to trigger TL1A expression in DC and monocytes/macrophages in 
draining lymph nodes. It is possible that under a pathophysiological condition, certain RA 
susceptible individuals have increased TL1A titres in secondary lymphoid organs upon 
environmental Ag stimulation; the augmented TL1A levels enhance the production of Ab, 
some of which might be autoreactive to joint tissues; this process then initiates RA 
pathogenesis. 
 
In this regard, it is noteworthy that DR3 gene duplication in chromosome region 1p36.3 is 
prevalent in RA patients35, raising the possibility that TL1A and DR3 interaction indeed plays 
a role in human RA pathogenesis.  
 
In summary, we demonstrated that TL1A is a novel mediator involved in RA pathogenesis, 
and is a possible therapeutic target for this disease. 
 
Note added in proof: While our manuscript was under review, Bull et al36, reported that DR3 
(the receptor of TLlA) gene knockout mice were resistant to antigen-induced arthritis (AIA). 
They further demonstrated that anti-TL1A mAb could reduce severity of both AIA and CIA in 
mice. These new findings support our conclusion that TL1A might have pathogenic roles in 
mouse CIA and human RA. 
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Figure legend 
Figure 1.  TL1A aggravates CIA clinical scores in mice 
A. Scheme of CIA induction and TL1A administration 
B. RA  incidence in mice receiving different treatments 
Naïve-PBS: naïve mice received PBS i.p. from day 5 to 20; CIA-PBS: mice received 
BTIIC immunization on day 0, and PBS from day 5 to 20; CIA-LPS: mice received BTIIC 
immunization on day 0, and a single LPS (60 mg/mouse) injection s.c. on day 15; CIA-
TL1A:  mice received BTIIC immunization on day 0, and daily i.p. TL1A (1 mg/kg/day) 
injection from day 5 to 20; CIA-HDTL1A: mice received BTIIC immunization on day 0, 
and daily heat-denatured TL1A (1 mg/kg/day) injection i.p. from day 5 to 20. n=10 for 
each group. 
C. RA clinical scores of mice receiving different treatments during 50 days of observation 
Mice from Fig.1B were scored for their RA condition on the days indicated, and mean 
scores + SEM were plotted. 
D. RA clinical scores of mice receiving different treatments on day 50 after initial BTIIC 
immunization 
Mice from Figure 1B were scored for their RA condition on day 50 after the BTIIC 
immunization. The horizontal lines represent mean scores of the group. Differences in 
scores between the CIA-TL1A and CIA-PBS groups, and between the CIA-TL1A and 
CIA-HDTL1A groups were highly significant (p=0.0015 and p=0.004, respectively; 
ANOVA t test).  
 
Figure 2. Effect of TL1A on CIA histology  
A. Histology of mouse joints 
DBA/1LacJ mice were immunized with BTIIC to induce CIA in the absence or presence 
of TL1A injection. They were sacrificed on day 50 and the hind paws were sectioned and 
stained with H&E. The left panel shows a hind paw from a CIA-PBS mouse, and the right 
panel, a hind paw from a CIA- TL1A mouse. 
B. Histopathological scores of mouse joints 
Mice from Figure 1B were sacrificed on day 50, and joint histology was scored semi-
quantitatively. The horizontal bars represent the mean scores of each group (n=10). The 
histopathological scores of the CIA-TL1A group are significantly higher than those of the 
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CIA-PBS and CIA-HDTL1A groups (p=0.0006 and p=0.002, respectively; ANOVA t 
test). 
 
Figure 3. TL1A enhances humoral immune responses 
 A and B. Effect of TL1A on serum collagen-specific Abs 
Sera from mice as described in Figure 1B were collected at the time of sacrifice (day 50 
after initial BTIIC immunization). Collagen-specific IgG Ab (Fig. 3A) and IgG2a Ab (Fig. 
3B) were measured by ELISA. The data are expressed as unit/ml of 1:100 diluted sera. 
The horizontal bars represent the means of each group (n=20). Serum collagen-specific 
IgG and IgG2a levels in the CIA-TL1A group are significantly higher that those in the 
CIA-PBS and CIA-HDTL1A groups (p values are indicated in the graphs; ANOVA t test). 
C. TL1A drastically increases spleen germinal center formation 
DBA/1LacJ mice were injected i.p. with TL1A (3 mg/kg/day) for 10 days, and spleen 
histology is shown. Left panel: normal spleen from a naïve mouse; right panel: spleen 
from a TL1A-injected mouse. 
 
Figure 4. TL1A production in humans 
A. Synovial fluid TL1A levels in patients with rheumatic diseases are elevated 
Synovial fluids from RA joints (n=7) or from non RA joints (n=4) were assayed for TL1A 
by ELISA. Mean + SD of triplicate samples are shown. Each bar represents an individual 
patient. Non-RA synovial fluid TL1A levels were below the detection level of the assay.  
 
B. Augmented TL1A mRNA expression in mouse CIA joints 
RNA was extracted from skinless proximal interphalangeal joints of CIA (3 weeks after 
collagen/CFA injection) or naïve mice, and TL1A mRNA was quantified by RT-qPCR, 
using β-actin mRNA as internal control. The signal ratios of TL1A mRNA/β-actin mRNA 
are presented. Each symbol represents an individual mouse. Short horizontal bars represent 
mean signal ratios of each group. TL1A signals of the RA group is significantly higher 
than those of the naïve group (p<0.01, Student’s t test) 
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C. TL1A and DR3 mRNA levels in human chondrocytes and SF  
Human chondrocytes and SF were cultured in the presence or absence of IL-1β 
(200pg/ml_) and TNF-α (10 ng/ml).  Samples were in duplicate. The cells were harvested 
from 45 min until 24 h after culture, and TL1A and DR3 mRNA levels were determined 
by RT-qPCR, using β-actin mRNA as internal control. The signal ratios of TL1A 
mRNA/β-actin mRNA are presented. 
 
D. Kinetics of TL1A mRNA expression from 45 min to 20 h after culture 
 
E. TL1A in SF culture supernatants 
Human SF were cultured in the presence of various concentrations of IL-1β and TNF-α for 
24 h (upper panel), or 24 h and 48 h (lower panel). Samples were in triplicate. Cytokine 
concentrations are indicated. TL1A in the supernatants were determined by ELISA. Means 
+ SD of TL1A concentrations in each sample are illustrated.  
 
Data of Figs. 4C-4E are from representative experiments, and similar results were obtained 
in 2-3 independent experiments. 
 
 
Figure 5. TL1A was upregulated in DC and macrophages/monocytes of inguinal lymph 
nodes of immunized mice 
A.  TL1A was upregulated in MHC-II and CD11c double positive DC cells 
DBA/1J mice were immunized with CFA+PBS or CFA+BTIIC, and sacrificed on day 14. 
TL1A expression on inguinal lymph node DC cells was assessed by MHC-II, CD11c and 
TL1A 3-color staining followed by flow cytometry. The MHC-II and CD11c double 
positive DC cells were gated for TL1A expression analysis.  
 
B. TL1A was upregulated in F4/80 positive monocytes/macrophages 
Cells isolated from inguinal lymph nodes of immunized mice were also stained with Abs 
against F4/80 and TL1A, expression of TL1A was showed in histogram. 
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Figure 6. Effect of TL1A on lymphokine production 
A.  Effect of TL1A on TNFα secretion by anti-CD3-stimulated T cells 
Purified T cells from DBA/1LacJ mice were stimulated by solid phase anti-CD3 (0.25 
µg/ml for coating) in the presence or absence of TL1A (concentrations indicated). Samples 
were in triplicate. After 48 h, the culture supernatants were harvested and TNF-α 
concentrations were measured by ELISA. Means + SD of a representative experiment are 
shown. Similar results were obtained in 3 independent experiments. 
 
B. Effect of TL1A on IL-17 secretion under a Th17-differentiation condition 
Naïve CD4+ cells from DBA/1LacJ mouse spleens were cultured under a Th17-
differentiation condition for 3 days. Samples were in duplicate. For the last 4 h of culture, 
the cells were stimulated with 10 nM PMA and 1 µg/ml ionomycin. The culture 
supernatants were then harvested and assayed for and IL-17 by ELISA. Means + SD of a 
representative experiment are shown. Similar results were obtained in 3 independent 
experiments. 
 
C and D. Effect of TL1A on INFγ and IL-4 secretion under Th1- and Th2-differentiation 
conditions, respectively 
Naïve CD4+ cells or total CD4+from DBA/1LacJ mouse spleens were cultured under Th1- 
or Th2-differentiation conditions for 5-7 days. Samples were in duplicated. For the last 12 
h of culture, the cells were washed and stimulated with 10 nM PMA and 1 µg/ml 
ionomycin. The culture supernatants were then harvested and assayed for IFN-γ and IL-4, 
respectively, by ELISA. Means + SD of a representative experiment are shown. Similar 
results were obtained in 3 independent experiments. 
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Figure 2.1 
 
 
 
 
 
 
 
 
  
 75 
 
Figure 2.2 
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Figure 2.3 
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Figure 2.4 
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Figure 2.5 
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Figure 2.6 
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CHAPTER 3 ARTICLE-2 
Gene knockout mice were widely used to study the functions of certain molecules related to 
the human disease. As shown in Section 1.3, gene knockout mice in combination with animal 
models of arthritis provided us invaluable knowledge to understand the pathogenesis of RA. In 
this study, we generated TL1A KO mice in order to investigate whether CIA could be affected 
in absence of TL1A. We also evaluated the immune systems of TL1A KO mice with both in 
vitro and in vivo approaches. The information generated in this study might be helpful to 
predict the potential side effects of TL1A-targeting therapies. 
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Abstract 
TNF-like ligand 1A (TL1A), also known as TNFSF15, is a member of the TNF superfamily.  
Its known receptor is death receptor 3 (DR3). In humans, TL1A also binds to a secreted TNF 
family member called decoy receptor 3 (DcR3), which interferes with the interaction between 
TL1A and DR3. TL1A/DR3 signal has been implicated in several autoimmune diseases in 
animal models as well as in clinical conditions. We generated TL1A gene knockout (KO) 
mice to assess its role in collagen-induced arthritis (CIA), a mouse model of human 
rheumatoid arthritis. The KO mice were fertile and had no visible anomalies. Their lymphoid 
organ size and cellularity, T and B cell subpopulations, helper T cell and regulatory T cell 
development in vivo and in vitro and anti-viral immune responses were comparable to those of 
wild type mice. However, the KO mice presented ameliorated CIA in terms of clinical scores, 
disease incidence and pathological scores. The KO mice had reduced titres of pathogenic anti-
collagen Abs in the sera. No apparent defect was found in the function of follicular helper T 
cells. We revealed that plasma cells but not B cells expressed high levels of DR3, and were 
direct targets of TL1A. In the presence of TL1A, they survived better and produced more 
pathogenic Ab. This study presented novel knowledge about the role of TL1A in humoral 
immune responses and its mechanism of action in CIA pathogenesis.    
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Introduction 
TNF-like ligand 1A (TL1A), also called TNFSF15, is a member of the TNF superfamily.  It 
was identified during homology searches in an endothelial cell cDNA library.  It is produced 
by the endothelial cells(1), monocytes, dendritic cells, T cells, natural killer T cells (NKT), 
synovial fibroblasts and chondrocytes, either upon stimulation or in situ in inflammatory 
sites(2-6).  Like other TNF superfamily members, TL1A can either be membrane-bound or 
soluble after being cleaved from the cell surface, but the cleavage happens on dendritic cells 
(DC) and not on T cells(1, 7). It was also discovered that the soluble form of TL1A was more 
potent in inducing IFN-γ production by T cells(8). 
The receptor of TL1A death receptor 3 (DR3) is also called TNFRSF25, Apo3, WSL-1, 
TRAMP or LARD(9).  In addition to the full length isoform, murine DR3 was reported to 
have two truncated variants: one secreted form displaying no transmembrane region and 
another lacking the fourth CRD in its extracellular sequence (10).  A repertoire of all DR3-
expressing cells has not yet been completed.  DR3 is detectable on T cells, NK cells, NKT 
cells, osteocytes, renal tubule epithelial cells and in vitro plasma cells, but primary B cells 
express very low levels of DR3(3, 11-13). Previous studies of the immunological functions of 
TL1A and DR3 primarily focused on T cells, NK cells and NKT cells(3, 12, 14-16). In 
addition to DR3, DcR3 could also bind to TL1A in humans, and blocks the interaction 
between TL1A and DR3(1). Mice do not have a human DcR3 orthologue. 
Earlier in vitro studies have shown that TL1A promotes T cell proliferation, Th17 
differentiation and the production of pro-inflammatory cytokines by T cells (9), indicating its 
potential role in inflammatory autoimmune diseases.  The presence of TL1A in diseased 
tissues, fluids and sera from patients of chronic colitis and rheumatoid arthritis (RA) 
corroborates the findings in animal models (2, 5, 17-19). In vivo studies of different animal 
models have provided direct evidence supporting the role of TL1A in autoimmune diseases. 
We have demonstrated that the administration of recombinant TL1A to mice with collagen-
induced arthritis (CIA) aggravates the disease (5). Furthermore, overexpression of TL1A in 
transgenic mice results in spontaneous inflammatory bowel disease (IBD) as well as increased 
number of T helper cells (9, 20, 21).  On the other hand, DR3 gene knockout (KO) mice have 
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reduced disease severity of allergic lung inflammation and antigen-induced arthritis  and 
present less effective anti-viral and anti-bacterial immune responses(15, 22-25). Blocking 
DR3-TL1A interaction by TL1A-neutralizing Ab would partially protect the KO mice from 
CIA, lung inflammation, and 2,4,6-trinitrobenzene sulfonic acid (TNBS)- and dextran sodium 
sulphate (DSS)-induced colitis(3, 4, 9, 23).  TL1A KO mice are less susceptible to 
experimental autoimmune encephalomyelitis (EAE) induction(22).   
Rheumatoid arthritis (RA) is a chronic polygenic autoimmune disease characterized by 
chronic systemic inflammation that may affect various tissues and organs.  Joints and their 
surrounding tissues are most frequently affected.  Often, there is persistent synovitis and 
presence of auto-Abs leading to progressive destruction of cartilage and bone in the joints 
(26).  The pathogenesis of RA is not fully understood with three primary, outstanding 
questions to be fully answered: (1) How is the immune response initiated by genetic and/or 
environmental factors? (2) How does the immune response lead to local joint inflammation? 
(3) How does the inflammation cause bone destruction.  There are some findings from patients 
and animal models that have provided some partial answers to these questions(27-36). 
In the current study, we generated TL1A knockout (KO) mice to study the role of TL1A in 
CIA pathogenesis.  We found TL1A KO mice had significantly lower CIA clinical scores and 
incidence, and lower serum anti-collagen Ab titres than their wild type (WT) counterparts.  
Deletion of TL1A minimally affected T cell functions; however, TL1A could directly deliver 
survival signals to plasma cells as a way to promote pathogenic collagen-specific Ab 
production.  Our findings revealed previously undocumented functions of TL1A in RA 
pathogenesis. 
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Materials and Methods 
Generation of TL1A KO mice  
A polymerase chain reaction (PCR) fragment amplified from the TL1A cDNA was used as 
probe to isolate genomic BAC DNA clone 112H6 from the 129/sv mouse BAC genomic 
library RPCI-22.  The targeting vector was constructed by recombination and routine cloning 
methods using an 11-kb TL1A genomic fragment from clone 112H6 as the starting material 
(Fig. 1A) (37).  The 2.05-kb ScaI-XhoI genomic fragment containing exon 1 was replaced by 
a 1.1-kb Neo cassette from pMC1Neo Poly A (Fig. 1A).  The final targeting fragment was 
excised from its cloning vector backbone by Not I digestion and electroporated into R1 
embryonic stem (ES) cells for G418 (38).   The targeted ES cell clones were injected into 
C57BL/6 blastocysts.  Chimeric male mice were mated with C57BL/6 females to establish 
mutated TL1A allele germline transmission.   
Southern blotting with a probe corresponding to the 5’ sequence outside the targeting region, 
as illustrated in Figure 1A (hatched rectangle) was used to screen gene-targeted ES cells and 
eventually for the confirmation of the gene deletion in mouse tail DNA.  The targeted allele 
showed an 11.7-kb StulI/StulI band, and the WT allele, a 5.4-kb StulI/StulI band.   
The TL1A-KO mice were subsequently backcrossed to the DBA/1LacJ for 8 generations for 
experimentation in this study.  The littermate WT mice served as controls.  In the beginning of 
the experiments, mice were on average 8 to 12 weeks of age.   
PCR was adopted for routine genotyping of the targeted allele(s).  The following PCR 
conditions were applied: 4 min at 94  oC, followed by 35 cycles of 30 s at 94 oC, 30 s at 68 oC, 
and 30 s at 72 oC with final incubation at 72 oC for 10 min.  One forward primer and two 
reverse primers (forward primer 5'- TCC ACA GCC AAC ATA GGC AAG GA-3'; reverse 
primers 1: 5'- GTG TGG CTT GCA ACA GGA AAT GGA -3'; reverse primer 2 5'- ACC 
TGC GTG CAA TCC ATC TTG TTC-3') were included in the PCR which amplified a 581-bp 
fragment from the targeted allele and a 335-bp fragment from the WT allele. All mice were 
housed under specific pathogen-free conditions and studied according to protocols approved 
by the Institutional Animal Protection Committees of the CRCHUM and INRS-IAF. 
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Reverse transcription-quantitative PCR (RT-qPCR) 
Murine TL1A and DR3 mRNA was measured by RT-qPCR.  Total RNA was isolated from 
cells or tissues with Trizol reagent (Invitrogen, Carlsbad CA).  For TL1A mRNA 
measurement, the forward primer 5’-TCA TTT CCC ATC CTC GCA GGA CTT-3’ and 
reverse primer 5’-TAA TTG TCA GGT GTG CTC TCG GCT-3’ were used to generate a 166-
bp fragment.  For measurement of mRNA of all 3 DR3 isoforms (the full length one, the one 
with transmembrane domain deletion and the one with deletion of the extracellular CRD 
domain), the forward primer 5’-AGA GGT ATG GCC CGT TTT G-3’ and reverse primer 5’-
AAG TGG TTG TCT CTG GTC AAG-3’ were used to generate a 133-bp fragment.  For 
mRNA of the full-length DR3 isoform, the forward primer 5’-TGC CTG GCT GGC TTC 
TAT ATA CGT G -3’ and reverse primer 5’-ACA GAC AGC AGT GCA AGC CTT A-3’ 
were used to generate a 92-bp fragment.  The PCR conditions for both reactions were as 
follows: 2 min at 95oC followed by 45 cycles of 10 s at 95oC, 15 s at 56oC and 20 s at 72oC.  
Samples were in triplicates.  β-actin mRNA levels was measured as described in our previous 
publication and taken as internal controls(5).  The data were expressed as signal ratios of 
either TL1A mRNA/β-acting mRNA or DR3 mRNA/β-actin mRNA. 
Flow cytometry 
Single cell suspensions from the thymus, spleen and lymph nodes (LN) were prepared and 
stained immediately or after culture for 2-, 3-, 4- or 5-color flow cytometry.  Mouse anti-
mouse TL1A mAb (Tandys1a) was from eBioscience (San Diego, CA). Anti-PD-1 mAb; anti-
GL7 mAb, anti-ICOS mAb, anti-CD40L mAb, anti-CXCR5 mAb, and anti-DR3 mAb were 
from BD Biosciences (Missisauga, ON, Canada) and eBioscience. The rest mAbs used in flow 
cytometry are described in our previous publications(39).   
Cell culture and in vitro T help cells (Th) differentiation 
In general, total spleen or LN cells, T cell subpopulations, B cell subpopulations or bone 
marrow cells were prepared, isolated with Miltanyii beads or sorted by flow cytometry as 
indicated and then cultured in RPMI1640 medium containing 10% FCS, 100 µg/ml 
streptomycin, 100 units/ml penicillin G, 1× nonessential amino acids, 1 µM sodium pyruvate, 
 87 
2.5 µM β-mercaptoethanol and other supplements as indicated.  In some cases, recombinant 
mouse TL1A (aa76-252; R & D systems, Minneapolis, MN) was added to the culture.   
In vitro Th differentiation was conducted as follows.  Naïve CD4 T cells 
(CD4+CD62L+CD44low) were isolated from TL1A KO or WT mouse spleens with MagCellect 
Mouse Naïve CD4+ T cell Isolation kits (R & D Systems). T cell-depleted TL1A KO or WT 
spleen cells were irradiated at 3000 Rad and used as feeder cells. The naïve CD4 cells 
(0.1×106/ well) were mixed with the feeder cells (0.5×106/well) and cultured in 96-well plates 
in the presence of soluble anti-CD3ε mAb (clone 145-2C11, 2 µg/ml; BD Biosciences). 
Cultures were supplemented with recombinant mouse IL-12 (10 ng/ml; R & D Systems) and 
anti-IL-4 mAb (10 µg/ml; R & D Systems) for the Th1 condition; recombinant mouse IL-4 (20 
ng/ml; R & D Systems), anti-IL-12 mAb (10 µg/ml; BD Biosciences) and anti-IFN-γ mAb (10 
µg/ml; R & D Systems) for the Th2 condition; recombinant mouse IL-6 (20 ng/ml; R & D 
Systems), recombinant human TGF-β1 (5 ng/ml; R & D Systems) and anti-IL-4 and anti-IFN-
γ mAb (10 µg/ml; R & D Systems) for the Th17 condition; recombinant human TGF-β1 (5 
ng/ml; R & D Systems), anti-IL-4 and anti-IFN-γ mAb (10 µg/ml; R & D Systems) for the 
Treg condition; and recombinant mouse IL-6 (20 ng/ml; R & D Systems), anti-IL-4 and anti-
IFN-γ mAb (10 µg/ml) for the Tfh-like cell condition, without any supplement for the Th0 
condition. 
Mouse CIA model 
Eight- to 12-week old TL1A KO mice and their WT littermates in the DBA/1LacJ background 
were used in the experiments. Details of the induction of CIA in these mice were previously 
described (5). Briefly, mice were immunized with single intradermal injection at the base of 
the tail with 100 µg of bovine type II collagen (BTIIC; Chondrex, Redmond, WA), which was 
emulsified in equal volumes of complete Freund’s adjuvant (CFA; 4 mg/ml Mycobacterium 
tuberculosis, strain H37Ra; Difco, Detroit, MI) on day 0. The mice were examined for their 
development and severity of arthritis from day 20 to 50. Disease severity was scored on a 
scale from 0 to 4 by visual inspection of each paw according to methodology of Brand et al. 
with some modifications as follows: 0 = normal paw; 1 = erythema and mild swelling 
confined to two or more digits, or the tarsal, or the ankle joint; 2 = erythema and mild swelling 
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of any two regions of the metatarsal, tarsal or ankle joint; 3 = erythema and moderate swelling 
extending from the ankle to metatarsal joints; 4 = erythema and severe swelling encompassing 
the ankle, foot and digits, or ankylosis of the limb (40). The scores for each of four paws were 
added to give a final score, such that the maximal severity score was 16 for each mouse. The 
mice were considered as having arthritis, if their clinical score was equal to or above 1. 
Histology 
Mice immunized with BTIIC/CFA were sacrificed on day 50, and then their paws including 
ankles were surgically removed and fixed in 10% buffered formalin. Following decalcification 
in 5% formic acid, the specimens were processed for paraffin embedding. Tissue sections (7 
µm) that were stained with hematoxylin/eosin and Safranin O (for cartilage staining) were 
scored according to three parameters, i.e., lining hyperplasia, bone erosion destruction and cell 
infiltration, in one-way blind fashion with the examiner not knowing the identity of the 
sections. Each parameter was scored on a 0–3 scale, as previously described, and all four paws 
(one section per paw) of each animal were scored. The overall score of an animal was the sum 
of the three parameters of the four paws(41).   
Isolation of infiltrating cells of hematopoietic origin in paws 
The mouse vascular system was perfused with 20 ml PBS under anaesthesia. The paws were 
then harvested, skinned and minced into small pieces, which was then digested with 
collagenase II (2 mg/ml, Chondrex, Redmont, WA) and dispase II (250 µg/ml, Roche 
Diagnostics, Indianapolis, IN) in 5 ml Hank’s balanced salt solution at 37 oC for 40 min. The 
digested product was washed and passed through cell strainers (BD bioscience, San Jose, CA) 
of 70 µm in pore size, consecutively. Cells in the passing-through liquid was enumerated and 
stained with anti-CD45.2, CD11c, CD11b, Thy1.2 and B220 mAbs, and analysed and counted 
with flow cytometry. 
Enzyme-linked immunoabsorbent assay (ELISA) for the titres of anti-BTIIC Abs 
ELISA was used to measure the titres of mouse serum anti-BTIIC Abs. Flat-bottom 96-well 
plates (Costar EIA/RIA plate #3590, Fisher Scientific, Pittsburgh, PA) were coated with 
BTIIC in PBS (100 µl/well) overnight at 4 oC. After blocking for 1 h at room temperature with 
3% BSA in PBS, the plates were washed with PBS containing 0.05% Tween 20. Samples in 
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duplicate were added to the wells (50 µl/well) and incubated overnight at 4 oC.  After 
extensive washes, 50 µl horse radish peroixdase-conjugated goat anti-mouse IgG1, IgG2a and 
IgG2b antisera (1:5000 dilution; Southern Biotechnology, Birmingham, AL) or rabbit anti-
mouse IgG (1:5000 dilutions; GE healthcare life sciences, Little Chalfont, Bucks, United 
Kindom) were added to each well.  Two hours later, the plates were washed, and 
tetramethylbenzidine (50 µl/well; BD Biosciences, San Jose, CA) was added followed by 10 
min incubation at room temperature in the dark. Finally, 2N H2SO4 (50 µl/well) was added to 
the wells to stop the reaction, and optical densities were determined at 450 nm. The serum 
anti-BTIIC Ab titre of a WT with the highest level of anti-BTIIC Ab on day 28 after the 
BTIIC/CFA immunization was arbitrarily designated as a titre of one and used as a standard to 
determine the titres of all the serum samples.   
ELISPOT for enumeration of anti-BTIIC Ab-producing cells   
Multiscreen® filter plate (Millipore, Billerica, MA) was coated with BTIIC as described for 
ELISA. The wells were blocked with culture medium (RPMI1640 medium containing 10% 
FCS) for 2 h at 37 oC and then washed. Cells from draining LN (1×105 cells/100 µl/well) or 
bone marrow (BM; 5×105 cells/100 µl/well) in culture medium were added to the wells and 
incubated for 4 h at 37 oC. The plates were then washed, and biotin-Streptavidin conjugated 
AffiniPure F(ab’)2 fragment of goat anti-mouse IgG Ab (Jackson ImmunoResearch, West 
Grove, PA) was applied. After overnight incubation at 4 oC, the plates were extensively 
washed. Alkaline-phosphatase conjugated-streptavidin (1:60 R&D systems) was added to the 
wells and incubated for 2 h at room temperature.  The spots were visualized by adding 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrate (R&D systems). Pictures 
of each well were taken with an ELISPOT reader (C.T.L., Shaker Heights, OH) and spots 
were counted visually.   
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Results 
Generation of TL1A KO mice and general features of their immune system  
To understand the role of TL1A in immune responses, we generated TL1A KO mice.  The 
targeting strategy was illustrated in Figure 1A.  Germ-line transmission of targeted TL1A was 
confirmed by Southern blotting using tail DNA (Fig. 1B), and PCR was used for routine 
genotyping of KO, WT and heterozygous pups (Fig. 1C). TL1A deletion of KO mice at the 
mRNA level was verified by RT/qPCR as shown in Figure 1D.  The deletion of TL1A protein 
in T cells from KO mice was demonstrated in Figure 1E according to flow cyotmetry.  The 
KO mice were fertile and had no visible anomaly.  Lymphoid organs such as the thymus, 
spleens and lymph nodes were of normal sizes and cellularity (data not shown). The CD4CD8 
double-negative (DN), CD4CD8 double-positive, CD4 single-positive and CD8 single-
positive subpopulations in the TL1A KO thymi were comparable to those in the WT thymi 
(Fig. 2A).  The CD4 and CD8 T cell percentages (Fig. 2A) and B (Fig. 2B) cell percentages in 
the spleen and lymph nodes of TL1A KO mice were in the normal ranges. These results 
indicate that TL1A KO does not significantly affect T and B cell development.  
We examined Th1, Th17 and Treg cell populations in the spleen and lymph nodes of TL1A 
KO and WT mice ex vivo, but no apparent differences were found (Fig. 2C). Th2 cells in the 
KO and WT spleens were below the reliable detection level (data not shown). We next 
assessed whether a lack of TL1A affected Th1, Th2, Th17 and Treg cell development in vitro. 
We compared WT and KO T cell-depleted splenocytes in their capacity to support the 
development of the said T cell populations, using naïve KO CD4 T cells as starting cells, 
which were used because they did not produce TL1A to confound result interpretation.  The 
KO non-T splenocytes were capable of supporting the naïve KO CD4 T cells differentiating 
into Th1, Th2, Th17 and Treg cells in a similar fashion as were their WT counterparts in 
supporting of naïve KO CD4 T cells (Fig. 2D). This suggests that a lack of TL1A minimally 
affects Th1, Th2, Th17 and Treg development in vitro. 
The anti-viral immune responses of TL1A KO mice were evaluated in a lymphocytic 
choriomeningitis virus (LCMV) infection model.  As illustrated in Supplementary Figure 1A, 
the number of CD4 cells and CD8 cells in the spleens on day 8 post-infection (8 dpi) presented 
 91 
no significant differences in WT and TL1A KO mice. The absolute numbers and relative 
percentages of LCMV-specific, tetramer-positive (gp33-41+ and np396-404+) CD8 cells in virus-
infected mice were all increased in comparison to uninfected control C57BL/6 mice (data not 
shown), but there were no significant differences between TL1A KO and WT mice with 
regard to these parameters (Supplementary Figs. 1B and 1C).  The absolute number and 
relative percentages of LCMV-specific TNF-α-producing CD4 (gp61-80+) and CD8 cells (gp33-
41
+) (Supplementary Figs.  1D and 1E), and LCMV-specific IFN-γ-producing CD4 (gp61-80+) 
and CD8 cells (gp33-41+) (Supplementary Figs. 1F and 1G) in TL1A-KO mice were comparable 
to those in WT controls.  This result indicates that TL1A is not essential in anti-LCMV 
immune responses.  
 
TL1A KO mice presented ameliorated CIA 
Our previous study demonstrated that administering recombinant TL1A aggravates CIA (5). 
Bull et al. demonstrated that neutralizing Ab against TL1A partially blocks antigen-induced 
arthritis (23). We wondered whether a total lack of TL1A would affect RA pathogenesis in the 
CIA model. TL1A KO and WT mice in the DBA/1LacJ background were immunized with 
BTIIC/CFA to induce CIA. The draining lymph nodes (dLN) of the immunized mice were 
assessed on day 14 after BTIIC/CFA immunization, a mid-term point between the starting of 
the immunization and a full-fledged CIA. The KO dLN were smaller in size (Fig. 3A, 1st 
panel) and lower in cellularity (2nd panel) compared to their WT counterparts. The absolute 
numbers of T cells and B cells in these KO dLN were significantly lower than those in the WT 
dLN (3rd and 4th panels). We assessed the size of the germinal centres (GC) and the percentage 
and absolute number of GC B cells in the dLN. As shown in Supplementary Figure 2A, TL1A 
KO dLN showed no abnormality in term of the size of the germinal centres. This is consistent 
with the fact that the percentages of GC B cells among the total dLNs cells were comparable 
between WT and KO (Supplementary Figure 2B). However, the absolute number of GC B 
cells in the dLNs was significantly lower in KO than in WT mice (Supplementary Figure 2C), 
due to a reduction of the cellularity of the KO dLNs. 
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The TL1A KO mice displayed slower onset of CIA and significantly lower clinical scores 
(Fig. 3B). Incidence of CIA in the TL1A KO mice was also lower compared to that amongst 
the WT controls before day 31 after the immunization, although all TL1A KO mice eventually 
developed CIA (Fig. 3C). At the end of the experiment, on day 50, the arthritic paws of the 
TL1A KO and WT groups were collected and then assessed histologically. As illustrated in 
Fig. 3D, the TL1A KO paws had less synovial membrane hyperplasia (asterisks), less immune 
cell infiltration and milder cartilage erosion (arrow heads). The pathological scores of the 
TL1A KO groups were significantly lower compared to the WT controls’ (Fig. 3E).  We 
isolated cells from paws on day 19 after BTIIC/CFA immunization, which was chosen 
because it was shortly before the onset of the disease and paws were still normal in 
appearance, so that the selection of the paws was in no way biased. The number of cells of the 
hematopoietic origin isolated from the paws was significantly smaller in TL1A KO mice than 
in WT mice, but the percentages of DC, neutrophils/macrophages/monocytes, T cells, and B 
cells among the total isolated cells from TL1A KO and WT paws showed no statistically 
significant differences (Fig. 3F).   
These results clearly show that a lack of TL1A diminishes the severity of CIA. 
TL1A KO mice had lower collagen-specific Ab titres after BTIIC/CFA immunization 
The non-immunized TL1A KO and WT mice had comparable levels of total serum IgG, IgM, 
IgA, and IgG subtypes IgG1, IgG2a and IgG2b, IgG3 (Supplementary Fig. 3). Auto-Abs are 
pathogenic in RA (42, 43), and anti-collagen Ab is especially so in CIA. We measured the 
BTIIC-specific Ab during the course of CIA from day 14 to day 50 after BTIIC/CFA 
immunization. The BTIIC-specific total IgG titres in the KO mice were significantly lower 
than their WT counterparts at all time points starting from day 21 (Fig. 4A).  Among the IgG 
isotypes, BTIIC-specific IgG2a and IgG2b but not IgG1 titres in the TL1A KO mice were 
significantly lower than in the WT mice (Figs.  4B-D). The reduced titres of collagen-specific 
Abs titres, especially the IgG2a and IgG2b isotypes, which are major pathogenic Ab isotypes in 
CIA (44), is likely a relevant factor for the observed reduced CIA severity in the TL1A KO 
mice.   
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CIA-related T cell functions in TL1A KO mice   
T cells are a major type of target cells of TL1A, and play vital role in RA pathogenesis 
including producing inflammatory lymphokines such as IFN-γ and IL-17 and providing help 
to B cells for pathogenic Ab production. We assessed the antigen-specific dLN T cells for 
their IFN-γ- and IL-17-production and proliferation upon in vitro collagen restimulation 
shortly before the onset of CIA on day 14 after the immunization, a time point these cells 
reportedly become detectable in this location (45, 46). However, no significant difference 
between TL1A KO and WT dLN was found (Supplementary Figures 4A and 4B). This finding 
is in agreement with a previous study concerning the role of TL1A in antigen-specific 
responses. In the OT-II system, deficiency of TL1A/DR3 signal does not affect Naïve T cells 
differentiation under antigen-specific stimulation, and DR3 KO dLN cells from EAE mice 
proliferate normally to the stimulation of MOG peptides in vitro(15). It is also compatible with 
the data of polyclonal T cell activation as shown in Figure 2. 
 
CRCXR5+/PD-1+ follicle T help cells (Tfh) express CD40L and ICOS on the cell surface and 
produce IL-21, all of which are essential in B cell survival, differentiation and eventually Ab 
production. We examined Tfh in the dLN on day 18 after the immunization, shortly before the 
lower titres of BTIIC-specific Abs in the KO CIA mice became apparent. The TL1A KO and 
WT dLN harboured similar percentages of CRCXR5+/PD-1+ Tfh (Fig. 5A, left column); 
TL1A KO and WT Tfh cells expressed comparable levels of CD40L and ICOS (Fig. 5A, right 
column). Probably as a consequence, the Fas+GL7+ germinal centre B cells percentages in the 
dLN of TL1A KO and WT were not different (Fig. 5B). With that said, since the absolute 
number of T cells in the KO dLN was reduced (Fig. 3A), the absolute number of Tfh in the 
KO dLN was still smaller than that of WT dLN. We confirmed that undifferentiated CD4 T 
cells (Th0) did not expression DR3, but Th1, Th17 and Tfh cells all expressed DR3, providing 
a basis for them to respond to TL1A  (Fig. 5C).  In vitro differentiated Tfh cells from naïve 
TL1A KO and WT CD4 cells were all capable of produce high levels of IL-21, compared to 
KO Th0, Th1 and Th17 cells (Fig. 5D). Exogenous TL1A did not enhance IL-21 production 
by KO Tfh cells (Fig. 5D).  The results of this section suggest that the deletion or exogenous 
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TL1A does not have significant effect on Tfh cells with regard to their B cell helper functions, 
such as their CD40L/ICOS expression and IL-21 production, although the diminished absolute 
number of Tfh in the KO dLN might be a factor contributing to the reduced level of collagen-
specific Abs in KO CIA mice.  
Plasma cells are direct target cells of TL1A 
It is puzzling that in TL1A KO CIA mice, there was an obvious decrease in antigen-specific 
Ab production, yet T cell’s B-cell-facilitating function showed no signs of compromise, with 
the exception of a decrease of absolute number of Tfh. To date, B cells and their derivative 
plasma cells are not known target cells of TL1A, as an earlier study demonstrate that B cells 
do not express or express very little DR3 (3, 13), although Pelletier et al. did reveal that in 
vitro generated human plasma cells express DR3 at the protein level(47). We confirmed that 
indeed, B220+CD138- B cells did not express DR3, nor did B220+CD138+ plasmablasts (Fig. 
6A, left and middle panel). However, we discovered that plasma cells from dLN of 
BTIIC/CFA-immunized WT mice expressed very high levels of DR3 (Fig. 6A, right panel). 
DR3 has a full-length isoform and also truncated isoforms (10). According to RT/qPCR, T 
cells and plasma cells expressed similar levels of the full-length DR3 isoform Fig. 6B, left 
panel), while the former expressed more isoforms with deletions (Fig. 6B, middle and right 
panels). The expression of the full length DR3 isoform on plasma cells provided a basis for 
them to respond to TL1A. We then interrogated the effect of TL1A on plasma cells. B cells 
and plasma cells from draining LN of KO mice 21 days after BTIIC/CFA immunization were 
negatively selected using B cell negative selection kit (STEMCELL Technologies) by 
eliminating T, NK, monocyte/macrophages and dendritic cells. The remaining B cells and 
plasma cells were cultured for six days in the presence of exogenous TL1A, as there was no 
endogenous TL1A in this system. In the presence of TL1A, significantly more plasma cells 
survived after the six-day culture (Fig. 6C, left panel) and there were higher levels of collagen-
specific IgG secreted into the supernatants (Fig. 6C, right panel), compared to the culture 
without TL1A. In support of such in vitro results, on day 28 after the BTIIC/CFA 
immunization, when the anti-BTIIC Ab production was actively produced and WT mice had 
significantly higher titres of serum anti-BTIIC Abs, draining LN cells and bone marrow cells 
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from WT mice presented significantly higher numbers of anti-BTIIC Ab-secreting plasma 
cells compared to those from TL1A KO draining LN, according to ELISPOT (Figs.  6D-6F). 
Collectively, the data from this section suggest that TL1A can directly promote plasma cell 
survival and function in terms of Ab production, and this effect in turn contributes to the 
elevated pathogenic Ab production in CIA.  Conversely, in the absence of TL1A, the well-
being of the plasma cells is compromised, and this is one of the factors leading to decreased 
levels of pathogenic anti-collagen Ab in TL1A KO mice.   
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Discussion 
In this study, we revealed that TL1A KO mice had ameliorated CIA compared to WT mice.  
No significant T cell dysfunction including Th17 and Treg differentiation was apparent in the 
absence of TL1A, and the TL1A KO mice had normal anti-LCMV immune responses. The 
KO mice presented reduced production of pathogenic anti-collagen Ab.  A novel finding in 
this study is that plasma cells were a direct target of TL1A, that these cells expressed high 
levels of the full-length isoform of TL1A receptor DR3. TL1A promoted plasma cell’s 
survival and Ab-production.  
The results of our current study and several previous studies support the general concept that 
TL1A can intensify inflammatory response.  For example, DR3 KO mice present reduced 
EAE and antigen-induced arthritis (15). The administration of exogenous TL1A aggravates 
CIA, while TL1A neutralizing Ab reduces the severity of CIA(5, 23). Transgenic 
overexpression of TL1A worsens DSS-induced colitis and causes intestinal mucosal 
inflammation(9, 20, 21, 48). Several mechanistic aspects of these disease models corroborate 
each other. For example, our data using TL1A KO mice showed that TL1A was not required 
for constitutive or induced Th1, Th2, Th17 and Treg cell development; studies using deletion 
of DR3 reached the same conclusion(15). However, there are also discrepancies between the 
conclusions obtained from DR3 KO mice versus TL1A KO mice, and from TL1A 
administration/overexpression vs. TL1A/DR3 deletion studies. The discrepancies and possible 
explanations are discussed as follows.   
It seems that excessive TL1A, either from exogenous recombinant protein or endogenous 
transgenic over-expression often results in enhanced IFN-γ and IL-17 expression, but TL1A 
KO or DR3 KO has minimal effect on constitutive or inducible Th1 and Th17 cell 
development (5, 9, 15, 48). A possible explanation for this discrepancy is that such Th cell 
development is vital to the biological system, and there is sufficient redundancy to compensate 
for the missing DR3 or TL1A in the KO mice. As a consequence, in the absence of DR3 or 
TL1A, Th cells could still be developed to near-normal levels. Alternatively, DR3 and TL1A 
are not utterly essential in Th cell development; the enhanced Th cell development in the 
presence of non-physiological high doses of exogenous or transgenic TL1A is due to its cross-
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reaction with other TNFR superfamily members (12). The results from CIA mice treated with 
TL1A neutralizing Ab favour the first explanation (23). In this model, there is no excessive 
exogenous TL1A, and the reduction of the bio-active TL1A occurs at the adult stage and is not 
complete, less likely triggering a drastic compensation. Such a neutralizing Ab treatment can 
hampers the development of Th1 and Th17 cells, which are reported essential in CIA 
pathogenesis, and results in reduced CIA severity (49).  
We demonstrated that TL1A KO mice showed no abnormality in anti-viral immune responses 
against LCMV. However, DR3-KO mice manifest compromised anti-MCMV immunity (24).  
Although TL1A is a ligand of DR3, there are around 20 other TNF superfamily members that 
share some degrees of homology with TL1A. In the absence of TL1A, other members of the 
TNF superfamily might individually or collectively bind to DR3, albeit at a lower affinity, and 
such binding might trigger some low level DR3 signalling, which could be sufficient to 
compensate for the missing TL1A. On the other hand, a missing DR3 will totally eliminate the 
DR3 signalling, resulting more drastic phenotype including compromised anti-virus immune 
responses. Although we favour this hypothesis, we cannot exclude the possibility that the 
observed difference in DR3 KO and TL1A KO regarding the anti-virus immune responses is 
caused by different viruses, i.e., MCMV vs. LCMV.   
Another interesting point is the role of TL1A in Treg development. In our TL1A KO and WT 
mice, no difference was found in constitutive or induced Treg populations. Not surprisingly, 
there was no aggravation but amelioration of CIA in the TL1A KO mice. In mice with 
transgenic TL1A expression or mice administered with exogenous recombinant TL1A, the 
immune/inflammation responses were aggravated but not ameliorated (5, 9, 21, 48).  In all the 
studies using either TL1A or DR3 KO mice models or TL1A neutralizing Abs(3, 15, 23-25), 
the immune responses were abated. Although the Treg status of the above mentioned studies 
are not always assessed, at least we could conclude that excessive TL1A does not lead to 
reduced immune response, a possible functional consequence of Treg upregulation. 
Conversely, TL1A or DR3 deletion does not lead to exuberant immune responses, which are a 
possible functional consequence of Treg downregulation.  
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Our ex vivo data indicated that the percentages of Th1, and Th17 cells in draining LN were 
comparable between CIA WT and CIA KO mice. However, since there was a drastic reduction 
of cellularity and absolute T cell number in the draining lymph nodes of KO mice, the 
absolute numbers of these effector cells were also reduced. Such reduction could likely cause 
a compromised CIA development in the TL1A KO mice.  
Several members of TNF family are involved in regulating the humoral immune responses. 
They could either affect the B cells directly or indirectly through T cells. A well-studied 
member is CD40L, which is essential to generation of plasma cells (50). CD40/CD40L 
signalling initiates GC responses, GC B cell proliferation, isotype switching and 
differentiation of B cells into plasma cells (51). Since DR3 was reportedly expressed mainly 
on T cells in the immune system, we assessed the effect of TL1A on Tfh cells. Our ex vivo 
data indicated that the percentages of Tfh cells in draining LN were comparable between WT 
and KO mice with CIA. The functions of KO Tfh cells, in terms of CD40L expression and IL-
21 production, were not compromised, neither. However, since there was a significant 
reduction of absolute T cell number in the draining LN of KO mice, comparing to that of WT 
mice, it is conceivable that absolute number of Tfh and GC B cells in the draining LN of KO 
mice was reduced. Such reduction might contribute to compromised collagen-specific Ab 
production in CIA TL1A KO mice. 
We found that the plasma cells also expressed functional DR3. This finding pin-pointed such 
plasma cells as a target cell population for TL1A’s effect. We demonstrated that TL1A could 
promote draining LN plasma cell survival in vitro.  The direct effect of TL1A on plasma cell 
survival might be one of the contributing mechanisms for the following observation: 1) TL1A 
KO results in reduced number of collagen-specific Ab producing plasma cells ex vivo, and 
reduced collagen-specific Ab titers in vivo; 2) recombinant TL1A enhanced collagen-specific 
Ab production in vitro. However, we noticed that in unimmunized KO mice, their total serum 
IgG levels and plasma cell population were comparable to those of WT mice. It is possible 
that the benefit of TL1A to plasma cells is only for a limited time during a humoral response, 
and perhaps even specific to a restricted stage of the plasma cells.  
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We demonstrated that reduced pathogenic Ab production is a mechanism contributing to 
milder CIA in the TL1A-KO mice. However, it is probably not the only mechanism 
responsible for this phenotype.  We have assessed several T cells function in the absence of 
TL1A, and did not find any anomaly, but such assessment is by no means exhaustive. We did 
find that there was a significant reduction of inflammatory immune cell infiltration in the CIA 
paws, and this phenomenon is consistent with the findings with several disease models in that 
there is always a reduction of inflammatory cells in the diseased organ or tissues when DR3 or 
TL1A is missing (15, 22). This is certainly an additional mechanism by which TL1A 
contributes to the pathogenesis of CIA. We tested TL1A KO T cell chemotaxis toward several 
CIA-related chemokines in vitro using Transwell, but no significant defect was detected. More 
comprehensive investigations in this aspect including assessing local chemokine secretion by 
T cells, monocyte/macrophages and DC, and the endothelium permeability in the excessive or 
absence of TL1A are warranted.   
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Figure legends 
Figure 1.  Generation of TL1A KO mice 
A.  Targeting strategy to generate TL1A KO mice. The shaded rectangle on the 5’ side of the 
mouse TL1A WT genomic sequence represents the sequence serving as a probe for 
genotyping by Southern blotting.   
B and C.  Genotyping of TL1A mutant mice. Tail DNA was digested with StuI, and analyzed 
by Southern blotting, with the 5’ probe whose location is indicated in A. Arrows indicate 11.7-
kb bands representing the WT allele and a 5.4-kb band representing the recombinant allele 
(B).  PCR was used for routine genotyping with ear-lobe tissue DNA. The 335-bp bands 
representing the WT allele and the 581-bp bands representing the recombinant allele are 
indicated by arrows (C). HET: heterozygous. 
D.  Absence of TL1A mRNA expression in TL1A KO T cells.  Spleen T cells from WT and 
TL1A KO mice were stimulated with solid anti-CD3 (2µg/ml) and anti-CD28 (2µg/ml) for 24 
h.  Cell RNA was extracted and analyzed by RT-qPCR for TL1A expression. The results are 
expressed as ratios of TL1A versus β-actin signals with means + SD indicated.   
E.  Absence of TL1A protein expression in KO T cells. WT and TL1A KO spleen T cells were 
stimulated as in (D) and stained with anti-CD4 mAb and anti-TL1A Ab and analyzed by 2-
color flow cytometry. The shaded lines represent the isotypic Ab control, and the thick lines 
represent TL1A staining of CD4+-gated T cells of WT (left panel) and KO (right panel) mice. 
Experiments in D and E were repeated at least twice and representative data are shown. 
Figure 2.  TL1A KO mice presented normal lymphocyte subpopulations  
Experiments in this figure were repeated more than three times, and representative data are 
presented (A, B and D).  
A.   T-cell populations in WT and TL1A KO LN, spleens and thymus. Thymocytes, mesenteric 
LN cells, splenocytes were analyzed by 2-color flow cytometry for percentages of different T 
cell subpopulations.   
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B.  B-cell populations in the LN and spleen of WT and KO mice. Mesenteric LN cells and 
splenocytes were analyzed by 2-color flow cytometry for percentages of CD19+/B220+ B cells.   
C.   Normal Th1, Th17 and Treg populations in TL1A KO mice ex vivo. WT or TL1A KO 
spleen cells were stimulated with PMA (50ng/ml) and ionomycin (1µg/ml) for 4 h in the 
presence of BD Golgistop, and analyzed by flow cytometry ex vivo for Th1, Th17 and Treg 
cell populations based on intracellular IFN-γ, IL-17 and FoxP3 staining. The bar graphs 
represent the summary of data from 3-4 experiments, with Mean + SD indicated.  
D.  Normal differentiation of TL1A-KO CD4 cells in vitro. Naïve TL1A-KO CD4 cells were 
cultured under conditions favouring Th1, Th2, Th17 and Treg cells, using WT or TL1A KO 
feeder cells, as indicated. Their intracellular cytokine or FoxP3 expression was quantified by 
3-color flow cytometry on day 3 for Th1, Th17 and Treg cells, and on day 5 for Th2 cells after        
4-h PMA (50ng/ml) and ionomycin (1µg/ml) stimulation in the presence of BD Golgistop 
before the assay.   
Figure 3.  TL1A-KO mice manifested less severe CIA 
A.  Reduced numbers of immune cells in KO draining lymph node during CIA induction. Mice 
were immunized with BTIIC/CFA at the tail base on day 0. On day 14 after the immunization, 
draining lymph nodes (dLNs) were collected and photographed (1st panel), cells from dLN of 
WT (n=10) and TL1A KO (n=11) mice were isolated, enumerated and analysed by flow 
cytometry for subpopulations.  The numbers of total dLN cells per mouse (2nd panel), CD4 T 
cells (CD4+) of the dLNs per mouse (3rd panel) and B cells (B220+) of the dLNs per mouse (4th 
panel) are shown. The horizontal bars indicate the means. Student’s t test was used to assess 
the statistical significance of the difference between WT and TL1A KO mice and the p-value 
is indicated.    
B.  CIA clinical scores of WT and KO mice after BTIIC/CFA immunization. WT (n=8) and 
TL1A KO (n=9) mice were immunized with BTIIC/CFA on day 0, and scored for their RA 
symptoms daily starting from day 21 until day 50.  Mean ± SEM scores are plotted. Scores for 
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the WT and TL1A KO mice were evaluated statistically by 2-Way ANOVA.  P-values are 
indicated.   
C.  CIA incidence in WT and TL1A KO mice.  The CIA incidence of the WT and TL1A KO 
groups in (A) is plotted. 
D and E.  Histology of mouse joints.  WT and TL1A KO Mice from (B) were sacrificed on 
day 50, and all the paws were sectioned and stained with haematoxilin/eosin (H&E) or 
safranin O (for cartilage staining) as indicated. Representative histology images from each 
group are shown (D). Asterisks indicate synovial hyperplasia and arrow heads indicate 
cartilage damage. Naïve: joints from normal unimmunized DBA/1 mice; WT-CIA: joints from 
WT mice immunized with BTIIC/CFA; KO-CIA: joints from KO mice immunized with 
BTIIC/CFA. The histology of each paw (one section per paw) was evaluated by blinded raters 
and scored semi-quantitatively based on lining hyperplasia, bone erosion and cell infiltration. 
Each parameter was scored on a 0–3 scale, and all four paws of each animal were scored. The 
overall score for each animal, which is the sum of the three parameters of the four paws, is 
shown in the plot and the horizontal bars represent the mean scores (E). Student’s t test was 
performed to assess the statistical significant of the difference between WT and TL1A KO 
mice and the p-value is indicated.   
F.  Reduced numbers of infiltrating immune cells in KO paws during CIA induction. On day 
19 after BTIIC/CFA immunization, before the onset of CIA symptoms, cells infiltrating the 
paws of WT and TL1A KO mice were isolated, enumerated and analysed by flow cytometry 
for subpopulations. The total numbers of infiltrating cells of hematopoietic origin (CD45.2+) 
per paw is shown in the left panel; percentage of dendritic cells (CD11c+), in the second panel; 
percentage of neutrophils/monocytes/macrophages (CD11b+), the third panel; percentage of T 
cells (Thy1.2+), in the fourth panel; and percentage of B cells (B220+), in the last panel. Mouse 
numbers per group are indicated. Student’s t test was used to assess the statistical significance 
of the difference between WT and TL1A KO mice and the p-value is indicated.   
Figure 4.  Reduced collagen-specific Ab production in KO mice with CIA   
Sera were obtained from WT (n=7) and TL1A KO (n=7) mice on 14, 21, 28, 35, 42 and 50 
days after BCTII/CFA immunization. Arbitrary titres of collagen-specific total IgG (A), IgG1 
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(B), IgG2a (C) and IgG2b (D) were determined by ELISA. Serum from a WT mouse exhibiting 
typical arthritis was arbitrarily given a titre of 1 and used as reference in each assay. For A, B, 
C, D, mean ± SEM are presented and evaluated statistically by 2-Way ANOVA. P-values are 
indicated.   
Figure 5.  TL1A T cells presented normal help to B cells  
The experiments in this figure were repeated three times and representative data are shown.  
A.  Flow cytometry analysis of Tfh in draining LN of mice after BTIIC/CFA immunization.  
WT or TL1A KO mice were immunized with BCTII/CFA and then sacrificed on day 18. 
CD4+ T cells from dLN were purified and stimulated with solid anti-CD3ε (2µg/ml) and anti-
CD28 (2µg/ml) Ab for 30 min. The percentage of CD4+PD-1+CXCR5+ Tfh cells among CD4+ 
cells were determined by flow cytometry and shown (right column).  The gated Tfh were 
further analyzed for their CD40L and ICOS expressions (left column), and the percentages of 
CD40L+ and ICOS+ cells among Tfh (PD-1+/CXCR5+) cells are indicated.  
B. Flow cytometry analysis of germinal centre (GC) B cell populations.  B220+ B cells from 
the draining LN of WT and TL1A KO mice on day 18 after BTIIC/CFA immunization were 
analysed for GL7 and Fas expression. The percentages of B220+GL7+ Fas+ GC B cells among 
B220+ B cells are indicated. 
C.  DR3 expression on Th and Tfh cells. Naïve CD4+ T cells were cultured on anti-CD3ε 
(2µg/ml for coating) and anti-CD28 (2µg/ml for coating) Ab-coated wells under Th1, Th17 
and Tfh-like cell differentiation conditions. After 3 days, DR3 expression on CD4+ cells was 
assessed by flow cyotmetry.  Shaded area: isotypic controls.  Thick lines: DR3 signals.  
D.  IL-21 production by in vitro differentiated WT and KO Tfh cells. WT or TL1A KO naïve 
CD4+ T cells were cultured in anti-CD3 and anti-CD28 Ab-coated wells under the Tfh-like 
cell differentiation condition. They were also cultured under Th0 (without reagents for Th 
differentiation except anti-CD3ε, anti-IFN-γ and anti-IL-4 Abs), Th1 or Th17 conditions as 
controls.  TL1A at 10 and 50 ng/ml was added to some cultures as indicated.  On day 3, the 
cells were re-stimulated with PMA/ionomycin for 9 hours and IL-21 in the supernatants was 
measured by ELISA. Samples in ELISA were in duplicate and means ± SD are shown.   
Figure 6.  The effect of TL1A on plasma cells 
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The experiments in A, B and C were repeated three times and representative data are shown.  
A.  DR3 expression in plasma cells. dLN cells from WT mice on day 15 after BTIIC/CFA 
immunization were gated on B220+CD138- regular B cells (left panel), B220+CD138+ 
plasmablast and Dump-B220-CD138+ plasma cells and analyzed for their DR3 expression by 
three-color or four-color flow cytometry. Shaded areas: isotypic controls. Thick lines: DR3 
signals. Dump staining used anti-CD8, anti-CD11b, anti-CD11c, anti-F4/80, anti-IgM, anti-
IgD and anti-CD4 mAbs.  
B.  DR3 isoform expression in CD4 cell and plasma cells. RT-qPCR was used to detect the 
mRNA of full-length DR3 and all DR3 isoforms (including the full-length and all truncated 
isoforms) in flow cytometer-sorted CD4+ T cells (as controls) and Dump-B220-CD138+ 
plasma cells. The results are expressed as ratios of DR3 (full-length or all isoforms) versus β-
actin signals with means + SD indicated. Left panel: full-length DR3 isoform expression in 
CD4 T and plasma cells; middle panel: the expression all DR3 isoforms (full-length plus all 
truncated isoforms) in CD4 T and plasma cells; right panel: ratios of full-length DR3 versus 
all isoforms of DR3. 
C.  Higher plasma cell numbers in and collagen-specific Ab production by WT dLN cells 
cultured in the presence of TL1A. dLN cells from WT mice 21 days after BTIIC/CFA 
immunization were cultured in the absence or presence of TL1A (50 ng/ml) for 6 days. The 
number of Dump-B220-CD138+ plasma cells were counted by flow cytometry four times on 
day 6 and the plasma cell numbers per 1×106 total dLN cells (means ± SD) are shown (left 
panel).  The culture supernatants were harvested on day 6 and collagen-specific IgG levels in 
the supernatants were determined by ELISA, which was conducted in triplicate samples. 
Arbitrary titres of anti-collagen IgG Abs (means ± SD) are shown (right panel). Experiments 
were repeated at least twice and representative data are shown. Student’s t test was used to 
assess the statistical significance of the difference and the p-value is indicated.   
D-F.  Reduced collagen-specific IgG-producing cells (CSIGGPC) in the dLN and bone 
marrow (BM). Twenty-eight days after BTIIC/CFA immunization, CSIGGPC in the dLN and 
BM  were enumerated by ELISPOT. Representative images of spots in wells were showed in 
D. The spots in 8 replicate wells of each experiment were counted, and the data of three 
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similar experiments were pooled and summarized bar graphs (E for dLN and F for BM). Mean 
± SEM are presented.  *p<0.05; **p<0.01 (Student’s t test). 
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Supplementary materials 
LEGENDS FOR SUPPLEMENTARY FIGURES 
Supplementary Figure 1.  Normal in vivo anti-LCMV immune responses of TL1A KO mice 
Mice were infected by the intravenous route with 2 x 106 focus-forming units of LCMV clone 
13. The mice were sacrificed 8 days post-infection, and their spleens were harvested for 
immunological analysis. The absolute numbers of CD4+ cells and CD8+ cells of WT littermate 
control and TL1A KO mice measured by flow cytometry were reported (A). The absolute 
numbers of gp33-41 and np396-404 tetramer-positive CD8 T cells per spleen (B) and the 
percentage of gp33-41 and np396-404 tetramer-positive cells among CD8 cells (C) were 
measured by flow cytometry. One million splenocytes from these mice were seeded in single 
wells of 96-well round-bottomed plates and cultured in 5% RPMI-1640 supplemented with 
100 units/ml interleukin-2, 10 µg/ml brefeldin A, 10 µM gp33-41 or gp61-80 peptide. After 5 
h of incubation at 37 °C, surface and intracellular staining were performed to stained CD4, 
CD8, TNF-α and IFN-γ. Absolute numbers of TNF-α-producing virus-specific CD4 cells 
(gp61-80-specific) and CD8 cells (gp33-41-specific) per spleen (D) and their percentages 
among total CD4 or CD8 cells (E) were measured by flow cytometry. Absolute numbers of 
IFN-γ-producing virus-specific CD4 cells (gp61-80-specific) and CD8 cells (gp33-41-specific) 
per spleen  (F) and their percentages among total CD4 or CD8 cells (G) were measured by 
flow cytometry.  Mean ± SD of data from three pairs of WT littermate controls and TL1A KO 
mice are presented. No statistically significant differences between the values of WT and KO 
mice shown in A-E are detected (paired Student’s t test). 
Supplementary Figure 2.  TL1A-KO mice had normal normal germinal centre sizes. 
Cryosections of dLNs from WT and TL1A KO mice on day 14 after BTIIC immunization 
were stained by Peanut agglutinin (PNA)-biotin followed by streptavidin-FITC, and anti-
B220-PE. Representative micrographs are shown in A.  The cells from dLNs of the 
immunized WT and KO mice were stained with germinal centre B cell markers and analyzed 
with flow cytometry. Percentages of GC B cells (B220+GL7+Fas+) among the total dLN cells 
were plotted, as shown in B. The absolute numbers of GC B cells per dLN were shown in C.  
WT: n=10; KO: n=11. 
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Supplementary Figure 3.  TL1A-KO mice had normal serum IgG and IgG isotype levels 
Total serum levels of IgG, IgM, IgA, IgG1, IgG2a, IgG2b and IgG3 in TL1A KO (n=5) and WT 
(n=5) mice were measure by ELISA. The total IgG, IgM and IgA levels were expressed as 
optical density of ELISA (upper panel). The IgG isotype levels were expressed as the 
percentage of total IgG levels (lower panel). Means ± SD are shown. No significant difference 
between TL1A KO and WT mice is found (Student’s t test) with regard to these parameters. 
Supplementary Figure 4.  T cells from TL1A-KO mice had normal antigen-specific Th1 and 
Th17 responses and proliferation 
Draining lymph node (dLN) cells from WT and TL1A KO mice on day 14 after the BTIIC 
immunization were collected and cultured in the presence or absence of BTIIC (25µg/ml). IL-
2 (50U/ml) or IL-23 (15ng/ml) was added to cultures for Th1 or Th17 cell expansion, 
respectively. Cells were cultured for 3 days and treated with PMA/ionomycin in the presence 
of Golgi-Stop for the last 4 hours of culture. The collagen-specific expansions of Th1 and 
Th17 cells were examined by intracellular staining of IFN-γ and IL-17. Fold changes of the 
percentages of IFN-γ- or IL-17-positive CD4 T cells in cultures with BTIIC versus those 
without BTIIC are shown (A).  WT: n=4; KO: n=5. 
The same cells were labelled with CFSE and cultured in the presence of IL-2 (50U/ml), with 
or without BTIIC (25µg/ml). After 3 days, the cells were harvested and analysed by flow 
cytometry. CD4 cells were gated for CFSE expression as shown in the left panel of B. Fold 
changes of the percentages of the gated CD4 cells in cultures with BTTIC versus without 
BTIIC were shown. WT: n=4; KO: n=5. 
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CHAPTER 4 ARTICLE-3 
As discussed in Section 1.5.4, plasma cells are hypersensitive to proteasome inhibitors due to 
their strong dependency on the proteasome activity. Proteasome inhibitors have shown 
effectiveness in protecting the mice from experimental models of SLE and MG by reducing 
the autoantibodies titers, the consequence of eliminating the plasma cells. Pno1 was reported 
to be essential for ribosome and proteasome assembly in yeast. We employed in situ 
hybridization (ISH), in vitro cell function analysis, Pno1 gene knockout (KO) and transgenic 
(Tg) over-expression in mice, in order to gain a better knowledge of the function of Pno1 in 
mammals and test whether it is suitable to be a novel drug target for treating RA. 
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Abstract 
Pno1 is a protein that plays a role in proteasome and ribosome neogenesis in yeast. So far, its 
functions in mammalian cells have not been investigated. To understand its function in 
mammals, we performed in situ hybridization analysis of Pno1 expression in different 
embryonic, postnatal and adult development stages and generated Pno1 gene knockout (KO) 
and Pno1 transgenic (Tg) mice lineages.  The results showed early lethality of homozygous 
Pno1 KO lineage caused, as demonstrated in parallel by ex vivo experiments, by arrest of 
embryo development before compaction stage. Though, heterozygous (HET) mice with 50% 
of normal Pno1 mRNA concentration were fertile and showed no obvious anomalies at 
adulthood.  The lymphoid organs of HET mice were normal in size, weight and cellularity, 
with normal T and B cell subpopulations. TCR-triggered activation and proliferation of HET T 
cells were normal. Proteasome activities in HET organs were uncompromised. Tg mice with 
actin promoter-driven Pno1 expression were also fertile, with no apparent anomalies, although 
they expressed 2-5-fold higher Pno1 mRNA levels. The lymphoid organs of Tg mice were of 
normal size, weight and cellularity with normal T and B cell sub-populations. TCR-triggered 
activation and proliferation of Tg T cells were normal. Tg organs and tissues presented normal 
proteasome activity as did their wild type counterparts. Tagged Pno1 over-expression in L 
cells and density gradient fractionation established that Pno1 existed in large complexes with 
sedimentation rates between 20S and 26S, bigger than mature 26S proteasomes. Pno1 in 
fractions did not coincide with 40S (small) or 60S (large) ribosome subunits. Our study 
indicates that Pno1 is essential for cellular functions, but only a small percentage of its normal 
level is sufficient, and excessive amounts are neither harmful nor useful. The nature of the 
large complexes it associates with remains to be identified, but it is certain that they are not 
mature proteasomes or ribosomes.   
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Introduction 
Ribosome neogenesis requires more than 200 assembly factors, most of which are not present 
in mature ribosomes. Many of these factors are needed at certain time points of ribosome 
maturation; they then dissociate from assembled intermediates and decay in an orderly fashion 
once their function is performed. Pno1 (partner of Nob1) is such a ribosome neogenesis factor. 
In yeasts, Pno1 is also called Dim2, Rrp2 or Yor145 [1]. It is highly conserved in yeasts up to 
mammalian species. Mouse Pno1 mRNA comprises a 746-nt open-reading frame encoding a 
248-amino acid peptide. Yeast and mouse Pno1 share 52% identity at their gene coding 
sequences and 46.7% homology (allowing amino acid substitution) at the protein level. Pno1 
contains a K homolog (KH) domain that is capable of binding RNA [2]. Pno1 protein shows 
dynamic distribution during different phases of yeast growth from nucleolus to cytosol [3]. It 
is associated with Nob1 [4], which is involved in 90S to 40S pre-ribosome maturation [5] and 
is an exonuclease [1]. The KH domain of Pno1 is also essential for its binding to Nob1 [6]. 
Pno1 binds to both 90S and 40S pre-ribosomes [3] via Nob1. During pre-40S ribosome 
maturation, the kinases Rio2, Nob1 and Pno1 form complexes attached to the front of the late 
pre-40S ribosome head [7]. Pno1 increases Nob1 RNA affinity, and regulates Nob1’s cleavage 
activity at the 3’ end of 18S rRNA [6]. Loss of Pno1 results in accumulation of 35S, 33S and 
32S rRNA [3] but with a decrease of 18S rRNA [8].  
Pno1 and Nob1 are also critical for proteasome maturation in yeasts [4]. Again, and in this 
case, Pno1 interacts with Nob1 and both proteins form complexes with the 19S regulatory 
particle of 26S proteasomes. Mutation of either Pno1 or Nob1 causes defective assembly of 
26S proteasomes [4].  
The above findings indicate that Pno1 performs important functions in both ribosome and 
proteasome biogenesis, but whether it undertakes both these functions at the same time or 
separately is not known.  
To date, to the best of our knowledge, all functional and binding studies of Pno1 have been 
conducted in yeasts. The Pno1 expression pattern in different tissues and organs of mammals 
is unclear. It is uncertain whether Pno1 is vital and irreplaceable in mammalian cells or if 
redundancy exists so that a lack of Pno1 will not be fatal to cells and/or animals. It is also not 
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known whether different Pno1 expression levels impede cellular functions. In this study, we 
employed in situ hybridization (ISH), gene knockout (KO) and transgenic (Tg) over-
expression in mice to address these questions. 
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Materials and methods 
In situ hybridization 
Full-length 1526-bp Pno1 cDNA in pSPORT1 (clone H3085H06; accession number 
NM_025443) from National Institute of Ageing, USA) was employed as a template for sense 
and anti-sense riboprobe synthesis, using SP6 and T7 RNA polymerase for both 35S-UTP and 
35S-CTP incorporation [9]. 
Tissues from WT mice were frozen in -35°C isopentane, and kept at -80°C until sectioned.  
ISH, x-ray film and emulsion autoradiography was performed using 10-µm thick cryostat-cut 
slices, as outlined previously[9].  
Generation of Pno1 gene knockout (KO) mice  
A polymerase chain reaction (PCR) fragment, amplified on the Pno1 cDNA sequence (clone 
H3085H06), was used as probe to isolate genomic BAC DNA clone 115L21 from the 129/sv 
mouse BAC genomic library RPCI-22. Targeting vectors were constructed by recombination 
and routine cloning methods with a 12.5-kb Pno1 genomic fragment from clone 115L21 
(illustrated in Figure 3A). A 3.6-kb SmaI-SaclI genomic fragment containing exons 1 to 5 was 
replaced by a 1.1-kb Neo cassette from pMC1Neo Poly A (Fig. 3A). The final targeting 
fragment was excised from its cloning vector backbone by Not I digestion and electroporated 
into R1 embryonic stem (ES) cells for G418 selection[10].  The targeted ES cell clones were 
injected into C57BL/6 blastocysts. Chimeric male mice were mated with C57BL/6 females to 
establish mutated Pno1 allele germline transmission. All mice were housed under specific 
pathogen-free conditions and used in accordance with a protocol approved by the Institutional 
Animal Protection Committee of the University of Montreal Hospital Center (NO9055JWs). 
Southern blotting with a probe corresponding to 3’ sequences outside the targeting region, as 
illustrated in Figure 3 (black square), screened for and confirmed gene targeting in ES cells 
and eventually in mouse ear DNA. The targeted allele showed a 8.5-kb BamHI/BamHI 
fragment, while the wild type (WT) allele had an 18.6-kb BamH1/BamHI fragment (Fig. 3B). 
PCR was adopted for routine genotyping of the targeted allele(s). The following PCR 
conditions were applied: 4 min at 95oC, followed by 35 cycles of 30 s at 94oC, 30 s at 58oC, 
and 60 s at 72oC, with final incubation at 72oC for 10 min. Two forward primers (5’- 
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CTGCGTGTTCGAATTCGCCAATGA-3’, forward primer 1; 5’-ACCACCTGTCAAG 
GGCAATAGGAA-3’, forward primer 2) and 1 reverse primer (5’-TGCTC CCAGT 
CCAGTC ACTA-3’) were included in the PCR, which amplified a 234-bp fragment from the 
targeted allele and a 548-bp fragment from the WT allele.  
Generation of Pno1 Tg mice 
1,526-bp mouse full-length Pno1 cDNA was excised from pSPORT1 with Not I/Sal I, blunt-
ended, and cloned into blunt-endedBamH I/Xba I sites in vector pAC, between the human β-
actin promoter and β-actin polyA signals. The resulting construct was named pAC-Pno1. The 
6.4-kb ClaI/ClaI fragment containing the β-actin promoter, Pno1 cDNA and β-actin polyA 
signals was excised and injected into fertilized C3H x C57BL/6 eggs. Tg mice were genotyped 
by PCR with tail DNA under the following conditions:  4 min at 95oC, followed by 30 cycles 
of 30 s at 94oC, 30 s at 58oC, and 30 s at 72oC, with final incubation at 72oC for 10 min. 
Primers 5’-GTCATGGCAGAAACTTGCAC-3’ (forward) and 5’- 
GAATGCAATTGTTGTTGGTAACTTG-3’ (reverse) amplified a 552-bp product.  
Reverse transcription and real-time PCR (RT-qPCR) 
Pno1 mRNA in cells or tissues from KO, Tg and WT mice was measured by RT-qPCR. Total 
RNA from cells was extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) and then 
reverse-transcribed with Superscript II™ reverse-transcriptase (Invitrogen).  The forward and 
reverse primers were 5’-TGTTCTTGGCTTTCAGGTGGAGGA-3’ and 5’-
TTCCTATTGCCC TTGACAGGTGGT-3’, respectively. A 125-bp product was detected with 
the following amplification program: 95oC x 15 min, 1 cycle; 94oC x 15 s, 55oC x 30 s, 72oC x 
30 s, 40 cycles.  
β-actin mRNA levels were measured as internal controls; the forward and reverse primers 
were 5’-TGGTACCACAGGCATTGTGAT-3’ and 5’-TGATGTCACGCACGATTTCCCT-
3’, respectively, with the same amplification program as for Pno1 mRNA.  
qPCR was performed in triplicate, and the results were expressed as the signal ratios of 
Pno1/β-actin. 
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qPCR was also employed for embryo genotyping. Embryos were digested at 55oC for 4 h in 2 
µl digestion buffer (proteinase K, 0.01% gelatin, 0.005% NP-40, 20 mM Tris (pH 8.35), 40 
mM KCl, 0.5 mM MgCl2). Forward primer 5’-GGTTTGCTCGACATTGGGGTGGAAA-3’ 
and reverse primer 5’-AGCGCGAGTATTCACCTAGAACAA-3’ detected a 185-bp fragment 
from the KO allele.  Forward primer 5’-GGTCCAAGAACGTTGCCAGGAAAT-3’ and 
reverse primer 5’-AGGGTCTGATTCCTCAATGCTCCA-3’ detected a 168-bp fragment from 
the WT allele.  PCR conditions for the reactions were as follows: 50oC x 2 min, 1 cycle; 95oC 
x 2 min, 1 cycle; 94oC x 10 s, 58oC x 20 s, 72oC x 20, 35 cycles. 
Flow cytometry 
Single cell suspensions from the thymus, spleen and in certain experiments the draining lymph 
nodes were prepared and stained for flow cytometry, as described in our previous 
publications[11,12].  
T and B cell proliferation 
T cell proliferation was assessed by 3H-thymidine uptake, as detailed elsewhere[13]. 
Mouse immunization and ELISA 
Eight- to 10-wk old WT, HET and Tg mice were immunized at the base of the tail with 100 µg 
of chick type II collagen (Chondrex, Redmond, WA), which was emulsified in equal volumes 
of Freund’s complete adjuvant (2 mg/ml Mycobacterium tuberculosis, strain H37Ra; Difco, 
Detroit, MI).  On day 21, the mice were sacrificed and sera were collected for collagen-
specific Ab assays[14]. 
Proteasome activities 
Lysates from WT, Tg, and heterozygous (HET) mouse thymus and spleen cells were assayed 
for 3 major protease activities (chymotrypsin-like activity, trypsin-like activity, and caspase-
like activity) of proteasomes based on enzymatic digestion of fluorogenic substrates (Suc-
LLVY-AMC for chemotrypsin-like activity, Z-LLA-AMC for trypsin-like activity, and Z-
LLG-βNA for caspase-like activity). 20 µg of lysate protein were reacted with the substrates 
(100 nM) in 100 µl buffer containing 100 mM Tris-HCl (pH 8.2) at 37oC for 20 min. The 
reaction was stopped by adding 4 µl 2M HCl, and fluorescence intensity of the reaction 
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solution was measured in a BioTek Synergy™ 4 Hybrid Microplate Reader with excitation at 
380 nm and emission at 460 nm for AMC-conjugated substrates, and with excitation at 335 
nm and emission at 410 nm for Z-LLG-βNA. 
Pno1 overexpression in L cells 
1,526-bp mouse full-length Pno1 cDNA was inserted downstream of the cytomegalovirus 
(CMV) promoter and upstream of hemagglutinin (HA) tags in mammalian expression vector 
pCEP4-HA. The construct, named pCEP4-Pno1-HA, drove HA-tagged Pno1 over-expression 
in mammalian cells. L cells were transfected by pCEP4-Pno1-HA with Lipofectamine 
followed by Hygromycin B selection.  
Protein fractionation by glycerol density gradients 
About 60 million pCEP4-Pno1-HA-transfected L cells were sonicated in 1 ml lysis buffer (25 
mM Tris, pH 7.6, 10 µg/ml PMSF, 1 mg/ml LA, 1 mM DTT, 2 mM ATP, and 2 mM MgCl2). 
The lysates were centrifuged at 12,000g for 30 min at 4oC to remove debris. The cleared 
supernatants (700 ml) were laid on top of a 15-ml 10-40% glycerol density gradient (diluted in 
lysis buffer) in a 15-ml centrifuge tube and centrifuged at 83,000g for 22 h at 4oC in a 
Beckman SW28 rotor. The gradient was separated into thirty 0.5-ml fractions for further tests.  
Immunoblotting 
200-ml aliquots from each gradient fraction were mixed with 800 ml cold acetone and stored 
at -20oC for 60 min to precipitate proteins dissolved in 30 ml RIPA buffer (25 mM Tris, pH 
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with 
protease inhibitors (Complete™ Protease Inhibitor Cocktail, Roche Diagnostics, Laval, 
Quebec, Canada) and centrifuged for 20 min at 12,000g at room temperature. Total 
supernatants were resolved by 12% SDS-PAGE and transferred to nitrocellulose membranes. 
The proteasome b5 subunit and b-actin were detected by blotting with rabbit anti-human b5 
antibody (Ab, Millipore, Billerica, MA, USA), followed by horseradish peroxidase-conjugated 
goat anti-rabbit IgG (GE Healthcare, Little Chalfont, Bucks, United Kingdom.). The 
membranes were then stripped and re-probed with horseradish peroxidase-conjugated rabbit 
anti-b-actin Ab (#4967, Cell Signaling Technology, Danvers, MA). Signals were detected with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA).  
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Results 
Pno1 expression pattern in WT mice according to in situ hybridization 
Based on the exposure time (optimal time: 4 days) necessary to produce X-Ray film 
autoradiogram, Pno1 mRNA belonged to a class of low abundant mouse mRNAs.  
At mid-gestation embryo on day 9 (e9), Pno1 signals in most tissues, including the rudimental 
brain (MB: midbrain; FB: forebrain; NT: neural tube) and cardiovascular system (H: heart; 
AA: aortic arch), were relatively high, as illustrated in Figure 1A-I. After this stage and at 
subsequent gestation ages, density and spatial hybridization patterns underwent substantial 
change. The large cerebral Pno1-positive area was reduced to the periventricular band region 
on e11 and e13 (Figs. 1A-II and 1A-III).  Pno1 mRNA level in the liver (Li) was moderate to 
high on e13 (Fig. 1A-III), but dropped significantly on e16 (Fig. 1A-IV).  In contrast, Pno1 
mRNA signals became perceptible in the kidneys (K) and Th, starting on e16 (Fig. 1A-IVD). 
Peak of Pno1 expression was observed in developing striated muscles (M) and intermingled 
adipose tissue on e16 (Fig. 1A-IV). Heart ventricles on e19 transiently displayed Pno1 mRNA 
levels (Fig. 1A-V) higher than on e9 (panel H in Fig. 1A-I). Around parturition (e19 and post-
natal day 1 [p1]), Pno1 mRNA was clearly present in the immune system such as the 
thymus(Th), the digestive system such as the submaxillary gland (SMax), stomach (St), 
intestine (Int) and colon (descending) (CD)), peripheral nervous system (dorsal root ganglia 
(DRG), sympathetic ganglia (SG)), and skin (Sk) (Figs. 1A-V and 1A-IV). However, Pno1 
mRNA signals were only slightly above background in the remaining tissues.   
The Pno1 expression pattern on p10 remained similar to that on p1 (Fig. 1A-VI). Several 
particular brain regions, such as the olfactory lobe (OL), olfactory neuroepithelium (ONE) and 
hippocampus (Hip), manifested high expression levels; signals in the molars (Mol), trigeminal 
ganglion (TriG), Int and bone marrow (BM) were also elevated; the spleen displayed moderate 
expression (Fig. 1B).    
In adulthood, Pno1 expression was noted in teeth, such as the incisors (Inc) (Fig. 1C-1), 
vertebrate bone marrow (Vb) (Figs. 1C-II and V) and testes (Ts) (Fig. 1C-IV). Pno1 
expression in adult Sk seemed to be less abundant than in p10 Sk (comparative data not 
included). In lymphoid organs, the Th continued to present high expression levels (Fig. 1C-V), 
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while expression in the Spl remained moderate or low (Fig. 1C-III). Expression in the Th 
occurred mainly in the cortex (Fig. 2A). Adult mouse BM cells displayed Pno1 signals both in 
x-ray film autoradiography (Fig. 2B-I) and emulsion autoradiography (Figs. 2B-II and III).  
BM in the Vb cavity showed labelled islands containing cells with small diameters (likely 
hematopoietic cells) in the midst of a meshwork of unlabelled connective tissue cells (Figs. 
2B-II and III).  The adrenal glands that are composed of amine- and peptide-producing 
medulla (Me), and steroid hormone-producing cortex (Cx) displayed Pno1 mRNA labelling in 
both regions, but predominantly in Cx (Figs. 2C-I, II and III). 
Generation of Pno1 gene KO mice  
To understand Pno1 function, we generated Pno1 gene KO mice. The targeting strategy is 
depicted in Figure 3A. With the 3’ end probe, the WT allele after BamHI digestion gave an 
18.6-kb band on Southern blotting, and the KO allele, a 7.7-kb band (Fig. 3B). Germline 
transmission was confirmed by Southern blotting of tail DNA, and WT and HET mice were 
thus identified (Fig. 3B, left panel). PCR was undertaken for routine genotyping of ear DNA. 
WT samples presented a 546-bp band, and HET samples, a 224-bp band (Fig. 3B, right panel). 
To ascertain if Pno1 gene deletion affected its expression, we measured Pno1 mRNA levels in 
different tissues by RT-qPCR. As shown in Fig. 3C, HET samples from the Li, Th and Spl 
presented lower Pno1 mRNA levels compared to WT samples. Pno1 was previously selected 
for study because it was inducible after T cell activation (data not reported). We activated T 
cells with solid phase anti-CD3 and anti-CD28 monoclonal antibodies (mAbs), and quantified 
Pno1 mRNA levels at different time points (1, 2, 6, 12 and 24 h after the initiation of culture). 
As expected, WT T cells presented augmented Pno1 mRNA levels between 6 and 24 h after 
activation. On the other hand, HET T cells only up-regulated Pno1 mRNA to about half of that 
in WT T cells (Fig. 3D). The data in Figures 3C and 3D confirmed the gene deletion of Pno1 
in HET mice. They also indicated that Pno1 expression was gene copy number-dependent, as 
HET cells only expressed half of Pno1 at the mRNA level compared to WT cells.  
 
Pno1 KO is lethal in embryos  
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We failed to generate any live Pno1 KO mice. Systemic tracking of fetus genotype in different 
gestation stages revealed that KO fetuses could only be found at e3.5 but not e6.5 (Table I). 
Therefore, the embros must have died between e3.5 and e6.5. We then cultured e1.5 embryos 
from HET male and HET female mating to observe their development in vitro. As depicted in 
Figure 4, up to e2.5, WT, HET and KO development seemed to be comparable. However, 
after e3.5, KO embryos stopped developing, while WT and HET embryos proceeded normally 
at this stage and beyond, indicating that Pno1 is vital in embryonic development.  
No detectable anomalies in the immune system of Pno1 HET mice 
As Pno1 was prominently expressed in the thymus and was up-regulated in T cells upon their 
activation, we set out to investigate whether a lack of Pno1 causes immune system 
abnormalities. HET mice, which expressed Pno1 at about 50% the normal Pno1 level, were 
used for this purpose because no KO mice could be produced. There were no apparent 
lymphoid organ anomalies in HET mice in terms of size, weight and colour (data not 
reported). T, B, CD4 and CD8 sub-populations in the Spleen and lymph nodes (LN) of HET 
mice were comparable to those in WT mice, as were thymocyte sub-populations, such as 
CD4CD8 double-negative, CD4CD8 double-positive, CD4 single-positive and CD8 single-
positive cells (Fig. 5A and B). 
Although HET T cells could only express Pno1 at about 50% the normal Pno1 level upon 
activation by anti-TCR mAb on solid phase, they proliferated as well as WT T cells (Fig. 5C). 
Activation markers, such as CD25 and CD69, were up-regulated in HET CD4 and CD8 T cells 
comparably to their WT counterparts (Fig. 5D). Therefore, it seems that 50% of normal Pno1 
expression is sufficient to maintain T cell development and function. 
We also assessed B cell subpopulations in the spleen and peritoneal cavity of WT and HET 
mice. In the spleen of WT and HET mice, there was no consistent difference in terms of the 
percentage of B220+CD21hiCD23lo/- mantel zone B cells (Fig. 6A), or the percentage of 
B220+CD21int/hiCD23hi follicular B cells (Fig. 6A).  For B cells of the WT and HET mouse 
peritoneal exudates, there was no consistent difference in terms of the percentage of 
B220+CD23-CD5+IgMhi B1a cells (Fig. 6B), B220+CD23-CD5-IgMhi B1b (Fig. 6B) and 
B220+CD23+IgMint/hi B2 cells (Fig. 6B). Spleen B cells from WT and HET mice proliferated 
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comparably upon anti-IgM plus IL-4, anti-CD40 plus IL-4, or anti-CD40 plus LPS stimulation 
(Fig. 6C). The upregulation of B cell activation markers CD86 and CD80 in WT and HET 
spleen B cells 24 h after the above-described stimulation showed no apparent difference 
neither (Fig. 6D). We next examined the percentage of IgD-IgM-CD138+B220lo/- isotype-
switched plasmablast/plasma cells in the draining lymph nodes of WT and HET mice 21 days 
after immununization with chick type II collagen, but not significant difference was found (Fig. 
6E). The serum collagen-specific Ab levels in these WT and HET mice 21 days after the chick 
type II collagen immunization showed no significant difference (Fig. 6F). Therefore, it seems 
that a 50% reduction of Pno1 level does not affect the B cells functions in vitro and in vivo. 
Normal proteasome activity in HET tissues 
Because Pno1 is involved in proteasome maturation, according to studies in yeasts, we 
questioned whether reduced Pno1 expression in HET mice leads to decreased proteasome 
activity in cells. We tested 3 major proteasome protease activities (i.e., chymotrypsin-like, 
trypsin-like and caspase-like proteases, but the caspase-like proteases activity is not 
detectable) in splenocytes and thymocytes of HET mice, and discerned that they were 
comparable to those of WT mice (Fig. 7A). We also measured the protein level of 1 subunit 
(β5) of the proteasome complex in the lungs, spleens, thymuses, livers and kidneys of HET 
mice, and found that it was comparable to that of WT tissues (Fig. 7B). Taken together, these 
data suggest that a 50% reduction of Pno1 expression does not elicit abnormal proteasome 
levels or activities.  
Generation of Pno1 Tg mice 
Since we could not obtain live Pno1 KO mice, and since HET mice manifested no apparent 
anomalies in general and in immune system and proteasome activities in particular, we 
wondered whether Pno1 over-expression in mice would reveal some phenotype. We generated 
Tg mice with β-actin promoter-driven Pno1 expression. The plasmid construct is shown in 
Figure 8A. Tail DNA was routinely genotyped by PCR, and Tg mice presented a 552-bp band 
(Fig. 8B). In Tg organs, such as the Lung, liver, kidney, thymus and spleen, Pno1 mRNA 
expression was universally heightened, although to different degrees (Fig. 8C). We also tested 
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chymotrypsin-like and Trypsin-like protease activities in the Tg thymus and spleen, and found 
that they were similar to those of their WT counterparts (Fig. 8D). 
Pno1 Tg mice manifest no apparent immune system anomalies 
Pno1 Tg mice were fertile and had no gross anomalies. Their immune organs, the thymus, LN 
and Spleen, were of normal size and cellularity (data not reported). T and B cell populations 
and CD4 and CD8 T cell populations in the Spleen and LN were comparable to those of WT 
mice (Fig. 9A). In the Tg Thymus, the different thymic sub-populations (e.g., CD4CD8 
double-negative, CD4CD8 double-positive, CD4 single-positive and CD8 single-positive 
cells) were similar to those in the WT thmus (Fig. 9B). Pno1 over-expression did not 
compromise T cell proliferation caused by solid phase anti-CD3 mAb stimulation (Fig. 9C). 
Tg CD4 and CD8 T cells up-regulated their activation markers CD25 and CD69 in comparison 
to their WT counterparts upon activation (Fig. 9D). Therefore, excessive Pno1 expression does 
not seem to affect proteasome activity. 
We also assessed B cell subpopulations in the spleen and peritoneal cavity of WT and Tg 
mice. In the spleen of WT and Tg mice, there was no consistent difference in terms of the 
percentage of B220+CD21hiCD23lo/- mantel zone B cells (Fig. 10A), or the percentage of 
B220+CD21int/hiCD23hi follicular B cells (Fig. 10A).  For B cells of the WT and Tg mouse 
peritoneal exudates, there was no consistent difference in terms of the percentage of 
B220+CD23-CD5+IgMhi B1a cells (Fig. 10B), B220+CD23-CD5-IgMhi B1b (Fig. 10B) and 
B220+CD23+IgMint/hi B2 cells (Fig. 10B). Spleen B cells from WT and Tg mice proliferated 
comparably upon anti-IgM plus IL-4, anti-CD40 plus IL-4, or anti-CD40 plus LPS stimulation 
(Fig. 10C). The upregulation of B cell activation markers CD86 and CD80 in WT and Tg 
spleen B cells 24 h after the above-described stimulation showed no apparent difference 
neither (Fig. 10D). We next examined the percentage of IgD-IgM-CD138+B220lo/- isotype-
switched plasmablast/plasma cells in the draining lymph nodes of WT and Tg mice 21 days 
after immunization with chick type II collagen, but not significant difference was found (Fig. 
10E). The serum collagen-specific Ab levels in these WT and Tg mice 21 days after the chick 
type II collagen immunization showed no significant difference (Fig. 10F).  
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The results from this section suggest that a normal endogenous Pno1 expression level is 
sufficient for the tested T cell functions. Pno1 over-expression does not confer additional 
advantages.   
Pno1 occurs in complexes larger than 26S proteasomes 
We wondered whether Pno1 is present in proteasome complexes in mammalian cells. For this 
purpose, we stably transfected L cells with a Pno1-expressing construct, pCEP-Pno1, in which 
Pno1 was fused with 3 copies of HA tags at the N-terminus. The transfected cells expressed 
greatly-enhanced Pno1 mRNA levels (Fig. 11A), but their proteasome activity remained 
similar to that of empty vector-transfected cells (Fig. 11B). L cell lysates were fractionated 
with glycerol density gradients, and the chymotrypsin-like proteasome activity of each fraction 
was quantified. As seen in Figure 11C, there were 2 peaks of enzymatic activity at fractions 13 
and 17, corresponding to 20S and 26S proteasomes, respectively. Western blotting showed 
that the proteasome β5 subunit was present from fractions 13 to 21, with trace amounts found 
up to fraction 23 (Fig. 11D), confirming that proteasome complexes (20S and 26S) were in 
these fractions, which contained 2 peaks of proteasome activities (Fig. 11C). Interestingly, 
Pno1, as detected by anti-HA Ab, made a major appearance, starting from fraction 19 and 
ending at fraction 25, with trace amounts occurring until fraction 27 (Fig. 11E). Its location 
did not correspond to that of 20S or 26S proteasomes based on both proteasome activity and 
β5 location, but obviously resided in fractions larger than 26S.  
Is Pno1 then a part of ribosomes?  We assessed small and large ribosome subunits in glycerol 
gradient fractions by anti-S6 and anti-L7 mAb Western blotting (Figs. 11F and 11G, 
respectively). S6 signals appeared from fraction 17 and ended at fraction 27, consistent with 
the size of the small 40S ribosome subunit. L7 signals presented from fraction 25 until fraction 
27, consistent with the size of large 60S ribosome subunits. Fractions containing the small 
subunit overlapped with but were not identical to those of Pno1.  
The results of this sedimentation study indicate that Pno1 does not co-localize exactly with 
proteasomes, small or large ribosome subunits, but seems to exist in complexes with 
sedimentation rates higher than 26S, probably between 30S to 40S, employing a low ribosome 
sedimentation rate as marker.  
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Discussion 
So far, all known functions of Pno1 are based on findings in yeasts, in which Pno1 is 
reportedly involved in both ribosome and proteasome biogenesis. In this study, we attempted 
to understand Pno1 function in mammalian cells, via a combination of ISH, gene KO, Tg and 
in vitro cell transfection techniques.  
First of all, according to signal intensity in ISH, Pno1 mRNA belonged to a class of low-
abundant species. In biological systems, such low-abundant species normally play regulatory 
roles so that a small change in their expression can be leveraged and amplified for much larger 
biological reactions at the molecular level. 
The general expression pattern from the fetal stage to adulthood indicates that this gene is 
highly expressed in organs or tissues containing fast-proliferating cells, such as the e9 fetus, 
thymus at different ages, skin, bone marrow, intestine and testes. This is compatible with the 
presumed function of Pno1 in ribosome and proteasome neogenesis, because fast-growing 
cells need high rates of protein synthesis as well as protein degradation. However, Pno1 was 
also expressed at high levels in certain tissues with no proliferation or enhanced protein 
synthesis, such as neuroganglia (DRG, SG and TriG), OL and ONE in the brain, and Me of the 
Ad. On the other hand, although the adult liver is very active in protein synthesis, its Pno1 
expression is very low. These observations raise an intriguing question that Pno1 might have 
important functions unrelated to either ribosome or proteasome neogenesis.  
We observed that a 50% Pno1 reduction in HET cells or 4-5-fold Pno1 increase in Tg cells did 
not cause any disruption of embryonic development, proteasome activity, T cell development, 
B cell development, or in vitro T and B cell activation and proliferation.  Proteasome is 
important to plasma cell generation, and the proteasome inhibitors could induce apoptosis in 
malignant and primary plasma cells both in vitro and in vivo as a result of activation of the 
terminal unfolded protein response (UPR)[15,16].  However, no anomaly was observed in 
HET and Tg mice in terms of plasma cell percentage and their antibody production.  
We introduced small interfering RNA into HET fibroblasts to further lower Pno1 expression 
to about 15% of the normal level, but the cells proliferated normally with proteasome 
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activities comparable to those of their WT counterparts (data not included). However, a 
complete lack of Pno1 is disastrous: it led to arrest of embryonic development before e3.5, at 
which time embryo contain about 8-30 cells[17]. There are 2 possible interpretations of this 
observation: 1) around e2.5, Pno1 is critical for a certain developmental event; or 2) 
embryonic cells before eight cell stage depend on maternal Pno1 protein or mRNA for their 
vital functions until its concentration drops below the critical level because of cell division 
(i.e., less than 1/8 of the normal Pno1 cellular level on e2.5 due to cell division) and the cells 
then cease to function owing to a lack of Pno1. In support of this hypothesis, it is worth 
mentioning that maternal ribosomes are exhausted before the blastocyst stage at e3.5 [18,19]. 
Regardless of what function Pno1 has, it is obviously a vital molecule with no redundancy and 
is absolutely required for cell function. Cells only need a small fraction of the normal Pno1 
level to be functional. Excessive Pno1 does not bring any perceivable benefit, but without it, 
cells will die. 
In yeasts, Pno1 has been implicated in ribosome and proteasome neogenesis. Whether it has 
similar functions in mammalian cells is not known. With density gradient sedimentation, we 
were able to identify fractions containing 20S and 26S proteasomes. However, Pno1 did not 
exactly fall in fractions containing proteasomes, but appeared in fractions containing 
complexes with sedimentation rates higher than 26S. This at least indicates that Pno1 is not a 
constitutive part of mature 20S or 26S proteasomes. In cells, the only macromolecules larger 
than proteasomes are ribosomes. In eukaryotic cells, mature ribosomes are 40S and 60S in size 
and derive from 90S precursors with some 66S and 43S intermediate products occurring 
during the maturation process [20,21]. We used S6, a component of the small ribosome 
subunit, and L7, a component of the large ribosome subunit, as markers to establish fraction 
profiles of small 40S and large 60S ribosome subunits. The fraction profile of Pno1 did not fit 
either of them. Pno1-containing fractions appeared earlier than large ribosome-containing 
fractions. On the other hand, Pno1 overlapped with but appeared about 2 fractions later than 
small ribosome subunit-containing fractions. Several possibilities exist: 1) If Pno1 is involved 
in mammalian ribosome neogenesis, it is not a part of mature ribosome particles, but could 
transiently associate with certain pre-ribosome species and play a critical role in their 
assembly and maturation. Indeed, it is known that more than 200 molecules transiently 
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associate with ribosomes during their neogenesis and are critical in their assembly. Pno1 could 
be one of them and an irreplaceable one at that. 2) As the size of Pno1-containing complexes 
is larger than 26S but smaller than 60S, the complexes might contain a 26S proteasome and 
some malformed ribosomes, smaller than 40S, to facilitate their elimination.  
Because of early embryo lethality, we could not obtain sufficient KO cells to study the roles of 
Pno1 in proteasome or ribosome functions. As a consequence, we could not confirm whether a 
lack of Pno1 compromises mammalian proteasome or ribosome maturation or function. We 
immunoprecipitated Pno1 and tried to find proteasome subunits or ribosome subunits in 
precipitates, or vice versa, but met with little success (data not reported). This has raised an 
intriguing possibility that if Pno1 does link with proteasome and/or ribosome precursors, the 
association is transient and probably of low affinity. Additional studies with inducible gene 
KO in mice are needed to reveal the possible role of Pno1 in mammalian cells.  
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Figure legends 
Figure 1. ISH analysis of Pno1 expression during ontogeny 
Abbreviations: AA: arch artery; Ad – adult; BM: bone marrow; Br: brain; Cb: cerebellum; 
CD: colon, descending; Cx: cerebral cortex; DRG: dorsal root ganglion; FB: forebrain; H: 
heart; Hip: hippocampus; Inc: incisors, teeth; Int: intestine; K: kidney; Li: liver; Lg: lacrimal 
gland; Lu: lungs; M: muscles, striated; MB: midbrain; Mol: molars, teeth; NT: neural tube; 
OL: olfactory lobe; ONE: olfactory neuroepithelium; R: rib; SG: sympathetic ganglion; Sk: 
skin; SMax: submaxillary gland; SpC: spinal cord; Spl: spleen; St: stomach; Th: thymus. TriG; 
trigeminal ganglion; Ts: testes; Vb: vertebrae. Bars = 1 cm. (s): sense cRNA used as a probe.  
The bars = 1 cm. Darkfield x-ray film autoradiography is shown. 
A. Pno1 expression from embryonic day 9 (e9) to post-natal day 1 (p1) 
Panels I-VI: anti-sense cRNA as probe. Panels I’-VI’: sense cRNA as probe.  
B. Pno1 expression on p10 
Panel I: anti-sense cRNA as probe. Panel I’: sense cRNA as probe.  
C. Pno1 expression in adulthood 
Panels I-V: anti-sense cRNA as probe. Panel V’: sense cRNA as probe.  
Figure 2. Pno1 expression in adult tissues according to ISH 
Ad: adrenal gland; B: bone; Me: medulla; Cx: cortex; SpC: spinal cord; BM: bone marrow; 
Vb: vertebrae. (s): sense cRNA as probe.  
A. Pno1 expression in Th 
Panel I: Dark field X-ray film autography with anti-sense cRNA as probe. Panel I’: sense 
cRNA as probe. Bar = 1 mm. Panels II to IV (antisense) and (II’ to IV’, sense) are brightfield 
images of emulsion autoradiography in p1, p10 and adult mice.     
B. Pno1 expression in the vertebrae region of adult mouse whole-body section 
Panel I: Dark field X-ray film autography with anti-sense cRNA as probe. Panels I (anti-sense 
cRNA as probe) and II (sense cRNA as probe): emulsion autoradiography seen under 
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brightfield illumination at higher magnification. Fine black grains represent Pno1 mRNA 
labelling. Bar = 1 mm (in I) and 50 µm (in II). Arrows point to small hematopoietic cells. 
C. Pno1 expression in the Ad 
Panels I-III: Anti-sense cRNA as probe. Panels I’-III’: sense cRNA as probe. Panels I and I’ 
are dark field X-ray film autography. Panels II, III, II’ and III’ are emulsion autoradiography 
seen under higher magnification.  Bar = 1 mm (in I) and 100 µm (in II). 
Figure 3. Generation of Pno1 KO mice 
A. Targeting strategy to generate Pno1 KO mice  
The black square marked as 3’ probe represents the sequence used as probe in Southern 
blotting for genotyping. A 18.6-kb BamH1 fragment detected by this probe represents the WT 
allele, and a 7.5-kb BamH1 fragment, the KO allele. 
B. Genotyping of Pno1 mutant mice 
Tail DNA was digested with BamHI, and analyzed by Southern blotting (left panel), with a 3’ 
probe whose sequence location is indicated in A. A 18.6-kb band representing the WT allele 
and a 7.5-kb band representing the recombinant allele are indicated by arrows. Ear lobe DNA 
without digestion was analyzed by PCR for routine genotyping (right panel). A 548-bp band 
representing the WT allele and a 224-bp band representing the recombinant allele are 
indicated by arrows. 
C. Reduced Pno1 mRNA expression in Pno1+/- tissues 
mRNA from the Li, Th and Spl of WT and heterozygous Pno1+/- (HET) mice were analyzed 
by reverse transcription-real time PCR (RT-qPCR) for Pno1 mRNA levels. The results are 
expressed as ratios of Pno1 versus β-actin signals with means + SD indicated. 
D. Reduced Pno1 mRNA up-regulation in Pno1+/- T cells upon activation 
T cells from WT and HET Spl were stimulated with solid phase anti-CD3 mAb and anti-CD28 
mAb (0.5 µg/ml and 4 µg/ml respectively for coating) for 1 to 24 h, and their Pno1 mRNA 
levels were quantified by RT-qPCR. The results are expressed as ratios of Pno1 versus β-actin 
signals with means + SD indicated. 
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Figure 4. In vitro development of WT, HET and KO embryos 
e1.5 embryos were harvested, and cultured in M16 medium and photographed daily until e4.5. 
Phase contrast micrographs are shown. At the end of culture on e4.5, the embryos were 
genotyped with qPCR. 
Figure 5. Sub-populations of lymphocytes in lymphoid organs and T cell function of Pno1 
HET mice 
A. T cell subpopulations in the spleen and LN 
CD4 and CD8 T-cell populations in WT and HET spleens, LN and thymuses were analyzed by 
2-color flow cytometry. Percentages are indicated.  
B. B cell population in lymphoid organs 
B cell populations in the spleen and LN were analyzed according to B220 and CD19 
expression by 2-color flow cytometry. 
C. T cell proliferation  
WT and HET spleen T cells were stimulated with solid phase anti-CD3 mAb (0.5 µg/ml for 
coating). The cells were pulsed with 3H-thymidine 16 h before harvesting. 3H-thymidine 
uptake by the cells was measured at 24, 48 and 72 h. Samples were tested in triplicate, and 
means + SD of CPM are shown.  
D. C69 and CD25 expression on activated WT and HET T cells 
WT and HET T cells were stimulated overnight by solid phase anti-CD3 mAb plus anti-CD28 
mAb (0.5 µg/ml and 4 mg/ml respectively for coating). CD69 and CD25 expression on CD4 
(left panel) and CD8 (right panel) T cells was measured by 2-color flow cytometry.  
All experiments in this figure were repeated at least 3 times and representative data are 
reported. 
Figure 6. B cell development and function in HET mice 
A. Normal marginal zone B cell and follicular B cell populations in the spleen of HET mice 
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Marginal Zone B cell (B220+CD21hiCD23low/-) and follicular B cell 
(B220+CD21int/hiCD23hi) populations in WT and HET spleens were analyzed by 3-color 
flow cytometry. Percentages are indicated.  
B. B1 B cell and B2 B cell subpopulation in peritoneal exudates of HET mice 
Peritoneal exudate B1a (B220+CD23-CD5+IgMhi), B1b (B220+CD23-CD5-IgMhi) and B2 
(B220+CD23+IgMint/hi) B cells of WT and HET mice were analyzed by by 4-color flow 
cytometery. Percentages are indicated. 
C.  Proliferation of B cells from HET mice 
WT and HET spleen B cells were stimulated with different stimuli as indicated (anti-IgM: 
5µg/ml; IL-4: 10ng/ml; anti-CD40 mAb: 2mg/ml; LPS: 2mg/ml). The cells were pulsed with 
3H-thymidine 6 h before harvesting. 3H-thymidine uptake by the cells was measured at 24 h 
and 48 after the initiation of the culture. Samples were in triplicate, and means + SD of CPM 
are shown.  
D. B cell activation markers CD80 and CD86 expression on activated WT and HET B cells 
WT and HET spleen B cells were stimulated as described in C. CD80 and CD86 expression on 
B220+ B cells was measured by 3-color flow cytometry 24 h after the initiation of the culture.  
E. Plasma cells in the draining lymph nodes of immunized WT and HET mice 
WT and HET mice were immunized with chick type II collagen with adjuvants at the tail base 
and sacrificed 21 days after the immunization. Isotype-switched plasmablast/plasma cells 
(IgD-IgM-CD138+B220lo/-) from the draining lymph nodes of WT and HET were analyzed 
by 4-color flow cytometry.  
F. Serum collagen-specific antibody production in WT and HET mice 
Sera from mice (WT n=7, HET n=4) as described in E were collected on day 21 after the 
immunization. Chick collagen-specific IgG Abs were measured by ELISA. The data are 
expressed as arbitrary titres. The titres between WT and HET groups were not statiscially 
significant (p=0.8724, Student’s t test).  
Experiments A-E were repeated at least 3 times and representative data are shown. 
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Figure 7. Proteasome activities WT and HET tissues 
A. Proteasome activities in spleen and thymus 
Lysates from the Sp and Th of WT and HET mice were assayed for chymotrypsin-like and 
trypsin-like proteasome protease activities. Samples were tested in triplicate, and means + SD 
are shown.  
B. HET and WT organs have similar proteasome levels 
Lysate proteins from the lung, spleen, thymus, liver and kidney were analyzed for proteasome 
content according to proteasome β5 subunit levels based on immunoblotting (upper panel). β-
actin levels were used to show even loading of lysate proteins (lower panel). 
Figure 8. Generation of Pno1 Tg mice 
A. pAC-Pno1 construct for Tg  mice generation 
The 6.4-kb ClaI/ClaI fragment was microinjected.  
B. Genotyping of  ear lobe DNA by PCR 
The 552-bp band specific to the Pno1 transgene is indicated by an arrow.  
C. RT-qPCR of Pno1 mRNA in different organs of Tg mice 
Means + SD of Pno1 versus β-actin signal ratios of the lung, kidney and spleen of Tg and WT 
mice. 
D. Proteasome activities in spleen and thymus 
Lysates from the Sp and Th of WT and Tg mice were assayed for chymotrypsin-like and 
trypsin-like proteasome protease activities. Samples were tested in triplicate, and means + SD 
are shown.  
Figure 9.  Sub-populations of lymphocytes in lymphoid organs and T cell function of Pno1 
Tg mice 
A. T cell sub-populations in the spleen and LN 
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CD4 and CD8 T cell populations in the WT and Tg spleen LN and thymus were analyzed by 
2-color flow cytometry. Percentages are indicated.  
B. B cell population in lymphoid organs 
The B cell population in the spleen and LN was analyzed according to B220 and CD19 
expression by 2-color flow cytometry. 
C. T cell proliferation 
WT and Tg spleen T cells were stimulated with solid phase anti-CD3 mAb (0.5 ìg/ml for 
coating). The cells were pulsed with 3H-thymidine 16 h before harvesting. 3H-thymidine 
uptake by cells was measured at 24, 48 and 72 h. The samples were tested in triplicate, and 
means + SD of CPM are shown.  
D. C69 and CD25 expression on activated WT and HET T cells 
WT and Tg T cells were stimulated overnight by solid phase anti-CD3 plus anti-CD28 mAbs 
(0.5 ìg/ml and 4 ìg/ml respectively for coating). CD69 and CD25 expression on CD4 (left 
panel) and CD8 (right panel) T cells was measured by 2-color flow cytometry.  
All experiments in this figure were repeated at least 3 times and representative data are shown. 
 
Figure 10. B cell development and function in HET mice 
A. Normal marginal zone B cell and follicular B cell populations in the spleen of Tg  mice 
Marginal Zone B cell (B220+CD21hiCD23low/-) and follicular B cell 
(B220+CD21int/hiCD23hi) populations in WT and Tg spleens were analyzed by 3-color flow 
cytometry. Percentages are indicated.  
B. B1 B cell and B2 B cell subpopulation in peritoneal exudates of Tg  mice 
Peritoneal exudate B1a (B220+CD23-CD5+IgMhi), B1b (B220+CD23-CD5-IgMhi) and B2 
(B220+CD23+IgMint/hi) B cells of WT and Tg mice were analyzed by by 4-color flow 
cytometery. Percentages are indicated. 
C.  Proliferation of B cells from Tg  mice 
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WT and Tg spleen B cells were stimulated with different stimuli as indicated (anti-IgM: 
5ìg/ml; IL-4: 10ng/ml; anti-CD40 mAb: 2ìg/ml; LPS: 2ìg/ml). The cells were pulsed with 3H-
thymidine 6 h before harvesting. 3H-thymidine uptake by the cells was measured at 24 h and 
48 after the initiation of the culture. Samples were in triplicate, and means + SD of CPM are 
shown.  
D. B cell activation markers CD80 and CD86 expression on activated WT and Tg B cells 
WT and Tg spleen B cells were stimulated as described in C. CD80 and CD86 expression on 
B220+ B cells was measured by 3-color flow cytometry 24 h after the initiation of the culture.  
E. Plasma cells in the draining lymph nodes of immunized WT and Tg mice 
WT and Tg mice were immunized with chick type II collagen with adjuvants at the tail base 
and sacrificed 21 days after the immunization. Isotype-switched plasmablast/plasma cells 
(IgD-IgM-CD138+B220lo/-) from the draining lymph nodes of WT and Tg were analyzed by 
4-color flow cytometry.  
F. Serum collagen-specific antibody production in WT and Tg mice 
Sera from mice (WT n=7, Tg n=4) as described in E were collected on day 21 after the 
immunization. Chick collagen-specific IgG Abs were measured by ELISA. The data are 
expressed as arbitrary titres. The titres between WT and Tg groups were not statiscially 
significant (p=0.1927, Student’s t test).  
Experiments A-E were repeated at least 3 times and representative data are shown. 
 
Figure 11. Pno1 is associated with macromolecules with a sedimentation rate greater than 
26S 
A. Pno1 mRNA over-expression in L cells stably transfected with the Pno1-expressing 
construct pCEP-Pno1-HA 
Pno1 mRNA levels were quantified by RT-qPCR. Samples were tested in triplicate and means 
+ SD of Pno1 versus β-actin signal ratios are shown. L cells stably transfected with empty 
vectors were used as controls. 
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B. L cells over-expressing Pno1 presented similar proteasome activity as vector-transfected 
cells 
The chymotrypsin-like activity of L cells stably transfected with pCEP-Pno1-HA was 
quantified, and L cells transfected with empty vectors were used as controls. The assay was 
conducted in triplicate, and means + SD are shown. 
C. Proteasome activities in glycerol density gradient fractions 
Lysates from L cells stably transfected with Pno1-expressing constructs or empty vectors were 
fractionated with glycerol gradients, and chymotrypsin-like proteasome activity in fractions 1 
to 30 was quantified. 20S and 26S fractions are indicated. 
D-G. Location of Pno1, β5, S6 and L7 in glycerol density gradients 
Proteins in fractions 1 to 27 of the glycerol gradient of L cells overexpressing Pno1 were 
analyzed by immunoblotting. The b5 proteasome subunit (D), Pno1 (E), S6 subunit of the 
small ribosome complex (F) and L7 subunit of the large ribosome complex (G) were detected 
by their respective Abs (Pno1 was detected by anti-HA Ab).  
Tables 
Table 4.1 Genotypic analysis of embryos from Pno1+/- ×  Pno1+/- mating   
 
 Genotype  
Stage +/+ +/- -/- Total 
e6.5 6 12 0 18 
e3.5 8 15 4 27 
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Figure 4.6 
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CHAPTER 5 DISCUSSION 
5.1 Summary of the Novel Findings in this Thesis 
In Chapter 2, we have provided direct evidence that TL1A could aggravate RA by showing 
that administration of exogenous TL1A significantly increases the disease clinical score, 
incidence, histopathological score and serum anti-CII antibodies titers in a mouse CIA model.  
We for the first time discovered elevated levels of TL1A in synovial fluids (SF) from RA 
patients and in arthritic mouse joint tissues in CIA, and further identified chondrocytes and 
synovial fibroblasts as the source of TL1A in the RA joints. Furthermore, dendritic cells and 
monocytes were shown in this study to produce TL1A in the secondary lymphoid organs 
during CIA. This suggests a systematic role of TL1A such as promoting antibody production, 
in the RA. Mechanistically, we demonstrated that TL1A specifically increases the TNF-α and 
IL-17 production in vitro. 
In Chapter 3, we generated TL1A gene knockout mice and found that the roles of TL1A in the 
immune system are negligible for mice under a normal condition, but it has important 
pathological functions in CIA. An absence of endogenous TL1A in mice caused opposite 
phenotypes to those found in mice with exogenous TL1A administration as shown in our 
earlier study (Chapter 2). Moreover, TL1A knockout mice have less cell 
infiltration/accumulation in paws and have smaller sizes and lower cellularity of their draining 
lymph nodes in CIA. We further explored the role of TL1A in humoral immune responses, 
and discovered, for the first time, plasma cells as potential targets of TL1A. TL1A might 
promote the humoral response by prolonging the survival of these cells. 
In Chapter 4, we performed whole body in situ hybridization to investigate the expression 
patterns of Pno1 in different developmental stages of mice. We found that, in fetal and adult 
mice, Pno1 is expressed in tissues with fast-proliferating cells. We further discovered that 
null-mutation of Pno1 in mice causes embryonic lethality at the pre-implantation stage, while 
reducing the Pno1 expression by half in heterozygous mice or overexpressing Pno1 in 
transgenic mice has no effect on the proteasome activities and immune responses. 
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Heterozygous Pno1 KO mice and Pno1 transgenic mice have similar anti-CII antibody levels 
in the CIA mouse model. 
5.2 Significance of the Major Findings in this Thesis 
5.2.1 The implication of TL1A in the RA 
Prior to our study, several reports have suggested a potential pathogenic role of TL1A and 
DR3 in RA. Early genome-wide association studies have identified several RA susceptibility 
loci in the dr3 gene (Borysenko et al., 2005; Cornélis et al., 1998; Kayamuro et al., 2009; 
Shiozawa et al., 1998). Experimental data have been later provided by two studies indicating 
the presence of TL1A in RA. Cassatella et al. showed that both DR3 and TL1A are deposited 
in the synovium tissues of RA patients, while Bamias et al. reported that increased levels of 
TL1A are detected in the sera of RA patients (Bamias et al., 2008; Cassatella et al., 2007). Our 
studies have confirmed the presence of TL1A in RA and mice CIA joints, and discovered that 
TL1A directly promotes local inflammation and systematic humoral immune responses in 
mouse CIA.  
5.2.1.1 TL1A promotes the immune cell expansion in RA 
Elevated levels of TL1A in the arthritic joints from patients and mice were observed in our 
studies. We further identified that, in addition to the cells of the hematopoietic origin, non-
immune cells as synovial fibroblasts (SFs) and chondrocytes, also produce TL1A upon 
stimulation (Cassatella et al., 2007; Zhang et al., 2009a). SFs are believed to be a key player in 
the initiation and perpetuation of RA. In RA, SFs acquire an activation status and produce 
various pro-inflammatory cytokines thereafter; this activation process may even happen prior 
to the onset of joint inflammation (Müller-Ladner et al., 2007). The fact that TL1A is 
produced by activated SF in the joints indicates that TL1A’s influences to the joint 
inflammation could start from a very early stage of CIA. This idea is supported by the findings 
in Chapter 3.  We observed that TL1A KO mice have reduced number of lymphocytes in their 
paws right before the onset of the disease, and displayed the delayed disease onset as a 
possible consequence. Positive correlation between the presence of local TL1A and 
accumulation of inflammatory cells was also well in line with pervious studies showing 
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reduced number of inflammatory cells in diseased tissues when TL1A/DR3 signaling is 
disrupted (Fang et al., 2008; Meylan et al., 2008; Pappu et al., 2008). This phenotype of 
reduced immune cells in the inflammatory sites could be caused by two events: 1) 
compromised cell migration; and/or 2) poor on-site expansion. We and another group have 
tried to assess these two possibilities using TL1A deletion or supplying exogenous TL1A, but 
failed to provide evidence to support the first possibility (Meylan et al., 2008). Based on the 
known function of TL1A in costimulating T cell proliferation, we speculate that the reduced 
cell infiltration in CIA paws in the absence of TL1A is probably due to an attenuated 
expansion of cells after their migrating to the CIA paws in KO mice (Meylan et al., 2011b). 
Nevertheless, further experiments are needed to provide direct evidence to prove this 
possibility. 
5.2.1.2 TL1A promotes the RA-related pro-inflammatory cytokines production 
TL1A is actively involved in IBD by promoting the production of disease-specific pro-
inflammatory cytokines (Fang et al., 2008; Pappu et al., 2008; Shih and Targan, 2009). For 
example, TL1A induces IFN-γ in Th1-mediated Crohn’s disease (CD), but IL-4, -5, and -13 in 
Th2-mediated ulcerative colitis (UC) (Shih et al., 2011b). Our results from Chapter 2 indicate 
that TNF-α and IL-17, the two most notorious pathogenic cytokines in RA, could be induced 
by TL1A in T cells (Zhang et al., 2009a). TL1A-induced TNF-α production by T cells has 
been confirmed by a recent study(Jin et al., 2012). Notably, TNF-α could, in turn, promote the 
TL1A production by the joint SFs, thus forming a self-feeding vicious circle in RA joints 
locally. The role of TL1A in Th17 cells is more complicated. Data from in vivo and ex vivo 
studies suggest that the presence of either endogenous or exogenous TL1A promotes the 
expansion of Th17 cells under disease conditions (Kamada et al., 2010; Meylan et al., 2008; 
Pappu et al., 2008; Takedatsu et al., 2008). In line with these in vivo and ex vivo data our 
results in Chapter 2 showed that exogenous TL1A promotes the IL-17 production under in 
vitro, dose dependently. However, two previous studies reported that the exogenous TL1A 
could inhibit the Th17 generation in vitro (Jones et al., 2011; Pappu et al., 2008). Based on in 
vivo data by most of the studies, there is little doubt that TL1A promotes inflammation 
(Meylan et al., 2011b). Therefore, it is contradictory for TL1A to inhibit Th17 generation in 
vitro. The observed inhibition in some studies could be due to some artificial factors during 
 167 
experimentation, such as feeder cells, the strength of TCR stimulation and/or kinetics of Th17 
measurement. Furthermore, the opposing roles of exogenous TL1A played during the Th17 
differentiation also implies the possibilities of having divergent net results (Jones et al., 2011; 
Pappu et al., 2008).  
5.2.1.3 TL1A and bone erosion in RA 
We have shown in Chapters 2 and 3 that TL1A aggravates joint inflammation and tissue 
destruction in CIA.  Consistent with our findings, Bull et al. also showed reduced pathological 
changes in mice treated with anti-TL1A antagonist antibodies (Bull et al., 2008). In addition, 
they showed that DR3 KO mice are completely protected from bone destruction in the AIA 
model and suggested a specific role of TL1A in promoting the osteoclastogenesis (Bull et al., 
2008). However, the TL1A KO mice in our study are still susceptible to bone destruction in 
CIA. Although the average pathological score in the TL1A KO mice is reduced, certain KO 
mice are still able to reach similar levels of disease severity as their WT counterpart. The 
reason for this discrepancy is most likely due to the different pathogenic mechanisms of these 
two animal models. However, different gene KO mice (i.e., DR3 KO versus TL1A KO) used 
in these two studies could also be a reason. Although DR3 is the known high affinity receptor 
for TL1A in mice, we cannot totally exclude the possibility that TL1A binds with some 
unidentified receptors, and vice versa. Therefore, it seems that DR3 KO does not equate to 
TL1A KO. 
5.2.1.4 TL1A promotes the humoral immune responses in RA 
Autoantibodies serve as important RA diagnosis factors in clinic for disease stages and 
severity (Conrad et al., 2010; Hirano, 2002; Stuart et al., 1984). As mentioned in Chapter 1, 
autoantibodies play essential pathogenic roles in several animal arthritis models. Our studies 
have discovered, for the first time, a novel function of TL1A in promoting humoral response 
in the murine CIA model. In accordance with our findings in mice, Bamias et al. showed that 
TL1A levels are augmented in sera of RA patients, particularly in those RF+ RA patients 
(Bamias et al., 2008). Moreover, Sun et al. recently reported that serum levels of TL1A in RF+ 
RA patients are positively correlated to those of RFs and ACPAs (Sun et al., 2013). This 
evidence consolidates the relevance of TL1A’s role in pathogenic antibody production in 
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human RA. In addition, the positive effect of TL1A in humoral response was also 
demonstrated in an interesting study showing that TL1A, acting as a mucosal adjuvant, 
escalates the antibody productions in both serum and mucosal secretions (Kayamuro et al., 
2009). Our studies indicate that TL1A affects the humoral responses in murine CIA by two 
different mechanisms.   
Firstly, TL1A enhances the general immune responses, as well as the humoral response, at the 
acute inflammatory stage. At the initial phase of CIA, the components in the adjuvant pose 
danger signals to those innate immune cells such as DC and macrophages, which then trigger 
the adaptive immune responses to break self-tolerance against CII (Benson et al., 2010; Billiau 
and Matthys, 2011; Bouaziz et al., 2007). The interplays between T and B cell are essential for 
the latter event, since the disruption of such interaction delays or protects the rodents from 
developing arthritis (Yanaba et al., 2007; 2005). Exogenous human TL1A increases the 
germinal center reaction in mice (Zhang et al., 2009a). In contrast, endogenous TL1A exhibits 
a limited effect on CII-specific T cell response and GC formation, but simply amplifies the 
general immune response in the dLN during the acute inflammation stage. The effects of 
TL1A on the general immune response are most likely starting with its costimulatory effect on 
the T cells; the expanded T cells then provide more help for the activation, proliferation and 
recruitment of B cells, as well as the other immune cells (Bai et al., 2008; Cantor and Haskins, 
2007; Martin-Fontecha et al., 2003; McHeyzer-Williams et al., 2011). Consequently, there are 
more anti-CII antibody-producing cells from the WT dLN after immunization than those from 
TL1A KO dLN, due to a significant increase of total dLN cells.  
Secondly, TL1A promotes the survival of plasma cells (PC). Previous studies concerning the 
functions of TL1A mainly focused on its co-stimulating role in T cells (Meylan et al., 2011b). 
Recent studies have extended the TL1A’s target cells to NKT cells, macrophages and tubular 
epithelial cells (TEC) (Al-Lamki et al., 2008; 2012; Fang et al., 2008; Kang et al., 2005; 
McLaren et al., 2010). Whether TL1A could affect plasma cells was never in the scope of 
previous studies, except one publication mentioning briefly that DR3 together with CD95 is 
expressed on the in vitro-generated human PC (Meylan et al., 2011b; Pelletier et al., 2006). 
We discovered that murine PCs express full-length DR3, and more importantly, the PCs 
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survive better in the presence of TL1A. Indeed, several other TNF family members such as 
BAFF (B cell-activation factor; TNFSF13B) and APRIL (a proliferation-induced ligand; 
TNFSF13) were reported to be involved in the survival of plasma cells (Cassese et al., 2003; 
O'Connor et al., 2004; Ou et al., 2012; Peperzak et al., 2013). BAFF binds to BAFF-R, and 
shares two other receptors, BCMA (B cell maturation Ag) and TACI (transmembrane 
activator and calcium modulator ligand interactor) with APRIL. BCMA is expressed not only 
on the plasma cells, but also on GC B and memory B cells. BAFF-R and TACI have even 
broader expression spectrums, which extend to all B cells (Darce et al., 2007). Therefore, in 
addition to helping PCs to survive better, BAFF and APRIL also affect the proliferation, 
differentiation, isotype-switching and survival of B cells (Batten et al., 2000; Moore et al., 
1999; Schneider et al., 1999; Thompson et al., 2000; Tsuji et al., 2011; Yu et al., 2000). Our 
findings indicate that, at least in the murine B cell lineage, full-length DR3 is only expressed 
on the PC but not any other upstream B cells. Furthermore, it is known that secondary 
lymphoid organs such as the spleen and dLN can only support the survival of a finite number 
of plasma cells. The excessive plasma cells either undergo apoptosis or migrate to the bone 
marrow (BM). The resident cells there are a mixture of PCs derived from germinal centers and 
extra follicular reactions (Sze et al., 2000). PCs that successfully migrate to BM receive 
survival signals and become so-called long-lived PCs (LLPCs), while those stay in the 
secondary lymphoid organs become short-lived PCs (SLPCs), and will eventually die within a 
period from a few days to a couple weeks due to a lack of environmental survival signals 
(Oracki et al., 2010). We have assessed the DR3 expression on the PCs from the BM, LN and 
spleen, and found that only a subset of PCs express DR3, no matter from where these PCs are 
isolated. Therefore, the expression of DR3 on PCs seems not to depend on whether or not they 
are LLPCs. In supporting of this notion, we have noticed that the benefits of TL1A for the 
survival of PCs during CIA occur in both dLN and BM.  More detailed studies are needed to 
determine the nature of this specific subset of PC that express DR3 and their potential roles 
compared to those DR3-negative PCs. It is worth mentioning that two murine hybridoma cells 
(OKT4 and 4610 used in our study) express DR3 according to flow cytometry, but DR3 
expressed on these two cell lines is a short isoform of DR3 (mDR3iIII) lacking the fourth CRD, 
according to PCR analysis. The functions of this truncated form of DR3 remain unclear. 
Collectively, this differential expression of DR3, either a full-length or truncated form, on the 
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B cell lineage implies a special regulatory role of different DR3 isoforms in the homeostasis of 
humoral responses during infection or autoimmune responses. 
 
5.2.1.5 TL1A and Treg cells 
Another interesting point is the role of TL1A in Treg development and function. In our TL1A 
KO and WT mice, no difference is found in constitutive or induced Treg populations. Not 
surprisingly, there is no aggravation but amelioration of CIA in the TL1A KO mice. Also, in 
mice with transgenic TL1A overexpression or mice administered with exogenous recombinant 
TL1A, the immune/inflammation responses are aggravated but not ameliorated (Barrett et al., 
2012; Meylan et al., 2011a; Shih et al., 2011a; Zhang et al., 2009a).  In all the studies using 
either TL1A or DR3 KO mice models, or using TL1A-neutralizing Abs, the immune 
responses are always abated. Although the Treg status of the above-mentioned studies is not 
always assessed, at least we could conclude that excessive TL1A does not lead to reduced 
immune responses, a possible functional consequence of Treg upregulation (Buchan et al., 
2012; Bull et al., 2008; Fang et al., 2008; Meylan et al., 2008; Twohig et al., 2012). 
Conversely, TL1A or DR3 deletion does not lead to exuberant immune responses, which are a 
possible functional consequence of Treg downregulation. Schreiber and colleagues reported 
that an agonist mAb against DR3 specifically induces Treg population and is protective 
against allergic lung inflammation (Schreiber et al., 2010). To some extent, the work by other 
two groups also provided evidence in supporting such Treg upregulation effect of TL1A, 
showing that transgenic overexpression of TL1A expands the nTreg in vivo. However, they 
also showed, in the same study, that TL1A attenuates suppressive function of nTreg and 
inhibits the differentiation of iTreg in vitro (Meylan et al., 2011a; Taraban et al., 2011). More 
importantly, the excessive TL1A in these transgenic mice upregulates the number of T effector 
cells as well as Treg cells, and the overall phenotype of the Tg mice is small intestinal 
inflammation (Meylan et al., 2011a). How do we reconcile these findings? A previous study 
found that in addition to the full-length DR3, murine Treg cells also express a short-form of 
DR3 (mDR3iIII) which lacks the forth CRD domain in its extracellular region (Pappu et al., 
2008). Thus, one possible explanation of these discrepancies could be that the agonist mAb 
against DR3 by Schreiber et al. specifically binds to mDR3iIII, but not full-length DR3, and 
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confers great proliferation ability only to those Treg cells. The same group later showed that a 
format of recombinant TL1A (aa68-252) with an Ig tag has similar effects with regard to Treg 
induction (Khan et al., 2013). The fact that they chose this special format of TL1A over the 
commercial one (aa76-252) implies that TL1A68-252-Ig possibly has certain unique features 
comparing to the regular full-length TL1A, given that a short form of TL1A (20aa shorter than 
regular TL1A) displays total different biological activity (Zhai et al., 1999). It is likely that 
TL1A68-252-Ig could bind specifically to mDR3iIII and selectively expand the Treg cells. 
Whatever the mechanisms could be, the Treg-enhancing and protective effect of this particular 
mAb clone and this particular format of TL1A68-252-Ig produced by Schreiber et al. are of 
therapeutic interest. However from the scientific point of view, it will certainly be necessary 
to: 1) confirm the physical interaction between TL1A68-252-Ig and mDR3iIII; 2) confirm such 
Treg expansion effect using other clones of anti-DR3 Ab or other formats of recombinant 
TL1A, to rule out the possibility of the agonist mAb or TL1A-Ig used in the studies binding to 
other unrelated TNFR superfamily members; and 3) prove that such an effect applies to 
immune/inflammation models other than allergic lung inflammation.  
 
5.2.2 Unidentified ligand(s) and receptor(s) of TL1A/DR3 pair 
It is known that TL1A in human has a soluble receptor called DcR3, which also binds to FasL 
and Light (Shi et al., 2003). Mice do not have a human DcR3 orthologue.  As many TNF 
family ligands share one or more receptors, it will not be surprising that TL1A has additional 
receptor(s) other than DR3 and DcR3, and vice versa (Aggarwal, 2003). In fact, there are 
many hints in studies conducted by us and other groups, suggesting the existences of 
additional binding partners of TL1A or DR3. We demonstrated in the supplementary data of 
Chapter 3, that TL1A KO mice had no abnormality in anti-viral immune responses against 
Lymphocytic choriomenigitis (LCMV). However, a previous study showed DR3-KO mice 
manifest compromised anti-MCMV immunity (Twohig et al., 2012). The observed difference 
between these two studies could have several explanations, and one of the possible scenarios 
could simply be that an unknown DR3 ligand (s) has compensated the missing TL1A. 
Similarly, both DR3 and TL1A KO mice were shown to develop EAE with reduced disease 
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severity comparing to the WT mice. However, deficiency in TL1A only reduces the disease 
clinical scores by 30%, while null-mutation of DR3 almost completely inhibits development 
of the disease (Meylan et al., 2008; Pappu et al., 2008). It seems that the missing of TL1A 
only partially disrupts the TL1A/DR3 pathway, and something else is compensating its 
function in its absence. Indeed, such functional compensation has been identified between 
several known ligands from TNF family members, such as LIGHT and LT, both of which 
could bind to herpesvirus entry mediator (HVEM) and trigger costimulating signals (Cai et al., 
2008). On the other hand, Al-Lamki et al. reported that TL1A is able to upregulate TNFR2 in 
renal tubular endothelial cells (TEC) without the presence of DR3 and suggested the existence 
of an unidentified receptor of TL1A on TEC (Al-Lamki et al., 2008). According to the 
characteristics of other members of TNF and TNFR superfamilies, it is not unusual that 
several ligands/receptors share one or more receptors/ligands. Interactions of these alternative 
ligand/receptor pairs are likely to trigger signal events that might be similar, irrelevant or even 
opposite to those induced by the orthologue combinations. Therefore, it will be interesting to 
explore the additional ligand(s) for DR3 and additional receptor(s) for TL1A, and identify 
their respective functions.  
 
5.2.3 Exogenous TL1A vs endogenous TL1A 
The results from Chapter 2 and several recent studies suggest that excessive TL1A aggravates 
the autoimmune diseases, even under conditions without disease induction (Meylan et al., 
2011a; Taraban et al., 2011; Zhang et al., 2009a). On the other hand, null-mutation of TL1A or 
DR3 has negligible effect on mice under normal circumstances. Furthermore, no anomaly is 
observed in the in vitro differentiation of TL1A or DR3 KO T cells (Meylan et al., 2008; 
Pappu et al., 2008). In addition to the possible reasons discussed in Chapter 3, another 
explanation would simply be that endogenous TL1A is barely expressed in cells or tissues of 
WT animal under a normal circumstance. As multiple studies have shown that although many 
types of cells are found to produce TL1A upon stimulation, very little TL1A is produced in the 
resting state by these cells (Cassatella et al., 2007; Meylan et al., 2008; Prehn et al., 2007; 
Zhang et al., 2009a). Therefore, those resting WT cells or unmanipulated WT mice without 
diseases might not express or express very low level of TL1A. Thus, no effect of “endogenous 
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TL1A” would be observed under such a condition. It is conceivable that the difference 
between WT and DR3/TL1A KO mice only appears in the disease models, in which the TL1A 
is upregulated in inflammatory tissues in WT mice but not in KO mice (Bamias et al., 2006; 
Kamada et al., 2010; Meylan et al., 2008; Pappu et al., 2008; Zhang et al., 2009a).  
 
5.2.4 Implication of Pno1 in RA 
Pno1 was brought to our attention because of its potential role in the assembly of proteasomes, 
which play an essential role in antigen presentation and humoral responses (Cenci et al., 2006; 
Lecker et al., 2006). Previous studies provided multiple evidence showing that inhibiting the 
proteasome activities decreases the number of plasma cells and antibody titers, and 
ameliorates the symptoms in mice with experimental autoimmune diseases (Gomez et al., 
2011; Neubert et al., 2008; Perry et al., 2009). In Chapter 4, we sought to understand the 
function of Pno1 in the mammals by using mouse models with Pno1 gene manipulated,, and 
test whether Pno1 could affect humoral immune responses in mouse CIA. We have 
demonstrated that mammalian Pno1 has a similar distribution profile in terms of sedimentation 
rates as that of yeasts and the rates overlap with those of both 20S and 26S proteasome (Tone 
and Toh-E, 2002). However, Pno1 seems only to participate in the assembling process of these 
proteasomes. It leaves the proteasome once the assembling process is finished. Due to the 
embryonic lethality of Pno1 KO mice at a very early gestation stage, we are not able to 
explore the consequences of Pno1 deletion in vivo or in primary cell cultures. On the other 
hand, 50% reduction or overexpression of Pno1 in the heterozygouos KO mice or in Tg mice, 
respectively, does not compromise the amount and functions of proteasomes, nor the functions 
of T and B cell and humoral immune responses of these mice in CIA. According to the 
disastrous consequence of gene knockout of Pno1 in mice, and the minimal effect of Pno1 
knockdown in heterozygous KO mice on the immune system and humoral responses, it seems 
that the therapeutic dose window of Pno1 inhibition is pretty narrow. Therefore, we suspect 
that Pno1 might not be a good target for treating RA. Collectively, although we have failed to 
provide evidence in Chapter 4 to support the idea of using Pno1 as a therapeutic target for RA, 
it will still be of great interests to explore the mechanisms by which Pno1 participates in 
proteasome neogenesis, using an inducible gene knockout approach. 
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5.3 Conclusions and Future Perspectives 
TL1A is discovered as a T cell costimulator and later found to be involved in several 
autoimmune diseases. Our studies revealed that TL1A participates in the pathogenesis of RA, 
by aggravating the local inflammation in the synovium, and by promoting the systemic 
humoral immune responses. Our findings also suggest that TL1A is a good therapeutic target 
for RA  
 
Consistent with findings in the yeast, Pno1 plays critical roles in maintaining certain basic 
cellular functions, most likely in proteasome or (and) ribosome neogenesis. However, Pno1 
might not be a good therapeutic target for RA.  
 
Following are some interesting questions to be explored in future studies: 
 
1. To identify the putative additional receptors for TL1A and ligands for DR3. 
 
2. To study the roles of DR3 in plasma cells, and find out survival signaling pathway triggered 
by TL1A. 
 
3. To study the roles of the short isoforms of DR3. 
 
4. Using conditional or inducible Pno1 gene KO mice to investigate the role of Pno1 in 
proteasome and ribosome neogenesis.  
 
5. To investigate whether Pno1 mediates the destruction of dysfunctional ribosomes by 
proteasome. 
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ABSTRACT 
Myeloid leukemia factor 1-interacting protein (MLF1-IP) has been found to exert functions in 
mitosis, although studies have been conducted only in cell lines up to now. To understand its 
roles during ontogeny and immunity, we analyzed its mRNA expression pattern by in situ 
hybridization and generated MLF1-IP gene knockout (KO) mice. MLF1-IP was expressed at 
elevated levels in most rudimentary tissues during the mid-gestation stage, between embryonic 
day 9.5 (e9.5) and e15.5. It declined afterwards in these tissues, but was very high in the testes 
and ovaries in adulthood. At post-natal day 10 (p10), the retina and cerebellum still expressed 
moderate MLF1-IP levels, although these tissues do not contain fast-proliferating cells at this 
stage. MLF1-IP expression in lymphoid organs, such as the thymus, lymph nodes, spleen and 
bone marrow, was high between e15.5 and p10, and decreased in adulthood. MLF1-IP KO 
embryos failed to develop beyond e6.5. On the other hand, MLF1-IP+/- mice were alive and 
fertile, with no obvious anomalies. Lymphoid organ size, weight, cellularity and cell sub-
populations in MLF1-IP+/- mice were in the normal range. The functions of MLF1-IP+/- T cells 
and naïve CD4 cells, in terms of TCR-stimulated proliferation and Th1, Th17 and Treg cell 
differentiation in vitro, were comparable to those of wild type T cells. Our study demonstrates 
that MLF1-IP performs unique functions during mouse embryonic development, particularly 
around e6.5, when there was degeneration of epiblasts. However, the cells could proliferate 
dozens of rounds without MLF1-IP.  MLF1-IP expression at about 50% of its normal level is 
sufficient to sustain mice life and the development of their immune system without apparent 
abnormalities. Our results also raise an intriguing question that MLF1-IP might have 
additional functions unrelated to cell proliferation. 
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INTRODUCTION 
Myeloid leukemia factor 1-interacting protein (MLF1-IP) has several other designations: 
Kaposi’s sarcoma-associated herpes virus latent nuclear antigen-interacting protein 1 (KLIP1); 
centromere protein of 50 kDa (CENP50); centromere protein U (CENPU); interphase 
centromere complex protein 24; polo-box-interacting protein 1 (PBIP1). 
Although MLF1-IP cDNA was identified by the human genome project, its initial functional 
attributes were reported by 2 groups. Yeast 2-hybrid screening by Pan et al. discerned that the 
protein interacts with the latent nuclear antigen of Kaposi’s sarcoma-associated herpes virus 
[1], while Hanissian et al. reported that it interacts with myeloid leukemia factor 1 [2]. More 
earnest functional characterization ensued in subsequent years. Minoshima et al. discovered, 
again by yeast 2-hybrid screening, that MLF1-IP is a constitutive component of centromeres 
and named it CENP50[3]. It interacts with a Rho GTPase-activating protein, MgcRacGAP. 
MLF1-IP-deficient cells are viable but undergo delayed mitosis and severe mitotic defects, 
such as chromosome misalignment and premature sister chromatid separation, demonstrating, 
for the first time, that it is located in centromeres and plays a role in mitosis. Employing 
multiple tandem affinity purification, Foltz et al. identified MLF1-IP in CENP-A nucleosome-
associated complexes in centromeres[4]. Yeast 2-hybrid screening by Kang et al. determined 
that MLF1-IP is associated with polo-like kinase 1 (Plk1), and its T78 is a substrate of this 
kinase[5]. MLF1-IP T78 phosphorylation creates self-tethering sites for interaction with Plk1, 
and such interaction is crucial for Plk1 recruitment to interphase and mitotic kinetochores. 
Lack of MLF1-IP T78 phosphorylation induces a chromosome congression defect and 
compromises the spindle checkpoint. Later in mitosis, Plk1 also evokes MLF1-IP degradation 
in a T78 phosphorylation-dependent manner. Recently, the same group established that 
MLF1-IP interacts directly with CENP-Q, and these interactions are necessary for the 
centromere localization of both CENP-Q and MLF1-IP to form ternary complexes with 
Plk1[6]. Hua et al. determined that MLF1-IP also interacts with Hec1, a kinetochore core 
component[7]. It not only binds directly to microtubules but also shows cooperative 
microtubule binding with Hec1. MLF1-IP knockdown results in impaired kinetochore-
microtubule attachment.   
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All the above-described MLF1-IP functions are based on in vitro experiments in cell lines. It is 
not known whether MLF1-IP has functions other than that in mitosis. Also, no in vivo study 
has explored whether MLF1-IP is essential in mouse development. In our investigation, we 
conducted in situ hybridization (ISH) analysis to assess the tissue-specific expression of 
MLF1-IP during ontogeny with a view to identifying its functions. We also generated MLF1-
IP gene null mutation in mice to evaluate the importance of this gene in vivo and in vitro.   
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MATERIALS AND METHODS 
ISH 
Full-length 1.25-kb MLF1-IP cDNA in pENBR/SD/D-TOPO was isolated with NotI/SalI and 
sub-cloned into NotI/SalI sites of pSPORT6[2]. The resulting plasmid was named pSPORT6-
MLF1-IP and was employed as a template for sense and anti-sense riboprobe synthesis, using 
SP6 and T7 RNA polymerase for both 35S-UTP and 35S-CTP incorporation[8]. 
 
Tissues were frozen in -35°C isopentane and kept at -80°C until sectioned. We studied 10-µm 
thick cryostat-cut slices by ISH and x-ray film autoradiography, as outlined previously[8].  
 
In situ hybridization in embryos was performed as described using digoxigenin-labeled RNA 
probes[9]. Hybridization was carried out with probes for Lim1 and Otx2[10,11]. 
 
Hematoxylin and eosin staining was performed using standard procedures. 
 
Generation of MLF1-IP gene knockout (KO) mice  
A polymerase chain reaction (PCR) fragment, amplified on the MLF1-IP cDNA sequence in 
pSPORT6-MLF1-IP, served as probe to isolate genomic BAC DNA clone 325N12 from the 
129/sv mouse BAC genomic library RPCI-22. The targeting vector was constructed by 
recombination and routine cloning methods, with a 10.6-kb MLF1-IP genomic fragment from 
clone 325N12, as illustrated in Fig. 1A[12]. A 2.39-kb BamHI/HpaI genomic fragment 
containing exon 1 was replaced by a 1.1-kb Neo cassette from pMC1Neo Poly A. The final 
targeting fragment was excised from its cloning vector backbone by NotI digestion and 
electroporated into R1 embryonic stem (ES) cells for G418 selection[13]. 
 
Southern blotting with a probe corresponding to the 5’ sequence outside the targeting region, 
as illustrated in Figure 1A (red square), screened for and confirmed gene-targeting in ES cells 
and eventually in mouse tail DNA. The targeted allele showed a 6.8-kb NcoI band, and the 
wild type (WT) allele, a 10-kb NcoI band (Fig. 1A). PCR was adopted for routine genotyping 
of the targeted allele(s). The following PCR conditions were applied: 4 min at 95oC, followed 
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by 35 cycles of 30 s at 94oC, 30 s at 58oC, and 30 s at 72oC, with final incubation at 72oC for 
10 min. KO forward primer 5’-GCC AAG TCC AAC GTC TTG AT-3’ and reverse primer 5’-
CTC TTG CAA AAC CAC ACT GC-3’ detected a 202-bp fragment from the targeted allele. 
WT forward primer 5’-TTA CTG CGG TAT TCT GTG CTG GGA-3’ and reverse primer 5’ 
ATC TAC TTG CAT CTG CCT CCG AGT-3’ detected a 588-bp fragment from the WT 
allele.  
 
The targeted ES cell clones were injected into C57BL/6 blastocysts. Chimeric male mice were 
mated with C57BL/6 females to establish mutated MLF1-IP allele germline transmission. All 
mice were housed under specific pathogen-free conditions and the project including the 
generation of the KO mice was approved by the Institutional Animal Protection Committee of 
the CRCHUM (NO9055JWs). 
 
Real time reverse transcription-quantitative PCR (RT-qPCR) 
MLF1-IP mRNA in cells or tissues from KO, heterozygous (HET) and WT mice was 
measured by RT-qPCR. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, 
USA) and then reverse-transcribed with Superscript II™ reverse-transcriptase (Invitrogen). 
The forward and reverse primers were 5’-GCA AGG AGA AGT TTG AGA TAC TCG GG-3’ 
and 5’-CCA GCT TTC TGT TTC CTG GAA TAT GTG C-3’, respectively. A 91-bp product 
was detected with the following amplification program: 95oC x 15 min, 1 cycle; 94oC x 15 s, 
55oC x 30 s, 72oC x 30 s, 35 cycles.  
 
Oct-4 and Nanog mRNA in ES cells was quantified by RT-qPCR. For Oct-4, a forward 
primier 5’- CCT ACA GCA GAT CAC TCA CAT C -3’ and a reverse primer 5’- GCC GGT 
TAC AGA ACC ATA CTC -3’ were employed; for Nanog, a forward primier 5’- TGC AAG 
AAC TCT CCT CCA TTC -3’ and a reverse primer 5’- CGC TTG CAC TTC ATC CTT TG -
3’ were used. 
 
 
 
 
viii 
β-actin mRNA levels were measured as internal controls; the forward and reverse primers 
were 5’-TGG TAC CAC AGG CAT TGT GAT-3’ and 5’-TGA TGT CAC GCA CGA TTT 
CCC T-3’, respectively, with the same amplification program as for MLF1-IP mRNA.  
 
RT-qPCR was performed in triplicate, and the results were expressed as the signal ratios of 
MLF1-IP/β-actin. 
 
RT-qPCR was also undertaken for embryo genotyping. Embryos were digested at 55oC for 4 h 
in 2 µl digestion buffer (proteinase K, 0.01% gelatin, 0.005% NP-40, 20 mM Tris (pH 8.35), 
40 mM KCl, 0.5 mM MgCl2). Forward primer 5’-GCC TGG AAT GTT TCC ACC CAA 
TGT-3’ and reverse primer 5’-CTG CGT GTT CGA ATT CGC CAA TGA-3’ detected a 144-
bp fragment from the KO allele, while forward primer 5’-TTA CTG CGG TAT TCT GTG 
CTG GGA-3’ and reverse primer 5’ CTT CCA AGG CGC ACC TTT CCA AAT-3’ detected 
a 193-bp fragment from the WT allele. PCR conditions were as follows: 50oC x 2 min, 1 
cycle; 95oC x 2 min, 1 cycle; 94oC x 10 s, 58oC x 20 s, 72oC x 20 s, 35 cycles. 
 
ES cell culture and small interfering RNA (siRNA) transfection 
ES cells were maintained in DMEM supplemented with 15% fetal bovine serum, 1×MEM 
non-essential amino acids, 2mM L-glutamine (WISENT, St. Bruno, Quebec, Canada), 100µM 
2-mercaptoethanol (Sigma, St. Louis, MO, USA) and 1000U/ml leukemia inhibitory factor 
(Chemicon, Billerica, MA, USA). siRNAs to MLF1-IP and negative control siRNAs were 
synthesized by Integrated DNA Technologies (Coralville, IA, USA). The sequences of the 
MLF1-IP-specific siRNA and control siRNA are listed in Table 1.  ES cells were transfected 
with a mix of 2 pairs of siRNAs (each pair at a final concentration of 30 nM), with FuGENE 
HD X-tremeGENE siRNA Transfection Reagent (Roche Applied Science, Mannheim, 
Germany). The transfected ES cells were further cultured for 48h. The MLF1-IP mRNA 
knockdown and mRNA expression of Oct-4 and Nanog were measured by RT-qPCR. 
 
Flow cytometry 
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Single cell suspensions from the thymus, lymph node and spleen were prepared and stained 
for flow cytometry[14].   
 
T-cell proliferation 
T-cell proliferation was assessed by 3H-thymidine uptake[15]. 
 
Naïve T-cell differentiation into Th1, Th17 and Treg cells 
The method has been described in a previous publication[16].    
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RESULTS 
MLF1-IP expression during ontogeny according to ISH 
So far, detailed tissue-specific expression of MLF1-IP during ontogeny has not been 
investigated. Our study provides ISH evidence of spatially- and temporally-restricted MLF1-
IP expression patterns in mice from mid-gestation through adulthood. Based on exposure time 
necessary for autoradiograms (optimal time: 10 days for x-ray films), MLF1-IP mRNA 
belonged to a class of very low abundant mouse mRNAs. A summary appears in Table 2, and 
details are given in Figures 1-3. Generally speaking, rudiments of multiple tissues (the brain, 
liver, optic vesicle and thymus) displayed relatively high MLF-IP mRNA levels, which peaked 
in the mid-gestation stage. At mid-gestation, on embryonic day 9.5 (e9.5), rudiments of 
multiple tissues, except for the mesenchymal region, displayed relatively high MLF1-IP 
mRNA levels (Fig. 1A-II); expression was particularly high in the central nervous system 
(CNS) structures, such as the mesencephalon, telencephalon, nasal tip and spinal cord (Fig. 
1A-II). On day e12.5, MLF1-IP-positive areas in the CNS were limited to a small region in the 
brain and optic vesicle (Fig. 1B-II). By day e15.5, ventricular wall, ventricular zone and 
cerebellum displayed MLF1-IP mRNA labelling (Fig. 1C-II). A number of tissues displayed 
changing levels of MLF1-IP expression through several stages. In the liver, a moderate level 
of MLF1-IP expression was evident on day e12.5, and it progressively diminished through 
e15.5, post-natal day 1 (p1), p10 to decline at adulthood (Figs. 1 and 2), showing a pattern 
reminiscent to that of erythropoiesis genes: such genes have peak expression at prenatal 
stages, before their function is fully taken by a bone marrow cells. In this respect, MLF1-IP 
was observed in postnatal p10 and adult mice bone marrow within vertebrae and long bone 
cavities (Fig. 2B and C), suggesting its possible involvement in the erythropoiesis. Transient 
expression in the kidney  nephrogenic zone was observed from e15.5 to p1. There was no 
evident MLF1-IP expression in the adult kidney (Fig. 2C-I and II). Long-lasting expression is 
observed in the intestine, from e15.5 until adulthood.  The skin manifested peak MLF1-IP 
expression on p10. From p1 until adulthood, MLF1-IP was expressed in the retina and 
cerebellum (Figs. 2A-II, B-II and C-II). MLF1-IP expression peaked in the submaxillary gland 
between e15.5 and p1 (Figs. 2A-II and 2B-II), but its expression in this gland was not evident 
in adults (Fig. 2C-II). In the immune system, the thymus and spleen presented moderate to 
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high MLF1-IP expression from e15.5 to p10; it declined to a detectable level in adulthood 
(Figs. 1 and 2), and was mainly concentrated in the thymic cortex (Fig. 3A), spleen white pulp 
(Fig. 3B) and lymph node follicles (Fig. 3C). In the reproductive system, MLF1-IP expression 
was already moderately high in the testes on p10; it became relatively high in adult testes (Fig. 
3D). Moderate to high MLF1-IP expression was found in growing follicles and corpus luteum 
of the ovaries (Figs. 3D and 3E).  
 
Generation of MLF1-IP gene KO mice  
We generated MLF1-IP KO mice to assess the role of MLF1-IP in live animals. The targeting strategy is depicted 
in Figure 4A. With the 5’ end probe, the WT allele after NcoI digestion presented a 10-kb band on Southern 
blotting, and the KO allele, a 6.8-kb band (Fig. 4A). Germline transmission was confirmed by Southern blotting 
of tail DNA, and WT and HET mice were thus identified (Fig. 4B, left panel). PCR was undertaken for routine 
genotyping of ear DNA. The WT allele presented a 588-bp band, and the KO allele, a 202-bp band (Fig. 4B, right 
panel). 
 
To ascertain if MLF1-IP gene deletion affected its expression, we measured MLF1-IP mRNA levels of WT, HET 
and KO embryos (Fig. 4C). E7.5 HET embryos only expressed MLF1-IP mRNA at a 50% level of WT embryos, 
while KO embryos at that time totally lacked the mRNA.  
 
MLF1-IP was previously selected for study because it was inducible after T-cell activation (data not reported). 
We activated T cells with solid-phase anti-CD3 and anti-CD28 monoclonal antibodies (mAbs), and quantified 
MLF1-IP mRNA at different time points (0, 24, 48 and 72 h after the initiation of culture). As shown in Fig. 4D, 
resting HET T cells (0 h, and cells cultured in medium for 24 h) expressed about 50% less MLF1-ip mRNA than 
their WT counterparts. After T cell activation, the MLF1-IP mRNA levels of both HET and WT T cells were 
upregulated with respect to their unstimulated controls, but the levels in HET T cells were about 50% that of the 
WT T cells. 
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The data in Figure 4C confirmed the gene deletion of MLF1-IP in KO embryos. Figure 4C and 4D also indicated 
that MLF1-IP expression was gene copy number-dependent, as HET cells expressed only one-half the level of 
MFL1-IP mRNA compared to WT cells.  
 
MLF1-IP KO is lethal in embryos  
We failed to generate any live MLF1-IP KO mice, nor could we obtain any KO embryos 
between e9 and birth. Systemic tracking of embryo genotype in different gestation stages 
revealed that intact KO embryos could only be found before and at e7.5 (Table 3) from MLF1-
IP+/- x MLF1-IP+/- mating, and the frequency of KO embryo occurrence on e3.5, e6.5 and e7.5 
was basically in agreement with Mendelian ratios. E3.5 KO embryos had no anomalies upon 
visual inspection (data not shown), while e6.5 KO embryos were moderately smaller than their 
WT counterparts (Fig. 5A). On e7.5, all KO embryos were much smaller size than their WT 
counterparts (Table 3 and Fig. 5A). We then cultured e3.5 embryos from HET male and 
female mating to observe their outgrowth in vitro. As depicted in Figure 5B, WT, HET and 
KO embryos manifested no discernible difference upon visual inspection 1 day after culture 
(e4.5), and their outgrowth seemed to be comparable until e6.5. All these data suggested major 
developmental blockage between e6.5 and e7.5 in the absence of MLF1-IP. 
 
To better understand embryonic lethality around E6.5, we performed Hematoxylin and eosin 
staining which revealed a degeneration of the epiblast and its detachment from the 
surrounding visceral endoderm in e6.5 KO embryos (Fig. 5C, top row), while HET embryos , 
showed no such anomaly. In situ hybridization with an Otx2 probe that marks both the epiblast 
and visceral endoderm revealed a hypocellular and disorganized epiblast tissue in KO but not 
HET embryos at e6.5 (Fig. 5C, middle row). In situ hybridization for Lim1 that marks 
primarily the visceral endoderm revealed a somewhat thicker but otherwise normal visceral 
endoderm in e6.5 KO embryos, as compared to that in HET embryos (Fig. 5C, lower row). 
 
These data indicate that MLF1-IP is vital in embryonic development, particularly for epiblast 
development around e6.5.  
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As shown in Figure 4C, MLF1-IP mRNA levels in heterozygous embryos was about a half of 
that in WT ones, but HET embryos develop normally. We failed to generate ES cells from KO 
embryos, but HET ES cells were generated. We wondered whether by further knocking down 
the MLF1-IP expression levels in the HET ES cells, we might reveal some anomaly in these 
cells in terms of their pluripotency. We transfected HET ES cells with MLF1-IP siRNA, and 
the mRNA knockdown was confirmed by RT-qPCR (Fig. 5D). The siRNA-or control siRNA-
transfected ES cells were cultured for 2 days, and their expression of Oct-4 and Nanog, two 
pluripotent markers was assessed by RT-qPCR[17]. As shown in Figure 5E, no apparent 
differences in Oct-4 and Nanog expression between the MLF1-IP and control siRNA-
transfected HET ES cells were observed. Thus, probably the remaining MLF1-IP is sufficient 
to maintain the pluripotency of ES cells.  
 
No detectable anomalies in cell sub-populations in lymphoid organs and bone marrow of 
MLF1-IP HET mice 
As MLF1-IP was prominently expressed in the thymus between e15.5 and p10, and was up-
regulated in adult T cells upon their activation, we set out to investigate whether reduced 
MLF1-IP expression causes immune system abnormalities. HET mice were used for this 
purpose because no KO mice could be produced. HET mice were viable and fertile with not 
visible abnormalities on either gross or anatomical visual inspection. No lymphoid organ 
anomalies were apparent in HET mice in terms of size, weight and cellularity (data not 
reported). 
 
T, B, CD4 and CD8 sub-populations in the spleen and lymph nodes of HET mice were 
comparable to those in WT controls (Fig. 6A), as were thymocyte sub-populations, such as 
CD4CD8 double-negative, CD4CD8 double-positive, CD4 single-positive and CD8 single-
positive cells (Fig. 6B). 
 
We also assessed the Lin-c-Kit+Sca-1+ stem cell population in bone marrow, but no significant 
difference between HET and WT mice was evident (Fig. 6C). Furthermore, populations of 
B220+CD43+CD19+AA4.1+ pro-B cells, B220+CD43-CD19+AA4.1+ pre-B cells, Mac-1+Gr-1+ 
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bone marrow myeloid cells, and CD71+Ter119+ erythroid precursors were comparable in the 
bone marrow of HET and WT mice (Fig. 6D).    
 
Assessment of HET and WT T-cell functions 
Although HET T cells only expressed MLF1-IP mRNA at about 50% the WT level upon 
activation by anti-CD3 and CD28 mAbs on solid phase, they proliferated as well as WT T 
cells (Fig. 7A). Activation markers, such as CD25 and CD69, were up-regulated in HET CD4 
and CD8 T cells comparably to their WT counterparts (Fig. 7B). Furthermore, HET-naïve 
CD4 T cells could differentiate into Th1, Th17 and Treg cells as efficiently as WT T cells 
(Fig. 7C). Therefore, it appears that 50% of normal MLF1-IP expression is sufficient to 
maintain T-cell proliferation and function. 
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DISCUSSION 
MLF1-IP came to our attention about 10 years ago when we screened genes whose expression 
was up-regulated during T-cell activation, but little was known about its functions at that time. 
Several years later, its functions in mitosis were reported by several groups (3-6). Our ISH 
analysis of its temporal and spatial expression during ontogeny in mice by and large concurs 
with its reported function in mitosis in that regions in organs containing fast-proliferating cells 
at any given ontogeny stage expressed high MLF1-IP mRNA levels. However, such was not 
always the case. For example, on p10, moderately high MLF1-IP mRNA expression was still 
obvious in the retina and cerebellum, although these regions do not have fast growing cells at 
that stage. This raises an intriguing question: does MLF1-IP have additional functions besides 
those in mitosis.  
 
Our study, for the first time, examines whether MLF1-IP is irreplaceable or its function can be 
compensated by other molecules. With complete MLF1-IP deletion, this question was clearly 
answered in the KO mouse model. At least until close to e6.5, MLF1-IP KO embryos were 
comparable to WT controls in regard to size and morphology. Multiple rounds of proliferation 
were carried out from inception to the time point near e6.5, starting from a fertilized egg to an 
embryo of about 0.5 mm in length containing several hundred thousand cells. Obviously, 
proliferation could go on without MLF1-IP, and was not absolutely needed for mitosis. On the 
other hand, it is obvious that without MLF1-IP, embryonic development cannot go beyond 
e6.5, indicating that certain vital developmental events around this time absolutely require 
MLF1-IP. We attempted to generate KO ES cells from e3.5 blastocysts. From 100 blastocysts, 
50-60 ES cell lines were obtained, but all of them were either WT or HET. Taken together, 
these findings suggest that MLF1-IP is essential in optimizing the embryonic developmental 
program: cells might develop without MLF1-IP, but once the condition is stringent, such as 
during ES cell derivation in vitro or near e6.5 in vivo, cells without MLF1-IP will fail to 
develop further.  It seems different types of cells in the early development require different 
levels of MLF1-IP expression; the epiblast is more sensitive to the lack of MLF1-IP at e6.5. 
We conclude that MLF1-IP is crucially required during embryonic development. However, the 
fact that a fertilized egg can grow into several hundred thousand cells without MLF1-IP raises 
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questions as to whether such irreplaceability is simply due to its roles in the proliferation 
program, or due to its vital roles in other particular cellular processes such as epiblast 
development around e6.5. 
 
Another useful piece of information from our study is that 50% of normal MLF1-IP 
expression is sufficient during ontogeny and immunity. HET mice were alive and fertile, with 
no visible anomalies. Their lymphoid organs and cells all developed normally, and no 
defective T cell function was observed in vitro based on our assays. Thus, normal MLF1-IP 
expression level has ample buffering latitude for its functions. 
 
In summary, our study, for the first time, demonstrated the irreplaceability of MLF1-IP during 
mouse embryonic development. It also raised an intriguing possibility that the molecule might 
have functions unrelated to proliferation, based on its expression pattern in the CNS and 
successful progression of embryonic development until e6.5. 
 
 
 
 
 
xvii 
REFERENCES 
1. Pan H-Y, Zhang Y-J, Wang X-P, Deng J-H, Zhou F-C, et al. (2003) Identification of a 
novel cellular transcriptional repressor interacting with the latent nuclear antigen of 
Kaposi's sarcoma-associated herpesvirus. J Virol 77: 9758–9768. 
2. Hanissian SH, Akbar U, Teng B, Janjetovic Z, Hoffmann A, et al. (2004) Oncogene - 
cDNA cloning and characterization of a novel gene encoding the MLF1-interacting 
protein MLF1IP. Oncogene 23: 3700–3707. 
3. Minoshima Y, Hori T, Okada M, Kimura H, Haraguchi T, et al. (2005) The constitutive 
centromere component CENP-50 is required for recovery from spindle damage. Mol 
Cell Biol 25: 10315–10328. 
4. Foltz DR, Jansen LET, Black BE, Bailey AO, Yates JR, et al. (2006) The human 
CENP-A centromeric nucleosome-associated complex. Nat Cell Biol 8: 458–469.  
5. Kang YH, Park J-E, Yu L-R, Soung N-K, Yun S-M, et al. (2006) Self-regulated Plk1 
recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper 
chromosome segregation. Mol Cell 24: 409–422. 
6. Kang YH, Park CH, Kim T-S, Soung N-K, Bang JK, et al. (2011) Mammalian polo-like 
kinase 1-dependent regulation of the PBIP1-CENP-Q complex at kinetochores. Journal 
of Biological Chemistry 286: 19744–19757. 
7. Hua S, Wang Z, Jiang K, Huang Y, Ward T, et al. (2011) CENP-U cooperates with 
Hec1 to orchestrate kinetochore-microtubule attachment. Journal of Biological 
Chemistry 286: 1627–1638.  
8. Marcinkiewicz M (2002) BetaAPP and furin mRNA concentrates in immature senile 
plaques in the brain of Alzheimer patients. J Neuropathol Exp Neurol 61: 815–829. 
9. Henrique D, Adam J, Myat A, Chitnis A, Lewis J, et al. (1995) Expression of a Delta 
 
 
 
xviii 
homologue in prospective neurons in the chick. Nature 375: 787–790.  
10. Narlis M, Grote D, Gaitan Y, Boualia SK, Bouchard M (2007) Pax2 and pax8 regulate 
branching morphogenesis and nephron differentiation in the developing kidney. J Am 
Soc Nephrol 18: 1121–1129. 11. Simeone A, Acampora D, Mallamaci A, 
Stornaiuolo A, D'Apice MR, et al. (1993) A vertebrate gene related to orthodenticle 
contains a homeodomain of the bicoid class and demarcates anterior neuroectoderm in 
the gastrulating mouse embryo. EMBO J 12: 2735–2747. 
12. Liu P, Jenkins NA, Copeland NG (2003) A highly efficient recombineering-based 
method for generating conditional knockout mutations. Genome Res 13: 476–484.  
13. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC (1993) Derivation of 
completely cell culture-derived mice from early-passage embryonic stem cells. Proc 
Natl Acad Sci USA 90: 8424–8428. 
14. Luo H, Charpentier T, Wang X, Qi S, Han B, et al. (2011) Efnb1 and Efnb2 proteins 
regulate thymocyte development, peripheral T cell differentiation, and antiviral immune 
responses and are essential for interleukin-6 (IL-6) signaling. Journal of Biological 
Chemistry 286: 41135–41152.  
15. Han B, Moore PA, Wu J, Luo H (2007) Overexpression of human decoy receptor 3 in 
mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum 56: 
3748–3758.  
16. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, et al. (2009) Role of TL1A in the 
pathogenesis of rheumatoid arthritis. J Immunol 183: 5350–5357.  
17. Loh Y-H, Wu Q, Chew J-L, Vega VB, Zhang W, et al. (2006) The Oct4 and Nanog 
transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 
38: 431–440. 
 
 
 
 
xix 
FIGURE LEGENDS 
Figure 1. ISH analysis of MLF1-IP expression in mid-gestation embryos e9.5, e12.5 and e15.5  
Sagittal sections of the embryos are shown as follows: (I) crystal violet staining under bright-
field illumination, and (II) antisense and (III) sense (control) hybridization x-ray film under 
dark-field illumination.  Column A: an e9.5 embryo with hybridization signal seen over a 
rudimental brain and spinal cord and with less signal within mesenchymal centers. Column B: 
an e12.5 embryo with hot spots of MLF1-IP hybridization in the brain, optic vesicle and liver. 
Column C: an e15.5 embryo showing further differentiation of MLF1-IP expression 
distribution. Strong hybridization signal is observed in the brain ventricular zone rich in 
neuroblasts and ventricle wall, submaxillary gland and thymus. Lung parenchyma, liver, 
kidney marginal zone and growing intestine showed moderate-level MLF1-IP mRNA 
labelling. Original magnifications: (A) 6.5X; (B) 4.5X and (C) 2.6X. 
 
Abbreviations used in Figures 2-4: Adr – adrenal gland; Al – alveolar bone; AR – aortic root; 
BM – bone marrow; Br – brain; C – calvaria bone; Cb – cerebellum; CL – corpus luteum; Cx 
– cortex; DA – dorsal aorta; F – follicles; Fe – femur, bone and bone marrow; H – heart; Int – 
intestine; K – kidney; LF – lymph follicle; Li – liver; LInt – Large intestine; LN – lymph 
node; Lu – lung; M – muscles, striated; Me – mesencephalon; Med – medulla; Mes – 
mesenchyme; NT – nasal tip; Ov – ovary; OV – optic vesicle; R – retina; Ri – ribs; SfT – 
seminiferous tubules; Sk – skin; SMax – submaxillary gland; SpC – spinal cord; St – stomach; 
T – telencephalon; Tes – testes; Th – thymus; V – ventricular wall; Ve – vertebrae; VZ – 
ventricular zone; WP – white pulp; (as) – antisense; (s) – sense. 
Figure 2. ISH analysis of MLF1-IP mRNAS expression in p1, p10 and adult mice 
Sagittal sections of p1, p10 and adult mice were stained with crystal violet (I), antisense 
probes (II) and sense probes (control) (III) as described in Figure 1.  Column A: sections of a 
newborn (p1) mouse with MLF1-IP mRNA labelling seen in the retina, cerebellum, 
submaxillary gland, thymus, liver, intestine and kidney marginal zone. Column B: sections of 
a p10 mouse displaying various levels of MLF1-IP expression in different organs, including 
bone marrow within vertebrae and testis. Non-specific hybridization is noted in dorsal aorta 
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(*), aortic root (**) and alveolar bone (***) according to sense probe hybridization. Column 
C: sections of an adult mouse showing low-level MLF1-IP mRNA in the cerebellum, thymus, 
spleen and bone marrow. There is no detectable hybridization in the liver and kidney.  Non-
specific hybridization is seen in the femoral, skull alveolar bones (*), ribs (**) and in the 
content of the large intestine (***). Original magnifications: (A) 1.5X; (B) 1.3X and (C) 1.0X. 
 
Figure 3. ISH analysis of MLF1-IP expression in individual adult tissues 
X-ray autoradiography was under dark-field illumination. The left column shows antisense 
hybridization, and the right column, sense (control) hybridisation. A and A’: thymus, showing 
ISH signal mostly in the cortex and less in the medulla. B and B’: spleen, very low-level ISH 
signal in the white pulp. C and C’: Lymph node, low-level ISH labelling in the lymphatic 
follicles; D and D’: testis, high-level MLF1-IP expression in seminiferous tubules. E and E’: 
MLF1-IP mRNA detectable in the follicles and corpus luteum. Original magnification: 10X. 
 
Figure 4. Generation of MLF1-IP KO mice  
A. Targeting strategy for generating MLF1-IP KO mice  
The red square on the 5’ side of the mouse MLF1-IP WT genome represents the sequence 
used as a probe in Southern blotting for genotyping.  
 
B. Genotyping of MLF1-IP mutant mice 
Tail DNA was digested with NcoI, and analyzed by Southern blotting (left panel), with a 5’ 
probe whose location is indicated in A (red square). A 10-kb band representing the WT allele 
and a 6.8-kb band representing the recombinant allele are indicated by arrows. Ear lobe DNA 
sample was analyzed by PCR for routine genotyping (right panel). A 588-bp band representing 
the WT allele and a 202-bp band representing the recombinant allele are indicated by arrows. 
 
C. MLF1-IP mRNA expression in MLF1-IP WT, HET and KO embryos 
mRNA levels from e7.5 WT, HET and KO embryos were analyzed by RT-qPCR. The results 
are expressed as ratios of MLF1-IP versus β-actin signals with means + SD indicated.  
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D. MLF1-IP mRNA expression in WT and HET T cells upon activation 
T cells from WT and HET spleens were stimulated by solid-phase anti-CD3 mAb and anti-
CD28 mAb (0.5 µg/ml and 4 µg/ml respectively for coating) for 0, 24, 48 or 72 h, and their 
MLF1-IP mRNA levels were quantified by RT-qPCR. The results are expressed as ratios of 
MLF1-IP versus β-actin signals with means + SD indicated. 
 
Figure 5. Development of WT, HET and KO embryos until e7.5 
A. Gross morphology of WT and KO mouse embryos  
E6.5 and e7.5 embryos dissected from decidua were photographed, and then genotyped by 
RT-qPCR. (Scale bar: 100 µm.) 
 
B. Normal outgrowth of HET and KO embryos from e4.5 to e6.5 in vitro 
E3.5 embryos were harvested with M2 medium, cultured in M16 medium and photographed 
daily on e4.5, e5.5 and e6.5. Phase-contrast micrographs are shown. At the end of culture on 
e6.5, the embryos were genotyped by RT-qPCR. (Scale bar: 100 µm.) 
 
C. Histology and differentiation marker expression at of foetuses e6.5 
Top row: Hematoxylin and eosin staining of e6.5 embryos 
Middle row: Oxt2 in situ hybridization. 
Bottom row: Lim1 in situ hybridization. 
VE: visceral endoderm; Epi: epiblast; *: detachment of the epiblast from the surrounding 
visceral endoderm. (Scale bar: 100 µm.) 
 
D. Knockdown of MLF1-IP mRNA expression in HET ES cells by siRNA according to RT-
qPCR. 
HET ES cells were transfected with MLF1-IP siRNA or control siRNA as indicated, and after 
2 days, their MLF1-IP mRNA expression was assessed by RT-qPCR.
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E. Oct-4 and Nanog mRNA expression in HET ES cells with MLF1-IP knockdown 
Oct-4 (left panel) and Nanog (right panel) expression levels of the cells from Fig. 5D were 
assessed by RT-qPCR. 
 
Figure 6.  Sub-populations of lymphocytes in lymphoid organs of MLF1-IP HET mice 
Cells of hematopoietic origin in lymphoid organs and bone marrow were analyzed by flow 
cytometry. The percentages of key sub-populations are indicated. The experiments were 
repeated at least 3 times, and representative histograms provided. 
 
A. T- and B -cell sub-populations in the spleen and lymph nodes 
CD4 and CD8 T-cell sub-populations in WT and HET spleens, lymph nodes and thymus were 
analyzed by 2-color flow cytometry. The B-cell population in the spleen and lymph nodes was 
analyzed according to B220 and CD19 expression by 2-color flow cytometry. Percentages are 
indicated. 
 
B. Thymocyte sub-populations 
Thymocytes from WT and HET mice were stained with CD4 or CD8 for 2-color flow 
cytometry, or with lineage markers (CD3ε, CD8β, TCRβ, CD11b, CD45R, B220, Ly6C, 
Ly6G, Ter-119), CD25 and CD44 for 3-color flow cytometry. Lineage- cells were gated and 
analyzed for their CD25 and CD44 expression.   
C. Lineage-negative bone marrow cell sub-populations 
WT and HET bone marrow cells were stained with lineage markers, c-Kit and Sca-1for 3-
color flow cytometry. Lineage- cells were gated, and analyzed for their c-Kit+Sca-1+ stem cell 
population. 
D. Pre-B, pro-B, pre-pro-B cell sub-populations and myeloid cell in bone marrow 
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WT and HET bone marrow cells were stained with B220, CD43, CD19 and AA4.1 and 
analyzed by 4-color flow cytometry for B220+CD43+CD19-AA4.1+ pre-pro-B cell (region II in 
column 2) B220+CD43+CD19+AA4.1+ pro-B cell (region I in column 2) and B220+CD43-
CD19+AA4.1+ pre-B cell (region III in column 3) populations. Bone marrow cells were also 
stained with Mac-1 and Gr-1 (column 4) for analysis of mature Mac-1+Gr-1+ neutrophils, or 
stained with Ter-119 and CD71 for analysis of CD71+Ter119+ erythroid precursor cells.   
 
Figure 7. MLF1-IP+/- T-cell functions in vitro 
All experiments in this figure were repeated at least twice and representative data are 
presented. 
 
A. T-cell proliferation  
WT and HET spleen T cells were stimulated with solid-phase anti-CD3 mAb plus anti-CD28 
mAb (0.5 µg/ml and 4 µg/ml respectively for coating) and pulsed with 3H-thymidine for 16 h 
before harvesting. 3H-thymidine uptake was measured at 24, 48 and 72 h after the initiation of 
culture. Samples were tested in triplicate, and cpm means + SD were reported.  
 
B. C69 and CD25 expression on activated WT and HET T cells 
WT and HET T cells were stimulated overnight by solid-phase anti-CD3 mAb plus anti-CD28 
mAb (0.5 µg/ml and 4 µg/ml respectively for coating). CD69 and CD25 expression on CD4 
(left panel) and CD8 (right panel) T cells was measured by 2-color flow cytometry.  
 
C. Naïve CD4 cell differentiation in vitro  
WT and HET Naïve CD4 cells were cultured under conditions favouring Th1 (second column), 
Th17 (third column), or Treg (last column) cell differentiation for 3 days. Cells without 
differentiation cytokines (TH0, first column) were included for comparison. Their intracellular 
cytokine expression was determined by flow cytometry. Experiments were repeated twice, and 
representative data reported.  
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TABLES 
Table 0.1 Sequences of siRNA specific to MLF1-IP and control siRNA 
	  	   Sets	  of	  siRNA	  sequences	  
	  Gene	   Sense	  sequences	   Antisense	  sequences	  
Control	   	  
5'-­‐rCrGrU	  rUrArA	  rUrCrG	  rCrGrU	  rArUrA	  
rArUrA	  rCrGrC	  rGrUA	  T-­‐3'	  
5'-­‐rArUrA	  rCrGrC	  rGrUrA	  rUrUrA	  rUrArC	  
rGrCrG	  rArUrU	  rArArC	  rGrArC-­‐3'	  
MLF1-­‐IP	  
	  	  
Duplex	  1:	   5'-­‐rGrGrA	  rArUrA	  rArArG	  rArUrU	  rArGrU	  rCrArG	  rArArU	  rArUrG	  T-­‐3'	  
5'-­‐rArCrA	  rUrArU	  rUrCrU	  rGrArC	  rUrArA	  
rUrCrU	  rUrUrA	  rUrUrC	  rCrUrC-­‐3'	  
Duplex	  2:	   5'-­‐rArGrA	  rGrUrA	  rGrArA	  rUrCrU	  rGrArA	  rArGrU	  rUrGrU	  rAAT	  C-­‐3'	  
5'-­‐rGrArU	  rUrArC	  rArArC	  rUrUrU	  rCrArG	  
rArUrU	  rCrUrA	  rCrUrC	  rUrUrU-­‐3'	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Table 0.2 Summary of MLF1-IP mRNA expression in various tissues and organs during mouse 
ontogeny according to ISH 
         Embryonic stage  
Tissue  e9.5 e12.5 e15.5 p1 p10 Adult 
Brain and spinal cord +++ ++++ - / +++ -/+ -/+ -/± 
Cerebellum - - - + ++ ± 
Eyes + ++ ne +++ ++ ne 
Olfactory neuroepithelium     + ne ne ne 
Liver + +++ ++ + + ± 
Kidneys - + ++ +++ ne ne 
Submaxillary gland - - ++ ++ + ± 
Vertebrae - - - + ++ - 
Calvaria - - - + ++ - 
Thymus - - +++ ++ ++ ± 
Spleen     ne +++ ne ± 
Lymph nodes 	  	   	  	       ne ± 
Ovaries 	  	   	  	       ne +++ 
Testes 	  	   	  	       ++ +++++ 
 
Arbitrary scale: absence of labelling (-);weak (+) to  high (+++++) concentrations; ne: not 
examined. 
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Table 0.3 Genotyping of embryos from MLF1-IP+/- × MLF1-IP+/- mating 
 Genotype  
Stage +/+ +/- -/- Total 
e3.5 3 18 9 30 
e6.5 12 18 8a 41 
e7.5 8 16 9b 33 
               
 aKO embryos were moderately smaller than WT ones. 
bKO embryos drastically shrank to smaller  sizes. 
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ABSTRACT 
In our unbiased survey of genes modulated during the early stage of T-cell activation, we 
discovered that STRA6 (stimulated by retinoic acid gene 6) was up-regulated within 3 h of 
TCR stimulation. STRA6 is the high-affinity receptor for plasma retinol-binding protein 
(RBP) and mediates cellular vitamin A uptake. We generated STRA6 knockout (KO) mice to 
assess whether such up-regulation was critical for T-cell activation, differentiation and 
function.  Unlike human STRA6 mutation, which causes severe defects in multiple organs, 
STRA6 KO mice under vitamin A sufficient conditions were fertile without apparent 
anomalies upon visual inspection. The size, cellularity and lymphocyte subpopulations of 
STRA6 KO thymus and spleen were comparable to those of their wild type (WT) controls. KO 
and WT T cells were similar in terms of TCR-stimulated proliferation in vitro and homeostatic 
expansion in vivo. Naive KO CD4 cells differentiated in vitro into Th1, Th2, Th17 as well as 
regulatory T cells in an analogous manner as their WT counterparts. In vivo experiments 
revealed that anti-viral immune responses to lymphocytic choriomeningitis virus in KO mice 
were comparable to those of WT controls. We also demonstrated that STRA6 KO and WT 
mice had similar glucose tolerance. Total vitamin A levels are dramatically lower in the eyes 
of KO mice as compared to those of WT mice, but the levels in other organs were not 
significantly affected after STRA6 deletion under vitamin A sufficient conditions, indicating 
that the eye is the mouse organ most sensitive to the loss of STRA6.    
 
Our results demonstrate that under vitamin A sufficient conditions, the elimination of STRA6 
altogether in T cells does no affect the T-cell immune responses so-far tested; 2) STRA6-
independent vitamin A uptake compensated the lack of STRA6 in lymphoid organs under 
vitamin A sufficient conditions in mice; and 3) STRA6 is critical for vitamin A uptake in the 
eyes even in vitamin A sufficiency. W also found no evidence that STRA6 can trigger STAT5 
signaling in lymphoid organs. 
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INTRODUCTION 
During T-cell immune responses, naive T cells are activated by stimuli through TCR in the 
company of co-stimulation signals, and undergo multiple rounds of proliferation before 
entering the differentiation phase, after which they become effector T cells. The expression of 
many molecules is modulated during activation and differentiation stages, with some of them 
playing pivotal regulatory roles, while others exert support and house-keeping functions to 
cope with increased metabolic demands. We undertook unbiased exploration with DNA 
microarray analysis of molecules up- or down-regulated in T cells within the first 16 h after 
stimulation by anti-CD3 with a view to identifying those that are critical in the early T-cell 
activation stage. A group of molecules with the highest levels of altered expression in 
activated T cells was chosen, with resting T cells as reference, and verified by Northern 
blotting analysis. STRA6 (stimulated by retinoic acid gene 6) is among those that have been 
validated. We generated STRA6 gene knockout (KO) mice to assess the significance of its up-
regulation in T-cell activation and, consequently, T-cell immune responses.   
 
At the outset of our investigation in 2004, no function was ascribed to STRA6, a 74-kDa 
protein with multiple transmembrane domains that was first identified in retinoic acid-
stimulated P19 embryonic carcinoma cells upon retinoic acid stimulation [1]. In 2007, 
Kawaguchi et al. used an unbiased technique to identify STRA6 as a specific cell-surface 
receptor for plasma retinol binding protein (RBP) and showed that STRA6 mediates cellular 
vitamin A uptake from holo-RBP (RBP/vitamin A complex) in bovine retinal pigment 
epithelium cells [2].  STRA6-mediated vitamin A uptake from holo-RBP is coupled to 
intracellular proteins as confirmed by several independent studies [1-5], and its mechanism in 
coupling to specific intracellular proteins has been elucidated [4].  Pasutto et al. [6] observed 
that mutations in STRA6 correlated with many eye, heart, diaphragm and lung malformations 
as well as mental retardation in Matthew-Wood syndrome in humans, corroborating its 
reported roles in vitamin A uptake by cells as vitamin A is vital in organogenesis. Recent 
reports indicate that single nucleotide polymorphisms or mutations in STRA6 gene are 
correlated with the congenital eye malformations microphthalmia, anophthalmia and 
coloboma [7,8] as well as Matthew-Wood syndrome [9]. Genetic null mutation of STRA6 in 
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mice results in significant retinoid reduction in the retinal pigment epithelium and 
neurosensory retina, diminished visual responses and eye morphology, although the last-
mentioned defect is not as serious as in patients with STRA6 mutations [10]. 
 
There is a report suggesting that STRA6 is not only a vitamin A transporter but can also 
function as a cytokine receptor. Upon binding with holo-RBP, STRA6 is phosphorylated at 
tyrosine residue 643, which, in turn, recruits and triggers JAK2 and STAT5 activation [11].  
 
The ascribed roles of STRA6 in vitamin A transport and the STAT5 signalling pathway are 
certainly relevant to T-cell activation and function. Retinoids are known to modulate Th1 (T 
helper 1), Th2, Th17 and reglulatory T (Treg) cell development and function [12-17]. At the 
molecular level, it has been demonstrated that retinoic acid opens up the FoxP3 promoter 
tertiary structure for activated FoxP3 transcription [18]. RARα can interact with STAT5a and 
b [19], which are critical molecules in the signaling pathway of a key T activation cytokine IL-
2 [20]. 
 
Vitamin A is absorbed from dietary nutrients. There are several possible modes of vitamin A 
transport to cells in different organs. Vitamin A in the diet can be transported to liver cells and 
other cell types in the form of chylomicron-bound retinyl ester [21,22]. The liver is the 
primary storage site for vitamin A in the form of all-trans-retinyl ester, which can be reverted 
to vitamin A [22]. As alluded to above, vitamin A associates with RBP in blood, and such 
complexes can deliver vitamin A to cells via the RBP receptor STRA6 [2].  Transthyretin can 
associate with vitamin A-bound RBP, and such coupling serve to prevent renal filtration of the 
holo-RBP [23], Recently, Alapatt et al. [24] discovered a second RBP receptor, a STRA6 
homologue called RBPR2. RBPR2 is expressed in the liver, intestines, fatty tissues, and 
spleen.  Like STRA6, RBPR2 is fully capable of binding to RBP and transporting vitamin A 
into cells. As vitamin A is hydrophobic, it should also be able to diffuse through cell 
membranes without any specific receptors.    
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The relative contribution of STRA6 to vitamin A cellular import in lymphoid organs has not 
been evaluated and is a secondary goal of our study. 
 
In this study, we demonstrated that STRA6 KO mice were vital and fertile, manifesting no 
apparent anomalies in their lymphoid organs and T cell-dependent immune responses under 
vitamin A sufficient conditions. Intracellular vitamin A concentrations in lymphoid organs, 
such as the thymus and spleen of the KO mice were comparable to those of WT controls, 
although the vitamin A content in cells from KO eyes was significantly lower that that from 
the WT eyes.  The implications of these data are discussed. 
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MATERIALS AND METHODS 
RT-qPCR 
STRA6 mRNA in cells and tissues from KO, heterozygous and WT mice was measured by 
RT-qPCR. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) and then 
reverse-transcribed with Superscript II™ reverse-transcriptase (Invitrogen). The forward and 
reverse primers were 5’-AGG CAT CTG AGA ATG GAA GCC AGA-3’ and 5’-AGC AGA 
ACC AGG AAC GAC AGT GAA-3’, respectively. A 184-bp product was detected with the 
following amplification program: 95oC x 15 min, 1 cycle; 94oC x 15 s, 55oC x 30 s, 72oC x 30 
s, 35 cycles. β-actin mRNA levels were measured as internal controls; the forward and reverse 
primers were 5’-TGGTACCACAGGCATTGTGAT-3’ and 5’-
TGATGTCACGCACGATTTCC CT-3’, respectively, with the same amplification program as 
for STRA6 mRNA. The data were expressed as ratios of STRA6 and β-actin signals. 
 
Generation of STRA6 KO mice  
A PCR fragment amplified with the STRA6 cDNA sequence served as a probe to isolate 
genomic BAC DNA clone 7O8 from the RPCI-22 129/sv mouse BAC genomic library. The 
targeting vector was constructed by recombination [25] and routine cloning methods using an 
11-kb STRA6 genomic fragment from clone 7O8 as the starting meterial. A 2.7-kb MunI-XbaI 
genomic fragment containing exon 2 was replaced by a 1.1-kb Neo cassette from pMC1Neo-
Poly A flanked by 2 diagnostic restriction sites, XbaI and ScaI, as illustrated in Figure 2A. The 
final targeting fragment was excised from its cloning vector backbone by Not I digestion and 
electroporated into R1 embryonic stem (ES) cells for G418 selection [26]. The targeted ES 
cell clones were injected into C57BL/6 blastocysts. Chimeric male mice were mated with 
C57BL/6 females to establish mutated STRA6 allele germline transmission.  
 
Southern blotting with probes corresponding to the 5’ and 3’ sequences outside the targeting 
region, as illustrated in Figure 2A (red squares),  were used to screen for gene-targeted ES 
cells and eventually to confirm gene deletion in mouse tail DNA. With the 5’ probe, the 
targeted allele should present a 7.8-kb XbaI band, and the WT allele, a 5.2-kb XbaI band. 
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With the 3’ probe, the targeted allele should present a 6.9-kb ScaI band, and the WT allele, a 
4.3-kb ScaI band (Fig. 2A). 
 
PCR was adopted for routine genotyping of the targeted allele(s). The following PCR 
conditions were applied: 4 min at 94 oC, followed by 35 cycles of 30 s at 94 oC, 30 s at 60 oC, 
and 30 s at 72 oC, with final incubation at 72 oC for 10 min. The KO forward primer 5'- GCG 
TCA CCT TAA TAT GCG AAG TG-3' and reverse primer 5'-CAA GAA GTC CGT GGC 
TGA GTC TA-3' detected a 400-bp fragment from the targeted allele. The WT forward primer 
5'-TCT CCC AGG TCT GGT TTG AG-3' and reverse primer 5'-TTA GGG CAA CAC CCT 
ACT GG-3' detected a 197-bp fragment from the WT allele. 
 
The KO mice were backcrossed to the C57BL/6 background for 8 generations and then used 
for experimentation. All mice were housed under specific pathogen-free conditions and fed 
with mouse chow (Teklad Global 2018, Teklan Diets, Madison, WI) containing 15 IU/g 
Vitamin A. The mice had access to water and chow ad libitum.  The studies were approved by 
the Institutional Animal Protection Committees of the CRCHUM and INRS-IAF. 
 
Flow cytometry 
Single cell suspensions from the thymus, spleen and lymph nodes were prepared and stained 
immediately or after culture with antibodies (Abs) against CD4, CD8, CD25, CD19, B220, 
CD69 and STRA6. In some experiments, intracellular proteins, such as FoxP3, IFN-γ, IL-4, 
IL-17, and TNF-α, were detected after the cells were pre-stained with Abs against cell surface 
antigens fixed with BD Cytofix/Cytoperm™ solution (BD Biosciences, San Diego, CA) and 
then stained with monoclonal Abs (mAb) against intracellular antigens. The Abs deployed for 
flow cytometry are listed in Table I. Flow cytometry analysis of the stained cells are described 
in our previous publications [27-30].  
 
Flow cytometry was also employed to assess lymphocytic choriomeningitis virus (LCMV)-
specific T cells. Synthetic peptides gp33-41: KAVYNFATC (LCMV-GP, H-2Db); np396-404: 
FQPQNGQFI (LCMV-NP, H-2Db); gp276-286: SGVENPGGYCL (LCMV-GP, H-2Db); and 
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gp61-80: GLNGPDIYKGVYQFKSVEFD (LCMV-GP, I-Ab) were purchased from Sigma-
Genosys (Oakville, Ontario, Canada). PE-gp33-41, PE-np396-404 and PE-gp276-286 H-2Db 
tetrameric complexes were synthesized in-house and used at 1/100 dilution as previously 
described [26]. These MHC-tetramers were used to detect LCMV-specific CD8+ T cells on 
day 8 post LCMV infection. Briefly, splenocytes were first stained with PE-gp33-41, PE-np396-
404 or PE-gp276-286 tetramers for 30 minutes at 37°C, followed by staining with FITC-rat anti-
mouse CD8α and APC-rat anti-mouse CD62L mAbs at 4°C for another 20 minutes. 7-AAD 
was used for exclusion of dead cells. After washing, cells were fixed in 0.5% 
paraformaldehyde and samples were analyzed by flow cytometry.  One million splenocytes 
from LCMV-infected mice were seeded in single wells of 96-well round-bottomed plates. 
They were maintained in 5% RPMI-1640 supplemented with 100 units/ml interleukin-2, 10 
µg/ml brefeldin A, 10 µM gp33-41 or gp61-80 peptide. After 5 h of incubation at 37°C, the cells 
were stained with PE-conjugated rat anti-mouse CD8α or CD4 mAbs and 7-AAD. They were 
then fixed, permeabilized and stained with APC-labeled rat anti-mouse TNF-α and FITC-
labeled rat anti-mouse IFN-γ mAbs. IFN-γ and TNF-α-secreting T cells were counted by flow 
cytometry [31].  
 
T-cell proliferation in vitro and in vivo after being transferred to sub-lethally-irradiated mice 
Spleen cells were loaded with carboxyfluorescein succinimidyl ester (CFSE; 5µM for 5 mins), 
and then cultured in the presence of soluble hamster against mouse CD3 mAb (clone 2C11; 
0.5 µg/ml) [27,28,32,33]. After 3 days, CFSE fluorescence of the CD4 and CD8 
subpopulations was analyzed by flow cytometry for TCR-stimulated proliferation. T-cell 
homeostatic expansion was evaluated by i.v. injection of 5 x 106 CFSE-loaded spleen cells 
into C57BL/6 recipients 5 h after sub-lethal irradiation (650 Rad). On day 5, the CFSE 
fluorescence of CD4 and CD8 cells from the spleen and LN was studied by flow cytometry.   
 
In vitro Th1, Th2, Th17 and Treg cell polarization 
In vitro Th and Treg cell differentiation was conducted as follows [27,34]. Naïve CD4 T cells 
(CD4+CD62L+CD44low) were isolated from KO or WT mouse spleens with MagCellect Mouse 
Naïve CD4+ T cell Isolation kits (R & D Systems). T cell-depleted WT spleen cells were 
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irradiated at 3000 Rad and used as feeder cells. The naïve CD4 cells (0.1×106/ well) were 
mixed with the feeder cells (0.5×106/well) and cultured in 96-well plates in the presence of 
soluble anti-CD3ε mAb (clone 145-2C11, 2 µg/ml; BD Biosciences). Cultures were 
supplemented with recombinant mouse IL-12 (10 ng/ml; R & D Systems) and anti-IL-4 mAb 
(10 µg/ml; R & D Systems) for the Th1 condition; recombinant  mouse IL-4 (20 ng/ml; R & D 
Systems), and anti-IL-12 mAb (10 µg/ml; BD Biosciences) and anti-IFN-γ mAb (10 µg/ml; R 
& D Systems) for the Th2 condition; recombinant mouse IL-6 (20 ng/ml; R & D Systems), 
recombinant human TGF-β1 (5 ng/ml; R & D Systems) and anti-IL-4 and anti-IFN-γ mAbs  
(10 µg/ml for each; R & D Systems) for the Th17 condition; recombinant human TGF-β1 (5 
ng/ml; R & D Systems), and anti-IL-4 and anti-IFN-γ mAb (10 µg/ml; R & D Systems) for the 
Treg condition. 
LCMV infection 
LCMV clone 13 was obtained from Dr. R.M. Zinkernagel (University of Zurich, Zurich, 
Switzerland). Viral stock was propagated in vitro, and viral titers were quantified by focus-
forming assay [31]. Mice were infected by the i.v. route with 2 x 106 focus-forming units of 
LCMV clone 13. They were sacrificed 8 days post-infection, and their spleens were harvested 
for primary immune response analysis.  
 
Glucose tolerance tests 
The KO and WT mice were fasted for 16 h and injected i.v. with D-glucose (2 mg/g body 
weight) in PBS. Blood samples from the tail vein were taken at 5, 15, 30, 60, and 90 min after 
the injection for glucose measurements with a glucose meter (Bayer, Toronto, Ontario). 
 
Measurement of serum and intracellular vitamin A and retinyl ester concentrations by high-
pressure liquid chromatography (HPLC) 
Serum and tissue samples, collected in a dark, cold room, were stored at -80oC until their 
analysis. Retinoids were extracted by homogenizing tissues in a butanol-acetonitrile mixture 
(1:1) with a tissue/solvent ratio of 200 mg/700 µl, in Eppendorf tubes on ice by 5 30-s pulses 
with 1-min intervals. K2HPO4 solution (6.89M) was added to the tubes in proportion to the 
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homogenized mixture (20 µl for 900 µl homogenized mixture). For retinoid extraction from 
sera, 200-µl butanol-acetonitrile mixture (1:1) was added to 200-µl serum, and the mixture 
was vortexed for 1 min; 20 µl K2HPO4 solution (6.89M) was then added to the mixture before 
30-s vortexing. The tissue and serum samples thus prepared were centrifuged for 20 min at 
14,000g at 4oC. Cleared supernatants were passed through Spin-X filters (0.45µm pore size; 
Costar, Batavia, Illinois, USA) at 14,000g for 10 min at 4oC. For retinyl ester measurement, 
the samples prepared as aforementioned before the step of filtration were vacuum-dried and 
re-dissolved in 100% methanol, followed by centrifugation at 14,000 g for 10 min. The 
supernatants were then analyzed by HPLC.  
 
Vitamin A in extracts was quantified by HPLC in an ÄKTA Purifier (Model UPC10; GE 
Healthcare, Baie d'Urfé, Quebec, Canada) and reverse-phase column (µ-RPC C2/C18 ST 
4.6/100; GE Healthcare). Samples (100 µl) were eluted with a linear gradient from 100% 
eluent A (acetontrile:water = 65:35) to 100% eluent B (acetontrile:water = 90:10) in 5-column 
volumes at a flow rate of 1 ml/min. Both eluates contained 10 mM ammonium acetate. 
Vitamin A was detected at 313 nm wave-length. Its characteristic retention volume was 
identified with pure Vitamin A from Sigma (Oakville, ON, Canada) as a standard. Areas under 
the curves were computed by UNICORN5.11 software (GE Healthcare). The sensitivity of the 
assay was 250 ng.   
 
Retinyl ester in extracts was quantified by HPLC in an Eclipse XDB-C18 reverse-phase 
column (4.6 X150 mm, 5 µm, Agilent, Santa Clara, CA). Samples (200 µl) were eluted with a 
linear gradient from 100% methanol to 100% ethyl acetate in 5 column volumes at a flow rate 
of 1 ml/min. Retinyl ester was detected at 324 nm wavelength. Its characteristic retention 
volume was identified with retinyl palmitate (Sigma) as standard. Areas under the curves were 
computed by Agilent LC software. Sensitivity of the assay was 1.5 ng.   
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RESULTS 
STRA6 expression in different organs and activated T cells 
STRA6 mRNA expression was assessed by RT-qPCR. Among the organs and tissues 
examined, the thymus had the highest expression level, followed by the heart and kidneys 
(Fig. 1A). STRA6 expression in the spleen was moderate. The skeleton muscles and liver had 
barely detectable STRA6 mRNA. The STRA6 mRNA expression levels in the lung, liver, 
spleen and kidney assessed by our RT/qPCR was consistent with Northern results reported 
previously by Bouillet [1]. High STRA6 expression in the thymus suggested that it might have 
some critical functions in T-cell development and T-cell function. As depicted in Figure 1B, 
STRA6 expression in resting spleen T cells (0 h) was modest, consistent with values of the 
whole spleen. The expression was augmented with in 3 h after T-cell activation by TCR cross-
linking, and reached a peak at 48 h. This result corroborates our initial DNA microarray data, 
through which STRA6 was found upregulated during T-cell activation.  
 
Generation of STRA6 KO mice 
To evaluate the roles of STRA6 in the immune system in general and T cell-mediated immune responses in 
particular, we produced STRA6 KO mice. The targeting strategy is illustrated in Figure 2A. Germline 
transmission was confirmed by Southern blotting of tail DNA (Fig. 2B). With the 5’ end probe, the WT allele 
after XbaI digestion presented a 7.8-kb band, and the KO allele, a 5.2-kb band (Fig. 2B, upper panel). With the 3’ 
end probe, the WT allele after ScaI digestion presented a 6.9-kb band, and the KO allele, a 4.3-kb band (Fig. 2B, 
lower panel). WT (mice 3, 4, and 5) and heterozygous mice (mice 1, 2 and 6) were thus identified. Mouse 1 was 
backcrossed to the C57BL/6 background for 8 generations, and then used in the experiments described hereafter.  
   
To ascertain whether STRA6 gene deletion results in its lack of expression, we measured STRA6 mRNA in 
spleen cells by RT-qPCR. STRA6 mRNA was detectable in WT but not in KO spleen cells (Fig. 2C). The lack of 
STRA6 expression in KO cells at the protein level was confirmed by flow cytometry, as STRA6 was detectable 
in WT but not KO thymocyte surface (Fig. 2D). 
 
Normal lymphoid organs and lymphocyte subpopulations in STRA6 KO mice 
STRA6 KO mice were viable and fertile with no apparent anomalies upon visual inspection. Weight and 
cellularity of the KO thymus and spleen were comparable to those of WT mice (Fig. 3A). T-cell (CD4+ plus 
CD8+ versus non T-cell (CD4-CD8-) subpopulations, and CD4 versus CD8 T-cell subpopulations in the spleen 
and LN of WT and KO mice showed no consistent differences (Fig. 3B). The percentages of B cells 
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(CD19+B220+) in the spleen and lymph nodes in WT and KO mice were also similar (Fig. 3C). In KO thymi, the 
percentages of CD4 single-positive and CD8 single-positive, CD4CD8 double-positive cells and CD4+/FoxP3+ 
Treg cells were comparable to those in WT thymi (Fig. 3D). The comparable percentages of Treg cells in the thymi 
of WT and KO mice were confirmed by the measurement of FoxP3+ cells among CD4+CD25+ thymocytes (Fig. 
3E).  
 
In the periphery, the percentages of FoxP3+ Treg cells among CD4 cells in the spleen (Fig. 3F) and lymph nodes 
(Fig. 3G) from WT and KO mice were also similar. 
 
These results show that STRA6 KO mice have normal lymphoid organ and T-cell development. 
 
Normal activation, proliferation and differentiation of STRA6 KO T cells  
KO and WT T cells were stimulated by solid-phase anti-CD3 mAb for 16 h. The activation markers CD25 and 
CD69 in CD4 and CD8 T cells were quantified by flow cytometry. KO and WT T cells showed similar up-
regulation of these markers (Fig. 4A). To assess T-cell proliferation, KO and WT T cells in total spleen cells were 
loaded with CFSE and stimulated by soluble anti-CD3 mAb. After 3 days, their proliferation was assessed by 
flow cytometry. CD4 and CD8 KO T cells proliferated like their WT counterparts, as shown in Figure 4B. To 
measure T-cell homeostatic expansion, spleen T cells were loaded with CFSE and then injected into sub-lethally-
irradiated syngeneic recipients. The proliferation of these transferred KO CD4 and CD8 cells in recipient spleens 
and LN during the 5 days after the injection was measured based on their CFSE content according to flow 
cytometry. As shown in Figure 4C, the cells from WT and KO mice proliferated similarly in vivo. Therefore, KO 
T-cell proliferation, whether caused by TCR stimulation in vitro or homeostatic expansion in vivo, was not 
defective. 
 
When KO and WT naïve CD4 cells were cultured under Th1, Th2, Th17 and Treg conditions, 
they achieved comparable Th1, Th2, Th17 and Treg cell percentages (Fig. 5), indicating normal 
differentiation of naïve KO CD4 cells into these subpopulations. 
 
The effect of STRA6 deletion in anti-LCMV immune responses in vivo 
The function of STRA6 KO T cells in vivo was evaluated in the LCMV infection model. As 
illustrated in Figure 6A, the number of total splenocytes, and CD4 and CD8 cells on day 8 
post-infection (8 dpi) presented no significant differences in WT and KO mice (Fig. 6A). The 
absolute numbers (Fig. 6B) and relative percentages (Fig. 6C) of LCMV-specific tetramer-
positive (gp33+, np396+ and gp276+) CD8 cells in virus-infected mice were all increased in 
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comparison to uninfected control C57BL/6 mice (data not shown), but there were no 
significant differences between KO and WT mice with regard to these parameters. The 
absolute numbers and relative percentages of LCMV-specific TNF-α-producing CD4 (gp61) 
and CD8 cells (gp33) (Figs. 6D and 6E), and LCMV-specific IFN-γ-producing CD4 and CD8 
cells (Figs. 6F and 6G) in KO mice were comparable to those in WT controls. These results 
indicate that the STRA6 deletion had no discernable effect on anti-LCMV immune responses.  
 
Normal glucose tolerance in STRA6 KO mice 
One report suggests that STRA6 stimulation by RBP induces the expression of SOCS3, which 
inhibits insulin signaling [12]. We assessed the glucose tolerance of KO mice, and found that, 
KO and WT mice showed no significant difference in glucose tolerance (Fig. 7), suggesting 
that in the absence of STRA6, the insulin signaling of the KO mice on a normal diet is not 
enhanced. 
    
Organ retinyl ester and retinol levels in STRA6 KO mice 
As vitamin A has been reported to play an important role in immune regulation [12-17], a lack 
of immunological phenotype so-far tested in the KO mice prompted us to examine vitamin A 
contents of lymphoid organs as well as several other organs including the eyes. Vitamin A is 
stored in organs predominantly in the form of retinyl ester, which is a lipid and can reach high 
concentrations. A minor stored form is retinol bound to CRBP, and the retinol content in the 
cells is limited by the availability of CRBP. Retinyl esters and retinol and can be quickly 
converted to each other inside the cells. We thus measured the contents of both retinyl esters 
and retinol in these organs.  
 
As shown in Figure 8A, the WT and KO spleen and thymus had no significant difference in 
their retinyl ester contents, nor did the brains and kidneys. The retinyl ester contents in WT 
eyes were much higher than that of other organs, and the contents in the KO eyes were 
significantly lower compared to those of the WT counterparts. WT or KO blood had no 
detectable retinyl ester (data not shown).  Retinyl ester is known to be high in the blood only 
right after a meal enriched in vitamin A.   
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The retinol levels in these WT and KO organs were of the same pattern as retinyl ester, 
although at much lower levels (Fig. 8B; note the scale difference). The KO spleen, thymus, 
kidney and brain had no significant difference in retinol contents compared to their WT 
counterparts. Unlike retinyl ester, the retinol was detectable in the sera, but was of similar 
levels in WT and KO sera. The eyes contained the highest levels of retinol. KO eyes presented 
significantly lower levels of retinol than the WT counterparts.    
 
These data indicate that under a vitamin A sufficient condition, lymphoid organs still take up 
vitamin A without STRA6 in mice. This explains the lack of immunological phenotype in the 
KO mice. However, even under such a vitamin A sufficient condition, the eyes still heavily 
depend on SRAT6 for vitamin A uptake, as they are the organ with the highest vitamin A 
demand.  
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DISCUSSION 
STRA6 is a receptor of holo-RBP (i.e., vitamin A-bound RBP) for cellular vitamin A uptake. 
STRA6 is up-regulated after T-cell activation. In this study, we generated STRA6 KO mice to 
assess whether such up-regulation was essential for T cell-mediated immune responses and 
STRA6’s role in vitamin A uptake.    Under a vitamin A sufficient condition, STRA6 KO 
mice developed normally and were fertile. Their T cells presented no signs of abnormality in 
terms of development, activation marker up-regulation, proliferation, and Th and Treg cell 
differentiation. KO mice also had normal anti-LCMV immune responses. There was no 
significant difference in intracellular vitamin A content, in the forms of both retinyl ester and 
retinol, in lymphoid organs from WT and KO mice. However, even under the vitamin A 
sufficient condition, the KO eyes contained significantly lower amounts of retinyl ester and 
retinol, indicating a critical role of vitamin A uptake in this organ. 
 
A caveat of whole organ retinoid analysis is that contribution of retinoid in the blood can 
affect the total retinoid levels. This is especially true if the organ is rich in blood, which 
contains RBP-bound vitamin A. Despite this caveat, whole organ retinoid analysis can be used 
as an approximation of cellular retinoid uptake. This is especially true as several of the organs  
we tested (i.e., the thymus, brain and eyes) are not blood rich. Moreover, sera had no 
detectable retinyl ester (data not shown); so the retinyl ester levels of the organs tested will not 
be upward influenced by the blood retinyl ester levels. The reduced vitamin A contents in the 
eyes of STRA6 KO mice is not unexpected, as the eyes have the highest concentrations of 
vitamin A among all the organs (Fig. 8) due to its heavy reliance on vitamin A for vision, and 
probably need all the capacities of vitamin A transport including the pathway of RBP/STRA6 
to achieve this high vitamin A content, even in vitamin A sufficiency. Consistent to our 
findings, RBP KO mice have normal vitamin A levels in most of their organs, but a reduced 
one in the eyes [35]. 
     
Vitamin A and its metabolites – retinoic acids – are clearly required in immune responses [13-
18, 36]. It is reported that in hepatocytes, holo-RBP triggers STRA6, leading to the activation 
of JAK2/STAT5 signaling pathway, which is also essential in the activation and function of 
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immune cells. STRA6 is up-regulated within 24 h of T-cell activation (Fig. 1B). Is such up-
regulation, or more fundamentally, the existence of STRA6, essential for T cell-mediated 
immune responses? We demonstrated that in STRA6 KO mice, a lack of STRA6 did not affect 
T-cell activation/proliferation/differentiation in vitro and anti-viral immune responses in vivo 
under a vitamin A sufficient condition. These observations suggest following possible and not 
necessarily mutually exclusive explanations: 1) STRA6 up-regulation/existence only becomes 
important for T-cell functions during vitamin A deficiency, when all capacities of vitamin A 
import to immune cells are required; 2) STRA6 homologue RBPR2 can compensate for 
STRA6 function in the immune cells, as this homologue is expressed in the spleen; also, 
retinyl esters bound to lipoproteins secreted by the small intestine can deliver vitamin A to 
peripheral organs under vitamin A sufficient conditions; 3) STRA6 plays a minimal role in 
modulating the JAK2/STAT5 signalling pathway in immune cells, and its upregulation after T 
cell activation has nothing to do with JAK2/STAT5 signaling; 4) We cannot exclude the 
possibility that STRA6 deletion might still affect certain T cell-mediated immune responses to 
some extent, but they have not been assessed in our experiments, or their magnitude was too 
small to be discerned by current assays; 5) Such up-regulation might be a parallel and 
irrelevant event during T-cell activation.  
 
There is little systemic documentation on vitamin A sufficiency status in wild mammals in 
today’s world. However, it is well-documented that vitamin A deficiency is prevalent in 
African and Southeast Asian populations, particularly affecting children and pregnant women, 
according to the World Health Organization [37], and such deficiency predisposes them to 
infectious diseases [38]. It is conceivable that, during evolution, mammals might have 
experienced vitamin A deficiencies in certain periods or regions in the world. Better cellular 
vitamin A transport will confer an evolutionary advantage to these animals with regard to but 
not restricted by their ability to cope with infectious diseases. If STAR6 is universally critical 
in all cell types for vitamin A uptake, its function should be revealed in immune responses in 
vitamin A deficiency. Experiments addressing this possibility are in progress.  
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STRA6 point mutations are found in some patients, with microphthalmia, anophthalmia, 
coloboma [7] and Matthew-Wood syndrome [referring to combinations of 
microphthalmia/anophthalmia, cardiac malformations, pulmonary dysgenesis, and 
diaphragmatic hernia; ref. 9]. In a study of 2 unrelated consanguineous families with 
malformation syndromes sharing anophthalmia and distinct eyebrows as common signs, 
homozygous mutations were identified in STRA6 [6]. Our STRA6 KO mice and those 
generated by Ruiz et al. [10] did not have dramatic phenotypes, such as a total absence of 
eyes, as seen in humans with STRA6 mutations.  
 
Why cannot STRA6 KO in mice reproduce human disease phenotypes caused by STRA6 
mutations? A simple explanation is that this is due to species differences.  It is not 
unprecedented that gene mutations in mice and humans have very different phenotypes. For 
example, partial or complete loss of ABCA4 functions cause many blinding diseases in 
humans including retinitis pigmentosa, cone-rod dystrophy and Stargdardt macular dystrophy, 
but ABCA4 KO in mice does not cause blindness unless combined with a deletion of other 
genes such as RDH8 [39-41]. On the other hand, disease loci of microphthalmia and 
anophthalmia have been mapped to multiple chromosomes [42-45]. Patients with Matthew-
Wood syndrome or malformation syndromes have quite large phenotype variations in terms of 
organ affliction and disease severity. Such observations suggest that these syndromes are not 
monogenic, and STRA6 mutation alone is not sufficient to evoke all such phenotypes. It could 
explain why no serious ophthalmic [13] or other organ malformations are apparent in STRA6 
null mutation mice. If STRA6’s major function is cellular vitamin A uptake, and human organ 
malformation syndromes are mainly caused by a lack of available intracellular vitamin A, it 
would support the notion that STRA6 only plays a minor role in cellular vitamin A uptake in 
vitamin A sufficiency, especially in organs other than the eyes. Unless other routes of cellular 
vitamin A uptake such as  those mediated by RBPR2 or by retinyl esters bound to lipoproteins 
are simultaneously compromised, vitamin A in the cells of most, if not all, organs vitamin A 
contents will remain in the normal range, and the organs will develop and function normally in 
vitamin A sufficiency. However, significant phenotype might be revealed in vitamin A 
deficiency. This hypothesis is supported by results from RBP KO mice. These KO mice are 
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fertile and have no organ abnormality other than the vision phenotype [46-48], as is the case of 
STRA6 KO mice when fed with a vitamin A sufficient diet. However, they manifest severe 
systemic phenotype of embryonic lethality under a vitamin A deficient condition [49,50]. 
Consistently, in mouse embryo culture where is no retinyl ester pathway, RBP knockdown 
also causes severe developmental defects [51].   
 
In summary, we conclude that, under normal dietary conditions, mouse lymphoid organ 
development, T-cell activation and differentiation, including Treg cell development, and anti-
LCMV responses, could proceed normally in the absence of STRA6 under vitamin A 
sufficient conditions.   
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FIGURE LEGENDS 
Figure 1. STRA6 mRNA expression in organs and activated T cells 
STRA6 mRNA in organs (A) and activated T cells (B) was measured by RT-qPCR. WT 
spleen T cells were cultured in wells coated with solid-phase anti-CD3 mAb and anti-CD28 
mAb (0.5 µg/ml and 4 µg/ml, respectively, for coating) for the durations indicated. The cells 
were then harvested and their STRA6 mRNA levels measured by RT-qPCR. Samples were in 
triplicate for RT-qPCR, and means + SD of ratios versus β-actin signals are reported. 
Experiments were conducted twice, and representative data are illustrated. 
 
Figure 2. Generation of STRA6 KO mice 
A. Targeting strategy for generating STRA6 KO mice  
The red squares on the 5’ and 3’ sides of the mouse STRA6 WT genomic sequence represent 
the sequences serving as probes for genotyping by Southern blotting.  
 
B. Genotyping of STRA6 mutant mice 
Tail DNA was digested with XbaI, and analyzed by Southern blotting (top panel), with the 5’ 
probe whose location is indicated in A. A 7.8-kb band representing the WT allele and a 5.2-kb 
band representing the recombinant allele are indicated by arrows. Similarly, tail DNA was 
digested with ScaI, and analyzed with the 3’ probe (bottom panel). A 6.9-kb band representing 
the WT allele and a 4.3-kb band representing the recombinant allele are indicated by arrows. 
 
C. Absence of STRA6 mRNA expression in STRA6 KO splenocytes 
STRA6 mRNA levels from WT and KO splenocytes were analyzed by RT-qPCR. The RT-
qPCR samples were in triplicate and the results are expressed as ratios of STRA6 versus β-
actin mRNA signals with means + SD indicated. The experiments were conducted twice and 
representative data of one experiment are shown. 
 
D. Absence of STRA6 protein expression in KO thymocytes 
WT and KO thymocytes were stained with goat anti-mouse STRA6 Ab, and analyzed by flow 
cytometry. The shaded area is the isotypic Ab staining control using WT thymocytes. The 
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thick line represents WT thymocytes stained with anti-STRA6 Ab, and the dotted line, KO 
thymocytes stained with anti-STRA6 Ab. The experiments were carried out three times and a 
representative histogram is shown. 
 
Figure 3. STRA6 KO mice presented normal lymphoid organs and lymphocyte subpopulations 
A. Weight and cellularity of WT and KO thymi and spleens 
Mouse number (n) in each group is shown. No significant difference is detected in weight and 
cellularity between KO and WT organs (p>0.01, paired Student’s t test). 
 
B. CD4 and CD8 T-cell subpopulations in WT and KO spleens and LN 
Splenocytes and LN cells were analyzed by 2-color flow cytometry for percentages of CD4 
and CD8 T cells.  
C. B cell populations in the spleen and LN of WT and KO mice 
Splenocytes and LN cells were analyzed by 2-color flow cytometry for percentages of 
CD19+/B220+ B cells.  
D and E. Normal thymocyte subpopulations and endogenous Treg cells in KO thymi 
CD4/CD8 double-negative, CD4/CD8 double-positive, CD4 single-positive and CD8 single-
positive cells and CD4+CD8-FoxP3+ Treg cells in KO and WT thymi were analyzed by 3-color 
flow cytometry (D). CD4+CD25+FoxP3+ Treg cells in the WT and KO thymi were also 
analyzed by 3-color flow cytometry (E).  
F and G. CD4+CD8-FoxP3+ Treg cells in KO and WT spleens and LN  
CD4+CD8-FoxP3+ Treg cells in KO and WT spleens (F) and LN (G) were analyzed by 3-color 
flow cytometry. 
The experiments in B through G were conducted more than 3 times, and representative 
histograms are presented. Percentages of relevant populations are indicated.  
 
Figure 4. Normal activation and proliferation of KO T cells 
A. Normal activation marker CD69 and CD25 expression on KO T cells 
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Total spleen cells were stimulated overnight by soluble anti-CD3 mAb (0.5 µg/ml). CD69 and 
CD25 expression on CD4 (left panel) and CD8 (right panel) T cells was measured by 3-color 
flow cytometry.  
 
B. Normal proliferation of KO CD4 and CD8 cells upon TCR activation in vitro 
Total spleen cells were loaded with CFSE and then stimulated with soluble anti-CD3 mAb 
(0.5 µg/ml). The cells were harvested after 72 h, and stained for CD4 and CD8; CFSE levels 
in these cells were analyzed by 3-color flow cytometry.  
 
C. KO CD4 and CD8 cells present normal homeostatic expansion in vivo 
Five million CFSE-loaded spleen cells were injected i.v. into sub-lethally irradiated (650 Rad) 
C57BL/6 recipients 5 h after the irradiation.  On days 6, the CFSE fluorescence of CD4 and 
CD8 cells from the spleen and LN was analyzed by flow cytometry.   
 
All experiments in this figure were conducted twice or more, and representative histograms 
are shown. 
 
Figure 5. Normal differentiation of STRA6 KO CD4 cells in vitro 
Naïve CD4 cells were cultured under conditions favouring Th1 (A), Th2 (B), Th17 (C) and 
Treg (D) cell differentiation. Their intracellular cytokine or FoxP3 expression was quantified 
by flow cytometry on day 3 for Th1, Th17 and Treg cells, and on day 5 for Th2 cells. 
Experiments were repeated more than 3 times, and representative histograms are shown.  
 
Figure 6. Normal in vivo anti-LCMV immune responses of STRA6 KO mice 
A.  Spleen cell numbers on day 8 after LCMV infection 
Means + SD of absolute numbers of total splenocytes, CD4+ cells, and CD8+ cells in spleens 
of WT littermate control (n=4) and KO (n=4) mice on day 8 post-LCMV infection are 
presented.  
 
B and C. LCMV-specific CD8 cells on day 8 post-LCMV infection 
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On day 8 post-infection, the absolute numbers of gp33, np396 and gp276 tetramer-positive 
CD8 T cells per spleen (B) and the percentage of gp33, np396 and gp276 tetramer-positive 
cells among CD8 cells (C) were measured by flow cytometry. Means + SD of data from 4 
pairs of WT littermate control and STRA6 KO mice are presented.  
 
D and E. LCMV-specific TNF-α-producing CD4 and CD8 cells on day 8 post-LCMV infection 
The absolute number of TNF-α-producing LCMV-specific CD4 cells (gp61-specific) and 
CD8 cells (gp33-specific) per spleen (D) and percentage (E) of these cells among total spleen 
cells of KO and WT mice on day 8 post-LCMV infection. Means + SD of data from 4 pairs of 
STRA6 KO mice and WT littermate controls are shown.  
 
F and G. Virus-specific IFN-γ-producing CD4 and CD8 cells on day 8 post-LCMV infection 
The absolute number of TNF-α-producing LCMV-specific CD4 cells (gp61-specific) and 
CD8 cells (gp33-specific) per spleen (D) and percentage (E) of these cells among total spleen 
cells of KO and WT mice on day 8 post-LCMV infection. Means + SD of data from 4 pairs of 
STRA6 KO mice and WT littermate controls are shown.  
 
Figure 7. Glucose tolerance of KO and WT mice 
WT (n=5) and KO (n=7) mice were fasted for 16 h, and then injected i.p. with D-glucose (2 
mg/g body weight). Blood glucose was measured at different time points from the time of 
injection until 120 min. Means + SD of glucose levels (mg/dL) are reported. No statistical 
significant difference is observed between the KO and WT groups (ANOVA). 
 
 
Figure 8. Intracellular retinoid contents in lymphoid and other organs of STRA6 KO mice 
were comparable to those of WT mice 
Retinoid (retinyl ester, A; retinol, B) contents (nmol/gram tissue or nmonl/ml serum) of the 
eyes, brain, kidney, spleen, thymus, spleen, thymus and sera from KO and WT mice were 
measured by HPLC. The mouse numbers (n) per grouop are indicated. The results are 
expressed as means + SD. The p-values are indicated when significant (Student’s t test). 
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TABLES 
Table 0.4 Antibodies and reagents for flow cytometry 
Antibody Supplier 
PE-donkey anti-goat IgG R & D Systems 
APC-rat anti-mouse CD25 (clone PC61) BD Biosciences 
FITC-rat anti-mouse CD25 (clone 7D4) BD Biosciences 
PE-rat anti-mouse CD4 (clones GK1.5 and H129.19) BD Biosciences 
PerCP-rat anti-mouse CD4 (clone RM4-5) BD Biosciences 
biotin-rat anti mouse CD8b (clone 53-5.8) BD Biosciences 
APC-Cy7- anti-mouse B220 (clone RA3-6B2) BD Biosciences 
PE- or APC-hamster anti-mouse CD3ε (clone 145-
2C11) 
BD Biosciences 
biotin- or FITC-rat anti-mouse CD44 (clone 1M7) BD Biosciences 
FITC- or PE-rat anti-mouse CD8α (clone 53-6.7) BD Biosciences 
APC-rat anti-mouse CD8α (clone H57-597) BD Biosciences 
PE-rat anti-mouse IL-17A BD Biosciences 
PE- and APC-rat anti-mouse IFN-γ BD Biosciences 
PE- and APC-rat anti-mouse IL4 mAbs BD Biosciences 
PerCP-streptavidin and 7-Amino-actinomycin D (7-
AAD) 
BD Biosciences 
APC-Cy7-Streptavidin™ BioLegend 
APC-rat anti-mouse TNF-α (clone MP6-XT22) eBioscience (San Diego, CA) 
FITC-rat anti-mouse IFN-γ (clone XMG1.2) eBioscience 
APC-rat anti-mouse IL17A (clone eBio17B7) eBioscience 
APC-rat anti mouse/rat Foxp3 (clone FJK-16s) mAbs eBioscience 
PE-Cy7-streptavidin eBioscience 
intracellular antigen fixation buffer eBioscience 
10X permeabilization buffer eBioscience 
 APC-Cy™ PE-rat anti-mouse CD25 (clone PC61) Cedarlane Laboratories Ltd (Burlington, Ontario, 
Canada) 
Goat anti-mouse STRA6 Ab Everest Biotech (Upper Heyford, Oxfordshire, UK) 
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